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Abstract
In combination with conferring resistance to ADP-ribosylation by Pertussis 
toxin, the substitution of a conseiwed cysteine residue (C351) four amino acids from the 
C-terminus of Giai has been shown to modulate the efficiency of coupling to the aiA  
adrenoceptor. Investigation of this phenomenon through systematic substitution of this 
cysteine residue for all other amino acids highlighted a relationship between the 
hydrophobicity of the substituted residue and the capacity of the a-subunit to 
functionally couple to the azA adrenoceptor. From the results of this investigation, it 
was noted that wild type Giai did not display optimal coupling at this receptor. Relative 
to wild type Giau coupling was enhanced by the substitution of a more hydrophobic 
residue at position C35I, but diminished upon the substitution of a more hydrophilic 
residue. In contiast to this, substitution of proline or a charged residue at this position 
essentially attenuated functional coupling with the a ik  adrenoceptor. Similarly, pECso 
values of the mutants also showed a high degree of correlation with the hydrophobic 
nature o f the substituted residue, with more hydrophobic residues reducing pECso 
values and more hydrophilic residues increasing pECso values respectively relative to 
wild type Gi«i. This change in coupling efficiency could not be attributed to a change in 
the affinity for nucleotides at the a-subunit or to a change in the rate of basal guanine 
nucleotide exchange. These data indicate that functional coupling of the Gi«i subunit to 
the aiA  adrenoceptor is in part modulated by the physiochemical properties of residue 
351 and that a relationship exists between the hydrophobicity of residue 351 and the 
capacity of the a-subunit to functionally couple to the a 2A adrenoceptor.
A series o f fusion constructs composed of the azA adrenoceptor covalently 
linked to selected Giai C351 mutants were used to assess the effects of substituting 
residue C351 in Gi«i on agonist intrinsic activity at the azA adrenoceptor. The agonist 
UK 14304 was shown to elicit a spectiiim of responses at the fusion constructs, closely 
miiToring the order of coupling efficiency previously detemiined in the separately 
expressed components. While UK14304 essentially acted as a full agonist compared to 
adrenaline at the fusion construct composed of wild type Gi«i (C351 Giai), it was shown 
to act as a partial agonist at an equivalent construct containing a glycine residue at 
position 351 in the Giai moiety. In contrast to this, relative to the wild type Giai fusion, 
UK14304 displayed greater relative intrinsic activity at the fusion construct containing
an isoleucine residue at position 351 in the Giai moiety. Analysis of a more extensive 
range of partial agonists demonstrated that the order of agonist relative intrinsic activity 
at the respective fusion constructs was conserved regardless of the agonist assayed. This 
discrepancy of intrinsic activity at the fusion proteins could not be attributed to a change 
in the pharmacological profile of the receptor moiety or to a modification of its affinity 
for agonist. These data indicate that the intrinsic activity of partial agonists, relative to 
adrenaline, can be modulated by the physiochemical properties of residue 351 in the 
Giai moiety.
The capacity of a series of chimeras containing substitutions o f the last 6 C- 
temiinal residues of Giai for those of Gsa, Gqa and Giea were assessed for functional 
coupling with a range of non Gi-linked receptors. Functional coupling was 
demonstrated at the Gi/Gs chimera with the Vz vasopressin receptor and Pz 
adrenoceptor. Similarly, the Gi/Gq chimera was shown to functionally couple with the 
PzY4, and TRH, receptors. No functional coupling was detected for the G1/G16 chimera. 
The inability of the Gi/G16 chimera to functionally couple to any of the receptors 
analysed was independent from its capacity to basally exchange guanine nucleotides, 
which was shown to be unchanged relative to the Gi/Gs, Gi/Gq chimeras and wild type 
Giai. The substitution of the 6 C-terminal residues of Giai for those of Gsa also 
conferred resistance to ADP-ribosylation by both pertussis and cholera toxins. This was 
demonstrated by functional coupling of the Gi/Gs chimera to a FLAG'^'^ -tagged version 
of the IP prostanoid receptor following treatment with both bacterial toxins. The GiaiGsa 
chimera was seen to couple more efficiently at the IP prostanoid receptor in the 
presence of these toxins than in non toxin treated samples, indicating that coupling 
efficiency of this chimera at the IP prostanoid receptor was not optimal. These findings 
indicate that the C-terminus of the G-protein a-subunit is an important determinant in 
defining G-protein/receptor coupling and that additional determinants, not present in the 
C-terminus of the a-subunit, are required for optimal coupling efficiency.
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Chapter 1 
Introduction
1.1 Introduction
Cell surface receptors allow the transduction of extracellular signals across the 
lipid bilayer into the cell. These receptors can be broadly divided into two groups, those 
characterised by a single membrane spanning domain and those characterised by a 
seven transmembrane domain structure. Of these two groups, seven transmembrane 
domain receptors (or G-protein coupled receptors) constitute the largest family of cell 
surface receptors, with over 1000 known family members. This enormous number of 
family members reflects the diversity of ligands that are Icnown to mediate responses 
tlirough these receptors. Such ligands include -  chromophores, nucleotides, cations, 
odours, small biogenic amines, large peptide hormones and chemokines. This list is by 
no means exhaustive. The constant cloning of new receptors has led to the discovery of 
receptors with no known ligands. These so-called “orphan” receptors serve to reflect the 
diverse nature o f G-protein coupled receptors. This diversity is mirrored by the broad 
distribution of receptors throughout virtually every cell in the body. The combination of 
ligand diversity and tissue specific localisation of receptor subtypes allows G-protein 
coupled receptors to mediate functions as disparate as reproduction, metabolism, vision, 
smell, neurotransmission, cardiovascular regulation and immune response.
Considering the diversity of responses mediated by G-protein coupled receptors, 
it is not surprising to note that mutations in the components of the signal transduction 
cascade can give rise to a variety of diseases. While such mutations provide potential 
therapeutic targets for the pharmaceutical industry, they can also be used to elucidate 
some of the many mechanisms involved in the G-protein signal transduction pathways.
1.1.2 Historicai overview
The path leading to the discovery of the G-protein mediated signal transduction 
pathway started in the late 1950’s with Sutherland and Rail’s observation that the 
enzyme adenylyl cyclase could be modulated in a concentration dependent manner by 
the addition of adrenaline or glucagon to preparations of canine liver (Sutherland et a l, 
1958; Rail et a l,  1957). Early research continued to be focussed on the modulation of 
adenylyl cyclase activity, with Murad et a l (1962) not only showing that the 
stimulatory effects of adrenaline could be antagonised by “adrenergic blocking agents”, 
but also demonstrating the existence of partial agonists. Using a strategy of elimination, 
Sutherland et a l finally resolved the cellular location of adenylyl cyclase to the cell
membrane in 1962, Despite the wealth of information regarding the function of adenylyl 
cyclase, in the early 1960’s adenylyl cyclase was still thought to be a membrane protein 
complex at which hormones exerted their effects thiough direct binding at regulatory 
subunits. It was not until 1969 that Bimbaumer and Rodbell concluded that hormones 
had discrete binding sites independent from the enzyme. Rodbell et (197la) went on 
to demonstrate that the hormone glucagon has specific binding sites which were 
saturable and finite in number and that glucagon binding at these sites was proportional 
to adenylyl cyclase stimulation. It was not until 12 years later that Nathans et a l (1983) 
cloned the first G-protein coupled receptor, the bovine opsin receptor, using degenerate 
primers designed from the amino acid sequence of the bovine rhodopsin receptor. From 
analysis of the amino acid sequence, Nathans et a l proposed that the receptor was 
composed of seven hydrophobic membrane spanning domains that in turn were 
connected by alternating intracellular and extracellular loops more hydrophilic in 
character. In Nathans's theoretical model, the N and C-termini of the receptor were 
positioned on opposite faces of the lipid bilayer, with the N-terminus on the 
extracellular face and the C-terminus in contact with the cytoplasm. This early model 
was corroborated when the second G-protein coupled receptor, the (32 adrenoceptor, was 
cloned 3 years later by Dixon et a l (1986). The true extent of receptor homology was 
not fully realised until 1993 when Baldwin analysed the sequences of over 100 cloned 
G-protein coupled receptors. From this study, Baldwin (1993) concluded that all G- 
protein coupled receptors shared a common seven transmembrane structure. Further 
evidence of a seven transmembrane structure was presented by Schertler et a l  (1993) in 
the from of a high resolution (9 angstrom) election density map of rhodopsin. This map 
not only illustrated the presence of seven membrane spanning regions of high electron 
density, but also provided the first insight into the relative orientation of the 
transmembrane domains. Due to the problems associated with purifying and 
ciystallising receptors, no further G-protein coupled receptor crystal sti'uctures have 
been resolved to date.
It was not until the early 1970’s that guanine nucleotides were recognised as 
important factors in cellular signalling. The first association between guanine 
nucleotides and receptor binding was made by Rodbell et a l (1971b) who demonstrated 
that GTP enhanced the dissociation of glucagon from its cognate receptor. Later, 
Pfeuffer and Helmi'eich (1975) linked the activation of adenylyl cyclase in turkey 
eiythrocytes with the non-covalent binding of GTP at a separate regulatory protein. In
the following year, Cassel and Selinger (1976) demonstrated agonist stimulated GTP 
hydrolysis by this regulatory protein and linked this activity with the attenuation of 
adenyiyl cyclase activation. Cassel and Selinger also demonstrated that abolition of this 
GTPase activity through cholera toxin treatment resulted in the constitutive activation of 
adenyiyl cyclase. After further experimentation Cassel and Selinger concluded that the 
guanine nucleotide binding regulatory protein acted as a signalling intermediate 
between the hormone activated receptor and the enzyme adenyiyl cyclase. In parallel 
with these observations, Ross and Gilman demonstrated that this guanine nucleotide 
binding protein could reconstitute hormone stimulated adenyiyl cyclase activity in the 
mutant S49 murine lymphoma eye" cell line (Ross and Gilman, 1977). This guanine 
nucleotide binding protein was finally purified and characterised by Northup, who 
demonstrated that this “regulatory component of adenyiyl cyclase” was actually 
composed of more than one polypeptide chain (Northup et a l, 1980). Northup et a l 
(1980) also showed that the effects of cholera toxin, as observed by Cassel and Selinger 
(1977), were a result of ADP ribosylation of one of the guanine nucleotide binding 
protein subunits. The high resolution structure of the active conformation of the 
transducin a-subunit was finally resolved 13 years later by Noel et a/.(1993). Analysis 
of this structure showed that the a-subunit was composed of two distinct domains 
separated by a deep cleft, which formed the guanine nucleotide binding pocket. One of 
these domains was detei-mined as being predominantly a-helical in structure, while the 
other was shown to closely resemble the structure of the small nucleotide binding 
protein Ras. The conformational changes involved in G-protein activation were finally 
resolved a year later when Lambright et a l (1994) ascertained the crystal structure of 
the transducin a-subunit in the inactive GDP-bound conformation. Direct comparison of 
the two crystal structures of Gt« showed that conformational changes were localised to 
three conserved “switch” regions in the nucleotide binding portion of the a-subunit. In 
the following two years the crystal structures of free |3y and py as part of a G-protein 
heteroti'imer were ascertained by Sondek et a/.(1996) and Wall et a/.(1995) 
respectively. Despite the extensive information provided by these X-ray diffraction 
studies, the structures of the extreme N-terminal helix and C-terminal tail still remain 
unresolved.
Characterisation of the basic components of the signal transduction pathway also 
led to the identification of further factors capable of regulating receptor and G-protein
activity. The first regulator of G-protein signalling (RGS), SST2, was identified in the 
yeast Saccharomyces cerevisiae by Chan and Ottie (1982). SST2, like all RGS proteins, 
regulates G-protein activity by accelerating the rate of guanine nucleotide hydrolysis 
and so the length of time the G-protein remains in the active conformation. It was not 
until 1995 that the fust human homologue G0S8 was isolated from a human cDNA 
library (Wu et a l,  1995), although this was initially incorrectly identified as a 
transcription factor. This discovery was rapidly followed by the isolation of another 
closely related human homologue, GAIP, by a yeast two hybrid screen with human Gia3 
as bait (DeVries et a l,  1995). Alignment of these RGS proteins has shown that 
members of the RGS family contain 3 highly conserved GOS8, or GH, homology 
domains (Dohlman et a l, 1996). At present 19 RGS proteins have been isolated from 
organisms as diverse as S.cerevisiae to C.elegans.
Knowledge in the field of G-protein coupled receptors has increased enormously 
since the first obseiwations of Sutherland and Rail in the late 1950’s. Many of the 
components o f the signal transduction cascade have now been isolated, and numerous 
molecular mechanisms involved in signal propagation are now well characterised. 
However, despite our current level of understanding, the continuous discovery of novel 
receptors and regulatory components of the signal transduction cascade leaves no doubt 
that much still remains to be learned.
1.2 G-protein coupled receptors
G-protein coupled receptors (GPCRs) play an important role sensing and 
transmitting extracellular signals across the cell membrane to intracellular effectors via 
GTP binding proteins (G-proteins). At present over 1000 G-protein coupled receptors 
have been identified. This enormous number of family members is reflected in their 
diversity of function and ligand specificity. Despite this diversity, all GPCRs share a 
common general structure o f an N-tenninal segment, seven putative transmembrane 
helices, which fold to form the transmembrane core, connected by three extracellular 
loops and at least three cytoplasmic loops (Fig. 1,1). The structure is completed by a C- 
terminal segment, which can be post-translationaly modified to fonn a fourth 
cytoplasmic loop.
Amino acid analysis of the first cloned GPCR, the bovine opsin receptor, by 
Nathans et a l  (1983) provided the first structural model o f a G-protein coupled 
receptor. The amino acid sequence highlighted the presence o f seven hydrophobic 
regions that were postulated to transverse the cell membrane as a-helical structures. 
These hydrophobic regions, while themselves relatively conserved in size, were thought 
to be linked by intracellular and extracellular loops more hydrophilic in nature and 
variable in length. From the subsequent cloning of the j3-adrenergic receptor three years 
later (Dixon et a l, 1986) it became apparent that G-protein coupled receptors shared a 
great deal of structural homology. The extent of this homology was demonstrated by 
Baldwin (Baldwin, 1993) who analysed the sequences o f over 100 cloned receptors and 
demonstrated that the seven hydrophobic, putative membrane spanning domains were 
common to all GPCRs. Up till 1993, all models of G-protein coupled receptors were 
based on the crystal structure of the functionally unrelated bacterial proton pump, 
bacterial rhodopsin. It was not until Schertler et a l  (1993) produced the first high 
resolution (9 angstrom) crystal structure of rhodopsin that it became apparent that the 
arrangement of the transmembrane domains varied between the two proteins. From the 
X-ray structure resolved by Schertler et a l  (1993) it could be observed that not all of the 
transmembrane domains were orientated perpendicular to the cell membrane as in 
bacterial rhodopsin. The transmembrane helices of rhodopsin appeared to cross the lipid 
bilayer at a variety of angles. Baldwin (1993) used this electron density map of 
rhodopsin in conjunction with sequence information of over 100 receptors to generate 
models o f possible transmembrane domain arrangements. This model has since been
Figure 1.1 A diagramatic representation of a typical G-protein 
coupled receptor
Figure 1,1 represents the structure of a typical G-protein coupled receptor. The 
N and C-termini of the receptor are positioned on opposite faces of the lipid bilayer 
separated by seven putative helical membrane spanning domains which are hydrophobic 
in nature. The N-terminus is located on the extracellular surface of the membrane and 
may contain potential glycosylation sites. In contrast to this, the C-terminus protrudes 
into the cytoplasm and is known to be post-translationally modified by both 
phosphorylation and palmitoylation. The intervening transmembrane domains, 
numbered I to VII, are arranged in a counter clockwise orientation as viewed from the 
extracellular surface of the cell and are themselves connected by alternating intracellular 
and extracellular loops more hydrophilic in character.
Figure 1.1
Potential Glycosylation sites
N-Terminus
C-terminus
Potential palmitoylation and Phosphorylation sites
refined by labelling experiments, mutational analysis and various forms of spectroscopy 
to formulate a detailed understanding of receptor structure in relation to function.
1.2.1 GPCRs [Structure and Function
Despite their diversity, all G-protein coupled receptors share two common 
features. The first o f these is that all G-protein coupled receptors are composed of the 
following structural elements. An N-tenninal segment, seven transmembrane domains, 
three extracellular loops, three cytoplasmic loops and an intracellular C-terminal 
segment. Secondly, all G-protein coupled receptors have the same function, which is to 
transduce extracellular signals across the cell membrane to intracellular effectors. The 
complex relationship between these two features will now be discussed below for each 
of the structural components.
1.2.2 The N-terminus
The N-terminus is hydrophilic in nature and is located on the extracellular side 
o f the cell membrane This region of the G-protein coupled receptors can be quite 
variable in both length (7-595 aa) and primary amino acid sequence. In many G-protein 
coupled receptors the N-terminal region plays a significant role in determining the 
specificity of ligand binding. There are two basic mechanisms by which the N-terminus 
may be involved in ligand binding. The N-tenninal region can either determine initial 
binding of the ligand, as in glycoprotein hormone receptors, or binding may involve 
synergistic contacts between both the N-terminus and the extracellular loops, such as for 
parathyroid hormone receptors (Ji et a/. 1998). In the exceptional example of protease 
activated receptors, the N-terminus is cleaved to generate what is essentially a tethered 
ligand which subsequently binds to the receptor’s extracellular loops. Ligand size has 
been shown to correlate weakly with the length of the GPCR N-terminus (Ji et a l ,
1995). However, there are exceptions to this rule, the most striking being the calcium 
receptor, which has an N-terminal segment approximately 600 residues in length.
Glycosylation at the N-terminal segment can account for a significant 
percentage o f the mass o f the receptor. For example Rands et al. (1990) have 
demonstrated that endoglycosidase treatment of the p2 adrenoceptor can decrease the 
molecular mass from 65 IdDa to 49 kDa. Despite accounting for a significant percentage 
of the mass of the receptor, glycosylation does not appear to play any significant role in 
receptor function. Through the use of glycosylation defective mutants, Rands ei al.
(1990) have demonstrated that glycosylation does not affect ligand binding, G-protein 
coupling or the capacity o f the receptor to activate it’s cognate secondary effector. In 
contrast, glycosylation did seem to affect correct localisation o f the P2 adrenoceptor in 
the cell. Rands et a i  (1990) observed that only half of the glycosylation defective 
mutants were correctly localised at the cell surface compared to the fully glycosylated 
wild type receptor.
1.2.3 The C-terminus
The C-tenninal segment is located on the intracellular face of the cell 
membrane, where it has been shown to play a role in detennining the specificity o f G~ 
protein coupling. In common with the N-tenninal region, the C-tenninal segment is 
variable in both length (12-359 residues) and primary sequence. The NMR structure of 
a peptide corresponding to the C-terminal segment of rhodopsin has revealed that the C- 
terminus is quite compact in nature (Yeagle et ai, 1996). This compact domain is 
thought to be orientated away from the membrane into the cytoplasm, where it can 
interact with both the G-protein a  and j3y subunits (Bourne, 1997). Other structural 
features of this compact domain include- an a-helix, presumed to be an extension of 
TM7, connected by a loop to cysteine residues, which are thought to be in close 
proximity with the cell membrane, followed by a hydrophilic (3-sheet structure (Yeagle 
et al., 1996)
Experimental evidence suggests that in certain receptors the C-terminal tail has 
the capacity to form a fourth cytoplasmic loop through palmitoylation at highly 
conserved cysteine residues (O’Dowd et a i,  1989). It is believed that the palmitate 
residue covalently linked to the conserved cysteine residue “anchors” itself to the cell 
membrane thereby forming an additional cytoplasmic loop. This theory would explain 
the close proximity between the cysteine residues and the cell membrane in the NMR 
structure of the C-terminal tail o f rhodopsin (Yeagle et a i,  1996). The significance of 
this fourth cytoplasmic loop appears to vary from receptor to receptor. O’Dowd et a i  
(1989) have demonstrated that substitution of the conserved cysteine residue for glycine 
in the P2 adrenoceptor results in a non-palmitoylated form of the receptor. This non- 
palmitolyated fonn exhibits a reduced capacity to stimulate adenyiyl cyclase upon 
isoproterenol stimulation when compared to the wild type receptor. Conversely, the
equivalent mutation in rhodopsin does not appear to adversely affect receptor function 
(Karnik 1988).
In addition to G-protein coupling, the C-terminal tail also appears to play a 
crucial role in determining the specificity o f receptor/G-protein interactions. Namba et 
al. (1993) have demonstrated that the primary sequence of the C-terminal tail can 
dictate G-protein coupling specificity in the EP3 prostanoid receptor. Four splice 
variants of the EP3 prostanoid receptor, differing only in the sequence of the C-terminal 
tail, were seen to couple to three different sets of G-proteins. O f the four splice variants, 
the E P 3a  receptor coupled to Gia, E P 3b coupled to Gsa, EP3c coupled to both G&a and 
Goa whilst E P 3d  coupled to Gi«, Gg», and Gq« (Namba et a i ,  1993).
Evidence suggests that the C-terminal tail of the receptor may be an important 
phosphorylation site in the process o f receptor desensitisation. Using reconstituted 
systems and site directed mutagenesis, Hausdorff et a i  (1989) have shown that the C- 
terminal tail of the P2 adrenoceptor can be phosphorylated by the two G-protein receptor 
kinases |3ARK1 and pARK2. Similarly, Premont et al. (1995) have identified two serine 
residues in the C-terminus of rhodopsin (Ser 338, Ser 343) which can be phosphoiylated 
by either pARKl/|3ARlC2 or the G-protein receptor Idnase GRK5.
1.2.4 Extracellular loop s
The extracellular loops of a G-protein coupled receptor can vaiy in length from 
2 to 230 residues. In many GPCRs the extracellular loops play an integral role in ligand 
binding, the nature of which varies from receptor to receptor. The extracellular loops 
can either play an auxiliary role in ligand binding in combination with other structures 
such as the TM core or the N-terminus, or they can be the sole sites for ligand binding.
Examples of receptor which use extracellular loops in ligand binding include- 
the formyl peptide receptor, parathyroid hormone receptors and protease activated 
receptors. Each of these receptors utilises the extracellular loops in a distinct way in 
ligand binding.
For example, ligand binding at the formyl peptide receptor is distributed 
between the extracellular loops and the transmembrane core. Mutational studies have 
shown that the N-fonnyl moiety of the ligand binds in the transmembrane core, while 
the C-terminal region of the ligand binds to both the N-terminal region of the receptor
and the extracellular loops 1 and 2 (Fay et a l,  1993). In contrast, ligand binding at the 
parathyroid hormone receptor is determined more by the N-terminal segment while 
interactions with extracellular loop 2 and the transmembrane domain 3 are involved 
more in receptor activation (Bergwitz et. al, 1997). The mechanism of activation of 
protease activated receptors differs from the other two receptors in that the receptor 
itself becomes its own ligand. Vu et al. (1991) have shown that protease action results 
in the cleavage of a section of the N-terminal segment of the receptor. Following 
protease cleavage the remaining N-terminal region essentially acts as a tethered ligand 
that in turn activates the receptor by binding to the extracellular loops. The principal 
contact point required for activation o f both the thrombin receptor, and the structurally 
related protease activated receptor 2, appears to be in extracellular loop 2 (Nanevicz et 
al, 1996; Lerner et a l ,  1996).
In addition to ligand binding there is evidence to suggest that conformational 
changes in extracellular loop structure can influence G-protein selectivity. Gilchrist et 
al. (1996) have demonstrated that while a mutation in the extracellular loop of the 
luteinizing hormone receptor abolishes its capacity to activate Gsa, it has no discernible 
effect on the capacity of the receptor to bind ligand or activate Gqa.
1,2.5 Cytoplasm ic loop s
Intracellular, or cytoplasmic loops, play a role in defining G-protein receptor 
specificity as well as in the transmission of the activated state o f the receptor to the 
cytoplasmic signalling molecule. In common with extracellular loops, cytoplasmic 
loops are variable in length and primary sequence. All G-protein coupled receptors 
possess at least 3 intracellular loops. In certain receptors, such as the pz adrenoceptor, a 
fourth cytoplasmic loop may be formed as a consequence of palmitoylation at 
conserved cysteine residues in the C-terminal tail (O’Dowd et a i ,  1989). Intracellular 
loops from receptors known to activate similar subsets of G-proteins vary considerably 
in primaiy sequence, and as of yet it has not been possible to determine a common rule 
for predicting the G-protein coupling specificity o f a receptor merely by analysing the 
primaiy amino acid sequence of the intracellular loops. Of the three loops, the first and 
second loops appear to be the most conserved, whilst the third intracellular loop linking 
transmembrane domains 5 and 6 appears to be the most variable in primary sequence 
and size. It is interesting to note that this variability in primary sequence can be related 
to the relative importance of the cytoplasmic loops in determining G-protein coupling
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and specificity. The order of importance in ascending order appears to be loopl, loop2 
and then loop3.
The importance of the cytoplasmic loops in determining G-protein specificity 
has been demonstrated through the use o f chimeric receptors in which one receptor 
donates either a portion or a majority o f the sequence for the third intracellular loop. 
Kobilka et al., (1988) have demonstrated that a chimeric adrenoceptor containing 
regions of the {32 adrenoceptor encoding most of transmembrane domain 5, intracellular 
loop3 and all o f transmembrane domain 6 can stimulate adenyiyl cyclase activity to a 
third of the level o f that seen with the wild type adrenoceptor. In contrast, a similar 
chimera containing only a small portion of the third intracellular loop displayed no 
activity at all. This would indicate that other determinants are required to determine 
efficient G-protein coupling and specificity. This is clearly demonstrated by the 
experiments of Wong et al. (1994) in which the third intracellular loops of the 
muscarinic acetylcholine receptors 1 and 2, which normally activate Gq« and Gia 
respectively, were replaced by the equivalent sequence of the p i adrenoceptor , a Gsa 
linked receptor. Interestingly, as opposed to activating the G-protein associated with the 
donor of the third intracellular loop, both chimeras activated all three classes of G- 
proteins with equal efficiency. Further introduction of both intracellular loops 1 and 2 of 
the p i adrenoceptor was required for the activation of Gsa exclusively. From these 
observations it appears that G-protein coupling determinants are scattered between the 
intracellular loops and that the three dimensional scaffold produced by all three 
intracellular loops may be more important than the contribution of any one loop alone 
(Bourne, 1997).
Many of the determinants involved in G-protein activation lie close to the 
junctions between the transmembrane domains and the intracellular loops. One well 
characterised example is the highly conserved glutamine/aspartate- arginine- tyrosine 
(ERY or DRY) sequence located at the junction of transmembrane domain 3 and 
intracellular loop 2. Substitution of the conserved arginine residue at the middle of this 
motif in rhodopsin has been shown to prevent activation o f bound Gta (Ernst et al.,
1995). The arginine residue of this DRY motif is thought to be constrained in a 
hydrophobic pocket formed by the interactions between polar residues from 
transmembrane domains 1, 2 and 7 (Scheer et al., 1996). It has been suggested that 
activation o f the aiB  adrenoceptor causes this arginine residue to leave the hydrophilic
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pocket and in doing so expose previously inaccessible sequences in the second and third 
intracellular loops (Scheer et al., 1996). Similar residues in the carboxyl end of the third 
intracellular loop of tire P2 adrenoceptor have also been shown to play an important role 
in G-protein activation. Deletion of residues at this position have been shown to 
significantly reduce the capacity of the receptor to activate adenyiyl cyclase (Hausdorff 
et al., 1990)
While many receptors contain only three intracellular loops, certain receptors, 
such as the p2 adrenoceptor and rhodopsin, can form a fourth intracellular loop through 
palmitoylation o f conserved cysteine residues in the C-terminal segment (O’Dowd et 
al., 1989). Where present, the relevance of the fourth intracellular loop appears to differ 
between receptors. O’Dowd et al. (1989) have demonstrated that substitution of 
conserved cysteine residues for glycine in the P2 adrenoceptor results in a non- 
palmitoylated form of the receptor which displays a reduced capacity to activate 
adenyiyl cyclase in response to isoproterenol stimulation. In contrast, the equivalent 
substitution in rhodopsin has been shown to have no discernible effect on receptor 
activity (Kam ikcr^/., 1988).
1.2.6.1 Transmembrane dom ains
All G-protein coupled receptors possess 7 putative transmembrane domains 
(TM’s) which are thought to span the cell membrane as a-helical structures. These 
transmembrane domains bundle together to fonn the transmembrane core. Not all of the 
a-helical transmembrane domains intersect the cell membrane at right angles. Analysis 
of the two dimensional crystal structure of rhodopsin by Schertler et al. (1993) provides 
evidence that some o f the a-helices cross the lipid bilayer at angles o f up to 30". The a- 
helices vary from 20 to 27 residues in length and may extend into both the cytoplasm 
and the extracellular environment. Evidence suggests that the a-helical structure may be 
further projected out of the cell membrane through a continuation of the helical 
structure by the connecting loops. Nuclear magnetic resonance (NMR) analysis o f the 
parathyroid hormone receptor by Mirke et al. (1996) has shown an a-helical structure at 
the amino terminus of the third intracellular loop. Similarly, NMR analysis of the C- 
terminal segment of rhodopsin by Yeagle et al (1996) has shown that the C-terminal 
segment of the receptor partially extends the a-helix o f transmembrane domain 7. Not 
all a-helices are of equal hydrophobicity, TMs 1, 4, and 7 are generally more
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hydrophobic than TMs 2, 3, 5 and 6. Differences in the hydrophobic potential of the 
helices may help detennine the relative orientation of the transmembrane domains in the 
lipid bilayer.
Many GPCR models are based upon the structure o f the functionally unrelated 
bacterial transporter, bacterial rhodopsin. A comparison of the high resolution crystal 
structure of bacterial rhodopsin with the structure of adrenergic receptors shows that in 
both proteins the transmembrane domains are arranged in a counter clockwise closed 
loop fonnation when viewed from the extracellular surface (Mizobe et al, 1996). 
Interactions between the transmembrane domains form the transmembrane core, which 
is thought to be stabilised by extensive intermolecular bonds including hydrogen 
bonding and salt bridges (Pebay-Peyroula et a i,  1997). These strong molecular 
interactions are thought to constrain GPCRs in their normally inactive conformation. 
Evidence of this comes from Robinson et al. (1992) who have shown that the disruption 
of a presumed salt bridge between TMs 3 and 7 in rhodopsin results in constitutive 
activation of the receptor in the absence of chromophore. It is presumed that this same 
salt bridge is broken upon normal receptor activation. Conversely, restriction o f 
movement between TMs 3 and 6 in rhodopsin through zinc binding at engineered metal 
binding sites has been shown to prevent receptor activation (Sheikh et al., 1996).
1.2.6.2 Functions of the transmembrane dom ains
Transmembrane domains are unique amongst all of the components of the G- 
protein coupled receptor in so far as that they can be involved in up to three different 
functions in the receptor. These include ligand binding, receptor activation and G- 
protein coupling. This multifunctional capability is due to the fact that the 
transmembrane domains are not only in contact with the lipid bilayer but also the 
extracellular environment and the cytoplasm. These three proprietary functions o f the 
transmembrane domains are examined in detail below.
1.2.6.3 Ligand binding
Ligand binding can either occur exclusively at the TM core, or in conjunction 
with ligand binding determinants present on the extracellular loops. Examples of 
receptors in which the ligand binds exclusively to the TM core include- biogenic amine 
receptors, nucleoside and nucleotide receptors, eicosanoid receptors and rhodopsin. Of 
these receptors rhodopsin and biogenic amine receptors are probably the best
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characterised. In rhodopsin the ligand 11-cis retinal is covalently bound as an inverse 
agonist through the formation o f a Schiff s base with a lysine residue in the middle o f 
TM 7 (Strader et a i,  1994). This protonated Schiff s base is in turn paired with a 
conserved glutamine residue present at the junction of TM3 and exoloop 1 (Strader et 
a i,  1994). Other interactions known to stabilise Tl-cis-retinal in the TM core include 
associations between the ionone moiety and residues in TMs 3, 5 and 6 (Han et al.,
1997).
Biogenic amine receptors have also been widely used to model ligand binding in 
the TM core. Of this subset o f receptors, the jJz adrenoceptor is the one that is probably 
the best characterised. Experiments using photoaffinity labelling (Wang et al., 1988) 
and fluorescent antagonists (Tota and Strader, 1990) have shown that catecholamine 
binding occurs 9 angstroms into the transmembrane core. The principal sites of ligand 
interaction being an aspartate residue in TM3 (asp 113) and the amine group o f the 
catecholamine ligand. Additional H-bonding between the meta and para hydroxyl 
groups of the catechol ring and serine residues in TM5 (ser 204, ser 207) are thought to 
constrain TM5 relative to TM3 and have been shown to be involved in receptor 
activation (Strader et al., 1994)
1.2.6,4 Receptor activation
In the absence of ligand the receptor is thought to be constrained in it’s inactive 
state by extensive intermolecular bonding in the transmembrane core. Evidence for this 
model comes from mutational studies in which intermolecular bonds in the TM core are 
either disrupted or strengthened. The introduction of additional bonds constraining the 
relative movement of the TM domains has been shown to prevent receptor activation 
even in the presence of extracellular stimuli. Elling et al. (1995) have demonstrated that 
zinc binding at engineered metal binding sites between transmembrane domains 5 and 6 
in the NK-1 receptor can prevent receptor activation. Similarly, Sheikh et al. (1996) 
have shown that zinc binding at equivalent sites between TMs 3 and 6 in rhodopsin has 
an equally restrictive effect. Activation of rhodopsin can also be prevented by the 
introduction of additional disulphide bonds into the TM core under oxidative conditions 
(Yu et al, 1995).
Ligand binding is thought to induce a conformational change in the receptor, 
which results in the disruption of constraining bonds in the TM core and so receptor
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activation. Once again evidence supporting this idea originates from mutational studies. 
Robinson et a l  (1992) have shown that the disruption o f a putative salt bridge between 
a lysine residue in TM7 and a conserved glutamate residue in TM3 of rhodopsin results 
in constitutive activity in the absence of chromophore. It is of interest to note that the 
same lysine residue in TM7 is thought to be linked to the ligand 11-cis-retinal through a 
protonated Schiff s base, and it is this bond which is thought to be broken upon 
isomérisation of 11-cis-retinal to the trans isomer.
The disruption of bonds in the TM core is thought to be followed by a 
movement of the TM domains into the plane o f the cell membrane resulting in receptor 
activation. Data supporting the movement of TM helices originates from site directed 
spin labelling experiments and spectroscopic methods. Using dual site directed spin 
labelling Farrens et al. (1996) have demonstrated that activation of rhodopsin results in 
the movement of TMs 3 and 6 away from each other, and the rest o f the helical bundle, 
into the plane o f the cell membrane. They also suggest that the activation o f rhodopsin 
causes TM6 to rotate 30" in a counter clockwise direction (when viewed from the 
extracellular surface) upon it’s own axis. This observation corroborates those of Lin and 
Sakmar (1996) who used tryptophan UV absorbance spectroscopy to arrive at the same 
conclusion.
1.2.6.5 G-protein coupling
Although there is no definitive proof of G-protein coupling at the TM domains, 
increasing evidence indicates that this may be a possibility. Through site directed spin 
labelling experiments Farrens et al. (1996) have demonstrated that activation of 
rhodopsin results in the separation of TM6 from TM3 at the cytoplasmic face of the 
receptor. Given the lack of movement seen in the rest of the transmembrane bundle, the 
movement of these two helices could open up a crevice to the TM core. The finding o f 
Javitch et a i  (1997) supports the existence of such a crevice. Javitch et al (1997) have 
shown that a cysteine residue in TM6 of a constitutively active p2 adrenoceptor is 
susceptible to modification by charged sulfhydryl specific reagents while the equivalent 
residue in the inactive wild type receptor is protected from such modifications. 
Photochemical cross linking experiments can position both G-protein a- and {3 subunits 
in close proximity to the third intracellular loop of the a- adrenoceptor (Taylor et a l,  
1994). Considering the close proximity of the G-protein with TM domains that have
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been shown to move upon receptor activation, it is not inconceivable that certain 
portions of the G-protein may protrude into the transmembrane core.
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1.3 G-proteins
Heterotrimeric GTP binding proteins, G-proteins, mediate the transduction of a 
signal from activated cell surface receptors, characterised by seven membrane spanning 
domains, to effector molecules. G-proteins are composed of three subunits designated 
a , p and y that vary in mass from 39-52, 35-36 and 7-8 IdDa respectively. The a-subunit 
is folded to form a guanine nucleotide binding pocket, which can accommodate either 
GDP or GTP. G-proteins can exist in either active or inactive conformations. In the 
inactive conformation the a-subunit contains GDP in the nucleotide binding pocket and 
is in tight association with the py subunits. G-protein activation occurs through receptor 
catalysed guanine nucleotide exchange in the a-subunit, resulting in the exchange of 
GDP for GTP. This guanine nucleotide exchange event causes a conformational change 
in the p-subunit binding site on the a-subunit. This conformational change in the P- 
subuttit binding site results in a lower affinity for the py dimer and consequently Py 
dissociation. The GTP bound a-subunit and the Py subunits are then free to interact with 
downstream effector molecules. G-protein signalling is attenuated by the hydrolysis of 
the terminal phosphate of GTP to yield GDP in the guanine nucleotide binding pocket. 
The hydrolysis of GTP to GDP results in a conformational change in the a-subunit that 
allows py subunit re-association and so reversion back to the inactive heterotrimeric 
state.
1.3.1 G-protein a-subunits
At present 20 members of the G-protein a-subunit superfamily have been 
identified encoded by at least 16 different genes. Family members vary in mass from 39 
to 52 kDa and constitute the largest single subunit in the G-protein heterotrimer. The a- 
subunit superfamily can be subdivided into four distinct classes based upon sequence 
homology and effector specificity. These four groups are designated Gsa, Gia, Gqa and 
Gi2/i3a- Of these four groups G-proteins from the Gi and Gs class have been shown to 
have opposing functions, with Gs and Gi stimulating and inhibiting the activity of the 
secondary effector adenyiyl cyclase respectively. Other classes of a-subunits couple to 
alternate effectors, for instance members of the Gqa subclass are known to stimulate the 
secondary effector phospholipase C-p. In contrast to the other classes of a-subunit, the 
functional roles of G12a and G ^a are poorly defined, although it has been proposed that
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these G-proteins may mediate activation of voltage dependent Ca^^ channels (Wilk- 
Blaszczak et a l ,  1997) and regulate Na' /^H'  ^exchange (Hooley et al, 1996).
1.3.2. Gs family
The term Gsa refers to the capacity of subunits in this class of G-protein to 
activate the secondary effector adenyiyl cyclase. Adenyiyl cyclase is an integral 
membrane protein which catalyses the formation of the secondary messenger cyclic 
AMP (cAMP). Cyclic AMP acts as a signalling molecule, relaying the initial signal to 
additional components of the signal transduction cascade. Signalling by cyclic AMP is 
attenuated by cAMP specific phosphodiesterases which hydrolyse cAMP to 5’-AMP.
The capacity of Gs a-subunits to activate adenyiyl cyclase was first observed by 
Pfeuffer and Helmreich (1975) who saw that adenyiyl cyclase activity in pigeon 
erythrocyte membranes could be stimulated by GTP binding at a specific GTP binding 
protein. This protein was later pui'ified and characterised by Northup et a l  (1980) who 
demonstrated that this “regulatory component of adenyiyl cyclase” was composed of 
more than one polypeptide chain. It is now known that alternate splicing of a single Gsa 
gene results in the production of four splice variants, termed Gsai, Gsa2, Gsa3 and Gsa4, 
which collectively show ubiquitous tissue distribution (Bray et a l ,  1986). This gene is 
approximately 20 Kb long and is subdivided into 13 exons and 12 introns (Kozasa et al, 
1988). Each of the splice variants differs in amino acid length, ranging from 380-381 
residues for Gsa3 and Gsa4 to 394-395 residues for Gsai and Gsa2 respectively (Bray et 
a l,  1986). Analysis of the primary sequence of these splice variants has highlighted 
many similarities between the splice variants. For example, with the exception of a 15 
amino acid sequence, Gsas and Gsa4 are identical. The loss of this sequence is a 
consequence of alternate splicing of exon 3 of the Gsa gene. A similar relationship exists 
between Gsa4 and Gsa2- In addition to this variation, Gsai/Gs«2 and Gsa3/Gsa4 are 
identical bar an extra amino acid which can be accounted for by 3 nucleotides (GAG) 
which reside 5’ to the end of exon 4.
The four splice variants are commonly known as Gsa long, Gsa(L) (Gsai/Gsa2) and 
Gsa short Gsa(S) (Gsa3/Gsa4) depending on the length of their sequence. Despite the 
diversity of these splice variants, no functional significance can be attributed to the 
insertion/deletion of amino acid sequences, and all four splice variants retain the
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capacity to activate the 9 known mammalian adenyiyl cyclases. The splice variants are 
also equally good substrates for ADP ribosylation by the bacterial toxin CTX.
The second subunit in this class of G-protein, Goifa, is quite distinct from the 
splice variants of Gsa in that it is largely localised to the olfactory neuroepithelium, 
where it is though to mediate signalling by the large family of olfactory receptors. 
Despite this centralised tissue distribution, Goifa shares 88% amino acid identity with 
Gsa and also activates adenyiyl cyclase (Hep 1er et al., 1992).
1.3.3.1, Gi family
Although the term Gi stands for inhibitor of adenyiyl cyclase activity, not all of 
the G-proteins in this class o f G-protein can regulate this function. In fact a-subunits in 
this class of G-protein probably modulate the most diverse set of effectors seen in any 
class of G-protein. Inclusion into this family is based more upon sequence homology 
than similarity in effector modulation. A noticeable similarity between all of the 
members of this group, with the exception of Gza, is their susceptibility to pertussis 
toxin catalysed ADP-ribosylation. Pertussis toxin, a toxin from the bacterium Bordetella 
pertussis, catalyses the transfer of the nucleoside ADP ribose from NAD to a conserved 
cysteine residue located four residues from the C-terminus in almost all o f the a- 
subunits in this class of G-protein. This covalent modification results in the uncoupling 
of the G-protein from its cognate receptor. No such modification is seen in G^a, which 
contains an iso leucine residue at this position.
At present the Gi class of G-proteins contains three Gia family members, termed 
Giai, Gia2 and Gias (Jones and Reed, 1987). Although all three members have been 
shown to directly inhibit the activity of the secondary effector adenyiyl cyclase in vitro 
(Taussig et a l,  1993), their physiological roles are thought to be more diverse.
1.3.3.2 Giai
At 40.3 kDa, Giai is the smallest of the thi'ee Giax subunits. Giai shows no 
distinct localisation, although it tends to be highly expressed in neural and endocrine 
tissues. With the exception of Gza, Gi family members have some of the highest 
catalytic activities of any of the a-subunits. The catalytic activity of Giai has been 
estimated to be kcat(min'^) =2.4 at 20 "C. This feature makes them particularly well
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suited for analysis by guanine nucleotide exchange based assays such as binding of the 
non-hydrolysable GTP analogue, [^^SjGTPyS ([^^SjGTPyS binding) or hydi’olysis of ^ ^P 
labelled GTP (GTPase). In common with most of the a-subunits of this class of G- 
protein, Giai contains a conserved cysteine residue 4 amino acids from the C-terminal 
tail . This residue allows the potential use of pertussis toxin (PTX) as a tool to 
functionally uncouple this G-protein from its cognate receptors.
The physiological role of Giai is thought to be quite distinct fr om its capacity to 
inhibit adenyiyl cyclase activity. The high neuronal tissue concentration of Giai has 
been linked to its capacity to indirectly regulate ATP sensitive and inwardly rectifying 
potassium channels through Py subunit dissociation.
1.3.3.3 G|a2
Gia2 has a slightly greater mass than Gjai at 40.5kDa and a catalytic activity of 
kcat(min'^) 2.7 at 20"C. O f the three Giax subunits, Gia2 shares the least homology with 
Giai with 88% amino acid identity. However, in common with other a-subunits of this 
class Gia2 contains the conserved PTX ADP-ribosylation site at its C-terminal tail. As 
with the other Giax family members, Gi«2 can be found in almost eveiy tissue type.
Although all three Giax subunits can directly inliibit adenyiyl cyclase activity in 
vitro (Taussig et al., 1993) evidence suggests that Gi„2 is the main regulator of this 
function in vivo. For example McKenzie and Milligan (1990) have shown that the 
inhibition of forskolin stimulated adenyiyl cyclase activity can be attenuated by a Giai 
specific antiserum in a NG-108-15 hybrid cell line. The inhibition of adenyiyl cyclase 
activity may not be the only physiological role of this subunit. Yatani et al. (1988) have 
demonstrated that the addition of activated Gia2 to membrane patches from cardiac 
myocytes stimulates potassium channel opening in a PTX sensitive manner.
1.3.3.4 Gict3
Although Gia3 has the same molecular mass as Giai (40.5kDa) it shares 
significantly more amino acid identity with Giai (94%) than Giai- As with the other two 
Giax subunits, this protein is nearly ubiquitous in all tissue types and is a substrate for 
pertussis toxin catalysed ADP-ribosylation. At kcat(min"^) of 1.8 at 20 "C, Gia3 has the 
lowest catalytic activity of the three Giax subunits. While Gi«3 can inhibit the activity of
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adenyiyl cyclase in vitro, its physiological role is thought to involve the activation of 
ion channels. For example, Schwiebert et al (1990) have obseiwed Gi«3 mediated 
stimulation of a large conductance renal apical C f channel in rabbit kidney CCD cells. 
Yatani et al {1988) have also shown that Gias can activate potassium channels in cardiac 
myocytes. Evidence also suggests that Gi«3 may modulate membrane trafficking in 
certain cell lines. For example, Stow et al. (1991) have shown that over expression and 
localisation of G;a3 in the Golgi apparatus of the LLc-PKl kidney cell line reduces the 
rate of protein secretion and trafficking in a PTX sensitive manner.
1.3.3.5 Goa
Goa cr “G-other” proteins were first purified from bovine brain where they 
account for a remarkable 1-2% of membrane protein. At present two splice variants are 
known. Goal and Goal, both of which share 73% amino acid identity with Giai- Both 
splice variants originate from the same gene and arise from alternate splicing of exons 7 
and 8 (Kaziro et al., 1991). The resultant a-subunits differ in both C-terminal sequence 
and molecular mass (Goai=40kDa, Goa2=40.1kDa). More significantly, unlike the splice 
variants of Gsa, the two alternately spliced Goa subunits appear to discriminate between 
different receptors. Evidence of this comes from Kleuss et a/. (1991) who observed that 
calcium channel activity in rat GH3 pituitary cells can be attenuated by Goal coupling to 
the muscarinic receptor or Goai coupling to the stomatostatin receptor respectively. In 
common with Gia3, Goa has an estimated catalytic activity of kcat(min'’) 1.8 at 20"C
1.3.3.6 Gta
At present two isoforms of Gta, or G-transducin, have been identified both of 
which shai*e a 68% amino acid identity with Giai- The two isoforms, termed Gtai and 
Gta2, are highly localised to two specific tissue types associated with light and colour 
perception. Gt«i is found exclusively in retinal rod cells where it couples with the visual 
receptor rhodopsin, while Gtai is located in retinal cone cells where it couples to cone 
opsin. Despite their discrete locations, both subunits are thought to activate a common 
secondary effector, a cyclic GMP (cGMP) specific phosphodiesterase (Chambre and 
Detene, 1989). The activated phosphodiesterase hydrolyses the secondary messenger 
cGMP, which in the absence of agonist has been shown to maintain various ion
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channels in an open state (Fresenko et al., 1985). Depletion in the levels of cGMP 
results in the closure of potassium ion channels and so membrane polarisation.
Gtai displays the highest catalytic activity o f any of the G-protein a-subunits 
(kcat(min'*)=3.6 at 20 "C). It is also one of the two members of the Gi family which can 
be post translationally modified by both pertussis toxin and cholera toxin.
1 ,3.3.7 O g u sta
G-gustducin, or Ggusta, was first identified by McLaughlin et al (1992) in taste 
receptor cells where its expression appears to be limited to 40% of the cellular 
population. Evidence suggests that Ggusta is involved in sweet/bitter taste perception 
(McLaughlin et al,, 1992). Gustducin is thought to be the taste receptor homologue of 
transducin, this is reflected by its tissue specific location and the fact that it shares 
greater homology with Gta (80%) than with Giai (68%). Additional evidence from Hoon 
et al. (1995) has shown that Ggusta and Gta share many functional similarities. Using a 
baculovirus expression system in insect Sf9 cells, Hoon et al. (1995) have demonstrated 
that Gta and Ggusta are functionally identical with regard to interactions with bovine 
rhodopsin, py heterodimers, cGMP specific phosphodiesterase activation and nucleotide 
exchange rate. In common with Gt«, Ggusta is thought to be modified by both PTX and 
CTX.
1.3.3.8 Gza
Gza displays highly specific tissue distribution in platelets, chromaffin and 
neuronal cells with long axonal processes (Fong et al, 1988; Casey et a i,  1990, 
Matsuoka et a l ,  1988). O f all of the Gi family members, Gza shares the least amino acid 
identity with Giai (60%), this is reflected in its unique biochemical properties.
In addition to having a slow guanine nucleotide exchange rate (koff= 0.02/miif ^ 
at 30°C) , Gza possesses one of the lowest catalytic activities seen in any of the a- 
subunits (kcat(min'^)=0.05 at 30"C). This low catalytic activity, which is approximately 
200 times lower than that of Giai, and guanine nucleotide exchange rate may be due to 
its unusually high Mg^ "^  requirements for guanine nucleotide binding. A similar Mg^^ 
dependence for GDP binding in small nucleotide binding proteins such as Ras has been 
shown to reduce GDP dissociation by up to four orders of magnitude (John et al., 1993).
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Gza is also the only a-subunit in the Gi family that cannot be modified by PTX 
treatment. An isoleucine residue as opposed to a cysteine residue four amino adds from 
the C-terminal tail confers insensitivity to this bacterial toxin.
Evidence suggests that Gza may play a role in regulating adenyiyl cyclase 
activity. Wong et al. (1992) have shown that co-transfection of Gza with the Di 
dopamine, Ai adenosine, lysophosphatidic acid or a i  adrenergic receptors into HEK293 
cells allows PTX resistant inhibition of adenyiyl cyclase activity upon activation of 
these receptors. Another study using intracerebroventricular injection of antisense Gza 
oligonucleotides into rats has highlighted a possible nociceptive role for this a-subunit 
(Sanchez-Blazquez a/., 1995).
1.3.4 Gqa family
The Gqa family contains 5 subunits designated Gqa, Gna, Gi4a, Gisa and Giea- 
All family members lack the conserved cystene residue seen in the C-terminal tail of Gi 
family members and are so resistant to PTX modification. Additionally, unlike the Gi 
family members, all members of the Gq family share a common effector, phospholipase 
C-p (PLC-p). Phospholipase C-p catalyses the hydrolysis of phosphatidylinositol 4,5 
bisphosphate to generate two secondary messengers, inositol 1,4,5 trisphosphate (IP3) 
and diacylglycerol (DAG). IP3 regulates the flow of Ca^ "^  from the endoplasmic 
reticulum to the cytosol, where in combination with the secondary messenger DAG it 
can activate the secondary messenger kinase, protein kinase C (PKC). Evidence 
suggests that members of this G-protein family activate at least two of the three 
isoforms of PLC-P, PLC-pi and PLC-Pi (Lee et al., 1992). Out of the five Gqa family 
members only Gq« and Gua show ubiquitous tissue distribution. Expression of Gi4a 
appears to be more localised to stromal cells, while Gisa and Giga expression is 
restricted to hematopoietic B and T cells respectively (Wilkie et al., 1991; Amatruda et 
al. 1991).
Differences in the N-terminal regions of Gqa and Gii« account for most of the 
disparity in sequence homology between these two proteins. The 12% difference in 
amino acid identity between Gqa and Gna lies in a region known to be concerned with 
nucleotide exchange and hydrolysis as well as py subunit binding. It has therefore been 
postulated that these differences may play a role in determining PLC-p isoform
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specificity as well as the catalytic activity of the G-proteins (Simon et a l ,  1991). Gq« 
and Glia also contain a unique 6 amino acid extension at the N-terminus of the protein. 
This extension may help define receptor selectivity, as a deletion or mutation at this 
region has been shown to allow coupling of these a-subunits to non Gq« coupled 
receptors (Kostenis et al., 1997; Kostenis et al., 1998). Other members of this subfamily 
aie more distantly related to Gq«, with G Ma, Gisa and Gica displaying 79%, 57% and 
58% amino acid identity respectively.
Despite their restrictive expression patterns in hematopoietic B and T cells, G Ma 
and the murine homologue Gisa appear to couple to a wide anay of receptors. 
Offermans et al. (1995) have demonstrated functional coupling of Giea and Gisa to the 
Mi muscarinic, Pi adrenergic, Vi vasopressin, dopamine Di and adenosine Ai receptors. 
In all cases stimulation of the receptor in question led to the activation of the G15/16a 
secondary effector PLC-p. This promiscuity in receptor coupling has led to the 
suggestion that Gi6a may function as a universal G-protein adapter (Milligan et a l,
1996), The potential use of such an adapter protein has been realised in the development 
of a novel assay to detect the activation of G-protein coupled receptors via an aequorin 
reporter system (Green et al., 1997). In addition to its unusual receptor promiscuity, 
Gi6a appears to discriminate between different PLC-p isoforms. Lee et al. (1992) have 
demonstrated that while Gqa and Gna preferentially activate PLC-p 1, G Ma shows 
greater stimulation of PLC-Pi. The activation of PLC-P may also serve to autoregulate 
the activity of Giea- As described earlier, activation of PLC-P generates the secondary 
messengers IP3, which increases cytoplasmic Ca^^ levels, and DAG that in combination 
with Ca^^ activates the secondary messenger kinase PKC. Aragay et al. (1999) have 
shown that direct stimulation of PKC activity can attenuate G Ma mediated TRH 
signalling in COS-7 cells co-transfected with G Ma and the TRH receptor. This effect 
can also be mimicked by repeated stimulation of the TRH receptor and is correlated 
with an increase in PLC-p activity. Furthermore, this attenuation of TRH response is not 
seen in cells co-transfected with a mutant G Ma isoform lacking four PKC 
phosphorylation sites.
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1.3.5 Gi2/i3a family
Gi2a and Gisa are both 44kDa proteins and share a 67% common amino acid 
identity. In common with Gza, Gna and Gua display low rates of guanine nucleotide 
exchange (Fields et a l,  1997). Despite their extensive tissue distribution, veiy little is 
known about the physiological roles of Gna and Gisa- Recent studies have revealed 
several possible roles for these subunits, although none of these have been proved 
conclusively. Since both proteins are ubiquitously expressed it has been suggested that 
they regulate a diverse array of effectors. Increasing evidence suggests that both Gna 
and G 13a can regulate Na'^/fff exchange. Dhanasekaran et al. (1994) have demonstrated 
that transfection of mutationally activated Gna or Gua subunits can increase Na^/H^ 
activity 2.5 fold in COS-7 cells. A similar effect has been observed upon activation of a 
Gi3a/Gza chimera by Gi coupled receptors (Voyno-Yasenetskaya et a i,  1994a). Gi3« 
stimulation of Na’*'/H^  exchange is thought to be mediated through Cdc42/MEKK and 
Rho dependent pathways (Hooley et a/., 1996).
Experimental evidence also suggests that Gna and Gi3a are also involved in 
growth regulation. Aragay et a l  (1995) have demonstrated increased AP-1 mediated 
transcriptional activation in 1321 astrocytoma cells upon expression of a constitutively 
active Gna mutant. Constitutively active mutants of Gna and Goa have also been 
shown to transfonn NIH 3T3 and RATI fibroblasts (Chan et al., 1993; Jiang et al., 
1993; Xu etal., 1993; Voyno-Yasentskaya et a l ,  1994b).
Conversely, many effectors have been excluded from direct regulation by either 
Glia or Gi3«. Using purified a-subunits, Kozaza et al. (1995) and Singer et al. (1994) 
have demonstrated that neither Gna or Gua can regulate the effectors PLC(pi, Pz, Ps 
and ôi), phospholipase D, adenyiyl cyclase (types I, II and IV) or phosphoinositidase 3- 
kinase activity in in vitro based assays.
1.3.6.1 Post translational modification of a-subunits
Following translation, the a-subunit may be modified by a variety of factors 
both endogenous (e.g. PKC) or of foreign origin (e.g. PTX). Endogenous factors have 
been shown to be involved in regulation of a-subunit activity and are required for 
correct G-protein function. In contrast, external factors which regulate G-protein 
activity are invariantly of pathogenic origin and therefore detrimental to G-protein
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signalling. There are four main post-translational events that affect G-protein a - 
subunits; these include phosphorylation, ADP-ribosylation, palmitoylation and 
myristoylation. Each of these events and their associated factors will now be discussed 
in detail below.
1.3.6.2 Phosphorylation
Regulation of G-protein mediated signalling by phosphorylation at the level of 
the receptor is a highly characterised, well-established phenomenon. Increasing 
evidence now suggests that phosphorylation of the G-protein a-subunit may play a 
similar role in the attenuation of signalling by this receptor superfamily. At present, 
phosphorylation has only been detected in four of the 20 known a-subunits; these 
include Gza, Giza, G Ma and the murine homologue Gisa* The limited number of a - 
subunits which are substrates for phosphorylation suggests that phosphorylation of the 
a-subunit may not be a universal system of G-protein regulation. In instances where no 
G-protein phosphorylation is detected, signalling may be attenuated by alternate means 
such as receptor phosphorylation.
Numerous studies suggest that the secondary messenger kinase PKC is the 
principal component in a-subunit phosphorylation. Evidence of this was first presented 
by Katada et al. (1985) who demonstrated phosphorylation of a 44 kDa Gi a-subunit in 
platelet membranes upon the addition of purified PKC. This phosphorylated a-subunit 
was later shown to be Gza through systematic elimination of all other a-subunits in this 
G-protein family (Loansbury et al., 1991). The mechanism by which phosphorylation 
attenuated Gza signalling was not resolved until 1995 when Fields and Casey (1995a) 
demonstrated that phosphorylation at the a-subunit inhibited Py subunit binding and so 
the formation of the G-protein heterotrimer. This was followed by a similar observation 
for Glia (Fields and Casey, 1995b), suggesting that phosphorylation may attenuate 
signalling through a single common mechanism.
The secondary messenger kinase, PKC, is activated by a combination of Ca^^ 
and diacylglycerol (DAG), the intracellular levels of which are elevated upon activation 
o f the secondary effector PLC-p. Since PLC-P is itself activated by the Gqa family 
members G Ma and Gisa, phosphorylation may serve as an autoregulatory feature at 
these G-proteins. Evidence of this autoregulatory feature has been demonstrated in two
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Gqa family members Gi6a and Gisa, by Aragay et a l  (1999). Aragay et al  (1999) have 
demonstrated that repeated stimulation of the Gqa linked TRH receptor results in 
eventual signal attenuation. This effect has been correlated to increased phosphorylation 
at Gi6a and the murine homologue Gi5a. The observation that this effect can be 
mimicked by PKC activators implicates the involvement of PKC in this regulatory 
pathway. The involvement of PKC was corroborated by the fact that attenuation of 
signalling was lost when a mutant Giga subunit lacking PKC phosphorylation sites was 
used in the above experiments. On a final note, this autoregulatory feature appears to be 
peculiar to Giea and Gisa as none of the other G-proteins in this family were seen to be 
phosphorylated (Aragay et a i ,  1999).
1.3.6.3 ADP-ribosylatîon
Various members of the G-protein superfamily have been shown to be substrates 
for ADP-ribosylation by bacterial toxins. Since ADP-ribosylation has the effect of 
disrupting signalling through susceptible G-proteins, bacterial toxins have proved to be 
useful tools in elucidating G-protein signalling pathways. Two bacterial toxins which 
have been used extensively in such studies are pertussis toxin (PTX) from the bacterial 
Bordetella pertussis and cholera toxin (CTX) from the pathogen Vibrio cholerae. Both 
of these toxins catalyse ADP-ribosylation at different residues on the a-subunit and 
therefore have vastly different effects. They also demonstrate a high degree of substrate 
selectivity, with very little overlap between the two toxins.
Pertussis toxin, from Bordetella pertussis^ was first discovered by Kadata and Ui 
in 1977. This toxin was previously designated “islet activating protein” in accordance 
with its capacity to abolish aa-adrenergic signalling in the pancreas. Peitussis toxin has 
since been shown to exert its effect through the Gi family of G-proteins. All members of 
this G-protein family, with the exception of Gza that contains an isoleucine residue, 
possess a cysteine residue four amino acids from the C-terminal tail. Pertussis toxin 
catalyses the transfer of an ADP-ribose group from a NAD^ molecule to this cysteine 
residue (West et al., 1985). This catalytic event involves the formation of a PTX/NAD^ 
transition state complex before final docking to the G-protein acceptor (Scheuring et aL,
1998). It appears that Py subunits are required for efficient PTX catalysed ADP- 
ribosylation, although it should be noted that they have little effect upon the catalytic 
rate of the toxin (Scheuring et a i ,  1998). This has led to the suggestion that py subunits
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may aid docking of the PTX/NAD ^  complex to the G-protein. Alternatively, py subunits 
may preseive the C-terminal tail of the a-subunit in a disordered conformation so 
allowing toxin access to the conserved cysteine residue. The acceptor site for PTX 
catalysed ADP-ribosylation lies in the C-terminal tail of the a-subunit. Numerous 
studies have shown this region to be a critical determinant in receptor coupling and 
specificity. It is therefore not surprising to learn that ADP-ribosylation at this site blocks 
G-protein receptor coupling tlnough presumably unfavourable steric interactions. 
Unable to couple to an activated receptor, the ADP-ribosylated heterotrimer is locked in 
the inactive GDP bound state.
The second toxin, cholera toxin (CTX), from Vibrio cholerae is quite distinct 
from PTX in both its site of ADP-ribosylation and its modulatory effect. Cholera toxin 
catalyses the transfer of ADP-ribose from NAD"  ^ to a conserved arginine (201) located 
in the middle of the Q^J Gta subunit. This arginine residue is proposed to stabilise a 
negative charge on the terminal phosphate of GTP, so aiding GTP hydrolysis (Sprang,
1997). It is therefore not suiprising to note that ADP-ribosylation at this arginine 
residue abolishes the capacity of the subunit to hydrolyse GTP. Since this modification 
does not alter the capacity of the subunit to bind GTP, once activated the a-subunit is 
locked in its activated state. In common with PTX, CTX requires Py subunits for 
efficient ADP-ribosylation. Although the requirements for Py subunits are unclear, it has 
been proposed that these subunits aid docking of the toxin or stabilise the a-subunit in a 
conformation amenable to the toxin. Despite their substrate specificities, both toxins can 
ADP-ribosylate transducin, which contains both acceptor sites (Van Dop et aL, 1983; 
West et aL, 1985).
1.3.6.4 Palmitoyiation and myristoyiation
Although palmitoyiation and myristoyiation occur independently, both 
modifications contribute to the membrane attachment of a-subunits. Palmitoyiation and 
myristoyiation appear to play different roles in this process, in so far as palmitoyiation 
appears to be a more temporary modification than myristoyiation.
The post-tianslational process of myristoyiation involved the addition of a 14- 
carbon fatty acid, myristate, to the N-terminus of the G-protein a-subunit. This event 
occurs at a well-defined consensus sequence chaiacterised by a glycine residue followed
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by a hydroxylamine residue four amino acids further downstream. G-protein a-subunits 
known to be myristoylated include Giai, Gi«2, Gias, Gta and Gza- Notable exceptions to 
this list are Gsa and Gq«, both of which have been shown to be alternatively modified by 
palmitoyiation. In contrast to palmitoyiation, myristoyiation is a permanent event and is 
therefore not expected to play a regulatory role in G-protein signalling.
Palmitoyiation and myristoyiation are not mutually exclusive events, and many 
of the a-subunits known to be myristoylated are also palmitoylated. Subunits known to 
be palmitoylated include Goa, Giai, Gia2, Gi«3, Gza Ggusta, Gqa and Gsa- Palmitoyiation 
involves the addition o f palmitate, a 16 carbon fatty acid, to a cysteine residue located at 
the N-tenninus of the G-protein a-subunit. Cysteine residues known to be palmitoylated 
include cysteine 3 in Gs« and Goa (Degtyarev et aL, 1993; Parenti et aL, 1993) and 
cysteine 9 and 10 in Gq« (Wedegaertner et al, 1993). Palmitoyiation is a reversible 
process, whose half-life has been estimated to be 50-90 minutes at the inactive a- 
subunit or 2 minutes upon G-protein activation (Wedegaerdner and Bourne, 1994). This 
has led to the suggestion that palmitoyiation may be used to regulate G-protein activity 
by varying the affinity of the a-subunit for the cell membrane. This could presumable 
attenuate signalling by removing the inactive G-protein from the immediate 
environment of the activated receptor (Wedegaertner et aL, 1995).
1.3.7 Py subunits
Although the Py heterodimer is composed of two independent polypeptides, it 
functionally acts as a monomer that cannot be divided into its individual components 
except in strongly denaturing conditions. At present six p and 12 y subunits have been 
identified, ranging in molecular mass from 35 to 36 kDa for the p subunit and 6-9 kDa 
for the y subunit respectively. P subunits show less sequence diversity (50-90% amino 
acid identity) than the significantly smaller y subunits that share between 30 and 80% 
amino acid identity. Not all combinations of p and y are possible. For example, the Gta 
associated yi subunit can form a dimer with pi but not p2 despite the 93% amino acid 
homology between these two P-subunits (Iniguez-Lluhi et aL, 1992; Pronin and 
Gautam, 1992; Schmidt et aL, 1992). Chimeric studies have highlighted a Phe residue at 
position 40 in the yi subunit that mediates the specificity of py heterodimer 
combinations (Lee et al, 1995) It is assumed that the side chain o f the Phe 40 residue
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slots into a complimentary cavity which is defined by a Leu residue at position 300 on 
the pi-subunit. The strength of this association is thought to be governed by the size of 
the side chain of residue 40 and the depth o f the cavity on the Pi subunit. (Sondek et aL,
1996).
Resolution of the crystal sti'uctures of both free Piyi and Piy? as pait of a Giai 
heterotrimer suggest that different isofonns of py share many common structural 
determinants (Sondek et aL, 1996; Wall et aL, 1995). Structurally, the p subunit appears 
to be composed of two distinct domains, an N-terminal helical domain and a 
significantly larger “p-propeller” domain (Fig. 1.2). The N-terminal domain is 
composed of a relatively simple helical structure approximately 20 residues in length. In 
contrast to this, the p-propeller domain is approximately 300 residues long and is 
composed of seven repeating WD motifs that fold to form a seven bladed P-propeller 
structure. Each of the WD repeats is approximately 43 residues long and is 
characterised by a conserved core of amino acids which are flanked by Gly-His (GH) 
and Trp-Asp (WD) motifs. The WD repeats are separated by a region more variable in 
length (6-94 residues). Each blade of the p-propeller structure is composed of four anti­
parallel strands, which associate to form a four-stranded twisted P-sheet. No single WD 
repeat corresponds to a p-propeller blade or any stable independently expressible 
domain. Instead, each WD repeat comprises the inner three stiands of a single blade and 
the C-terminal strand of the adjacent propeller blade. The outer strand of the seventh 
blade is provided by the N-terminal strand of the first WD repeat. This serves to close 
and presumably stabilise the seven bladed circular structure. Additional stabilisation of 
the structure may be provided by hydrogen bonding between highly conserved Asp 
residues in the middle of the WD repeat and the histidine residue in the GH flanking 
sequence.
In contrast to the p subunit, the y subunit has little or no tertiary structure and is 
composed of two helical segments joined together by a loop. The y subunit is subject to 
post-translational modification and may be isoprenylated at a CAAX (C-aliphatic- 
aliphatic-any amino acid) motif at the C-terminus. Isoprenylation may take the form of 
farnesylation or geranylgeranylation depending upon the identity of the terminal amino 
acid in the motif (Casey et aL, 1994). Isoprenylation is considered to be important for 
membrane localisation of the Py dimer and so correct flinction of this subunit. The
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Figure 1.2 A 3-Dlm ensional representation of the piy2 
heterodimer
Figure 1.2 represents the three dimensional structure of the Piya heterodimer as 
resolved by Wall et al.{1995). The y subunit is represented as a darkened region 
extended across the circumference of the p-subunit. The first WD repeat in the p- 
subunit is also shown as a darkened region, with shading heavier than at the y subunit. 
The propeller blades of the P-subunit are numbered 1-7 from the N-terminus of the 
protein.
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Figure 1.2
1
association between the p and y subunits is stabilised at two distinct points. The first o f 
these is a coiled coil interaction between the N-terminal helices of both subunits. 
Secondly the y subunit extends across the circumference of the p-propeller where it 
makes extensive hydrophobic interactions with the outer strands of blades 1 , 5 , 6  and 7 
(Fig. 1.2). The lack of intrachain interactions in the y subunit may explain the sti'ong 
association between the py subunits.
The G-protein a-subunit is thought to associate with the Py dimer tlirough two 
principal contact sites, the N-terminal helix and the switch II region. The N-terminal 
helix of the G a subunit is thought to dock alongside the residues in the C-D stiands of 
first propeller blade of the p subunit, parallel to the central tunnel of the p-propeller. 
This interaction is presumed to be stabilised by hydrophobic modifications at the C- 
terminus o f the y subunit and the N-terminus of the a-subunit. These modifications are 
thought to localise the two subunits in the same general vicinity of the lipid bilayer 
(Lambright et aL, 1996; Wall et al, 1995). Removal of the N-terminus has been shown 
to disrupt heterotrimer formation in Gt« , Go«, Giai and Gsa (Navon et ai, 1987; Graf et 
a l,  1992; Joumot et a l ,  1991). The switch II region of G a is orientated directly above 
the central tunnel formed by the blades of the p-propeller. In the pi subunit, 
hydrophobic interactions are thought to be centred around the conseiwed Tip 99 and Trp 
332 residues. This is supported by evidence that a mutation of a residue equivalent to 
that of Trp 99 (Trp 136) in the P-subunit of S.cerevisciae to glycine results in 
constitutive activation of the mating pathway by presumably disrupting heterotrimer 
formation (Whiteway et aL, 1994). The switch II region of the a-subunit is known to 
undergo a conformational change upon binding GTP. It is therefore presumed that 
nucleotide exchange in the a-subunit results in the switch II region being drawn into the 
a-subunit, thereby disrupting a-py subunit interactions and so allowing heterotrimer 
dissociation. Dissociation of the G-protein heterotrimer is thought to uncover important 
effector contact sites on both the a - and the py subunits.
A functional role for Py was not discovered until 1987 when Logothetis et aL 
Demonstrated activation of cardiac channels by py subunits purified from bovine 
brain. Since then the list of effectors known to be regulated by py has grown to the point 
where py subunits are recognised as important signalling molecules in their own right, 
py subunits can function both independently of the G a subunit or they can act in
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combination with the G a signalling molecule in either a synergistic or antagonistic 
manner. Examples of effectors known to be modulated by py subunits include- 
phospholipase Az, yeast mating response, Ca^^ channels, adenylyl cyclases, 
phospholipase C and receptor kinases (Clapham and Neer, 1993). Of these examples, 
adenylyl cyclase is probably the best characterised effector known to be modulated by a 
combination of both a- and py subunits. The effects of py have been shown to be both 
antagonsitic (Type I) and synergistic (Types II, IV) for the various adenylyl cyclase 
isoforms (Tang et aL, 1991). However, the effects of py on these isoforms is conditional 
upon prior activation by Gsa- In contrast, the synergistic or antagonsitic activity of Py 
subunits on the secondaiy effector PLC-p are not conditional on priming by either 
subunit. These obsei*vations suggest that convergence of signalling between Py and a- 
subunits may provide a “fine tuning” mechanism to modulate the intracellular effects of 
an agonist.
At present, the effector contact sites on the py subunit are not well defined. 
However, the similarity in the structure of the free py subunit with its counterpart in the 
G-protein heterotrimer suggests that the principal effector contact sites are sequestered 
by a-subunit binding. Evidence supporting this comes tfom Chen et aL (1995) who 
demonstrated that a peptide fi'om adenylyl cyclase type II can block py subunit 
activation o f both PLC-P and an inward rectifier IC^  channel. This peptide was later 
cross linked to a region on the P-subunit known to be involved in a-subunit binding 
(Chen et aL, 1997). Other regions thought to be involved in effector regulation include 
the N-terminal coiled coil and P-propeller blades 1 and 7 (Hamm, 1998).
1.3.8 G-protein a-subunit structure
The three dimensional crystal structures have been resolved for a variety of GTP 
binding proteins complexed with both guanine nucleotides and guanine nucleotide 
analogues. Analysis of the crystal structures of Ras, Giai and Gt« have provided insights 
into the relationship between G-protein structure and function (Pal et al., 1990; 
Coleman et aL, 1994; Noel et aL, 1993). The G-protein a-subunit appears to be 
composed of two distinct domains designated the GTPase, or G domain and an a- 
helical domain (Fig. 1.3(a)). The GTPase domain is a highly conserved domain that is 
structurally similar to the nucleotide binding domain of the small nucleotide binding 
protein As the name implies, the GTPase domain is primarily involved in
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Figure 1.3 A 3-Dimensional representation of Gta in both the 
active and inactive conform ations
Figure 1.3 represents the two crystal structures of Gta in both the GTPyS bound 
"active" (Fig. 1.3 (a)) and the GDP bound "inactive" (Fig. 1.3(b)) conformations as 
resolved by Noel et a/.(1993) and Lambright et a/.(1994) respectively. The three switch 
regions associated with G-protein activation are represented as darkened regions on the 
active representation of Gt« (Fig. 1.3 (a)). Other regions annotated on the active 
representation include the helices of the a-helical domain (designated A to F from the 
N-terminus) and the P-sheets of the G-domain (labelled 1-6 from the N-terminus of the 
subunit).
Figure reproduced from Sprang (1997)
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guanine nucleotide binding and hydrolysis, although it also contains sites necessary for 
receptor, effector and (3y subunit binding. The GTPase domain is composed of 5-a- 
helices surrounding a six stranded p-sheet, each of which are designated a-1 to 5 and p 
1 to 6 respectively. In common with other GTPase proteins, the guanine nucleotide 
binding site is formed from 5 polypeptide loops (P- or G-loops) designated G l to G5. 
These loops are the most highly conserved structural elements across all members of the 
G-protein superfamily. These G-loops contain the consensus sequences known to be 
involved in GTP binding (GXGXXGKS in G l), binding (DXXG in G3) and 
binding of the guanine ring (NKXD in 04).
The second domain, the a-helical domain, as its name suggests, is composed 
entirely of a-helices. Six a-helices, designated A to E, bundle together to form an 
independently folded domain which can be stably expressed in the absence of the G- 
domain (Markby et aL, 1993). The helical domain is connected to the GTPase domain 
by two polypeptide linker segments 4 and 6 residues in length. The second domain 
appears to be unique to heterotrimeric GTP-binding proteins, and as of yet no stiuctural 
equivalent has been detected in the smaller GTP binding proteins. The function of the 
helical domain is poorly defined, although it is expected to act as a “lid” shielding and 
stabilising the GTP/Mg^^ complex in the guanine nucleotide binding pocket (Noel et aL, 
1993). It has also been postulated that the a-helical domain may function as a GAP and 
facilitate nucleotide hydrolysis and exchange (Sprang, 1997).
1.3.9 G-protein structure v s  function
In the inactive state, the G-protein is present as a heterotrimer of a , (3 and y 
subunits and contains GDP in the nucleotide binding pocket (Fig. 1.3(b)). In order to 
switch from the inactive to the active state, the inactive G-protein must associate with 
an activated cell surface receptor. Association of the G-protein with an activated 
receptor is aided by lipid modifications at the a- and y subunits, which not only attach 
the G-protein to the cell membrane but also define its orientation relative to the 
activated receptor. Although the conformational change is transmitted to the a-subunit, 
increasing evidence suggests that all three subunits may be involved in receptor 
coupling.
Experimental evidence suggests that the extreme C-terminus of the a-subunit 
defines the specificity of G-protein receptor coupling. The substitution of as little as 3
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amino acids in the C-terminal tail of Gqa for the equivalent sequence of Gia2 has been 
shown to be sufficient to switch the selectivity of the chimera to Gi coupled receptors 
(Conklin et aL, 1993). Similarly, a 5 amino acid substitution of the C-terminal tail of 
Gi3a for Gza Creates a chimera that can activate NaVH^ exchange upon stimulation of 
the dopamine 0% receptor (Voyno-Yasentskaya et aL, 1994). This principal has been 
conclusively demonstrated by Komatsuzaki et al. (1997) who have shown that 
Gsa/Gia(i/2), Gsa/Gi4a, and Gsa/Gi6a chimeras can channel stimulation of the 
somatostatin SSTR3 receptor to the Gsa effector adenylyl cyclase. In all of these 
examples, substitution o f the C-terminal sequence resulted in a switch of receptor 
coupling specificity but did not prevent the chimera from interacting with its natural 
effector. The efficiency of receptor/chimera interactions appears to be related to the 
length of the C-terminal substitution. Conklin et a i (1993) have demonstrated that 
increasing the length of the amino acid substitutions in the C-terminal tail of Gq« to 
those o f Gia2 first increased receptor coupling efficiency, but then resulted in a gradual 
loss o f receptor/G-protein coupling. It is interesting to note that the optimal number of 
substitutions was around 8 amino acids, which is exactly the same number of residues 
which are observed as being disordered in the G-protein crystal structure (Noel et aL, 
1993). It has been proposed that these C-terminal residues adopt an ordered 
conformation in the free a-subunit which prevents their association with the activated 
receptor (Kisselev et aL, 1998). Finally, antibodies directed against the C-terminus of 
G a and PTX catalysed ADP-ribosylation of a cysteine residue four amino acids from 
the C-terminus in most Gi family members has been shown to disrupt G-protein 
receptor coupling (Simonds et aL, 1989; Gilman et aL, 1987).
Potential points of a-subunit/receptor interaction have been mapped thi*ough 
chimeric experiments and photochemical cross linking. Liu et ai. (1995) have 
demonstrated that a C-terminal 5 amino acid substitution of Gqa for those of a Gi family 
member is sufficient to allow coupling of this chimera to Gi coupled M2 muscarinic 
receptor. However, this same Gqa/Gi chimera cannot couple to the wild type form of the 
Gqa specific M3 muscarinic receptor. By substituting varying length of intracellular loop 
3 (IC3) o f the Gi coupled M2 muscarinic receptor, Liu et aL were able to generate a 
mutant M3 muscarinic receptor capably of coupling to the Gqa/Gi chimera. Subsequent 
M2/M3 muscarinic receptor mutants were used to map the points of interaction between 
the C-terminus of the chimera to four non-contiguous residues (Val 385, Thr 386, He
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389 and Leu 390) located at the C-terminus in IC3. This four amino acid motif is 
conserved between both the M2 and the M4 Gi coupled muscarinic receptors. IC3 has 
also been implicated in other receptor/G-protein contact sites. Evidence suggests that 
IC3 does not interact exclusively with the C-terminus of the a-subunit. Taylor et al. 
(1994) have demonstrated that the N-terminal 17 residues of Goa can be chemically 
cross linked to a peptide corresponding to the C-terminal region of a-adrenoceptor IC3.
Alanine scan mutagenesis has also highlighted other residues in the C-terminal 
half of Gta and Gia that may be involved in stabilising receptor coupling. For example 
Mazzoni and Hamm (1996) have demonstrated that the Arg 310 residue located in the 
a 2P4 loop of Gta is protected from tryptic cleavage in the presence of activated 
rhodopsin. Similarly, the a 2 ^ 6  loop has been implicated in Gi coupling to the 5 H T ib  
serotonin receptor (Bae et al., 1997).
Py subunits may also contribute significantly to heterotrimeric G- 
protein/receptor interactions. Taylor et al. (1996) have demonstrated tliat a peptide 
corresponding to the C-tenninal region of the a 2 adrenergic receptor can be chemically 
cross linked to the C-terminal 60 residues of Gp. Although there is no direct evidence of 
y subunit/receptor coupling, experiments have shown that the y subunit is able to 
influence receptor specificity tlnough the prenyl group at its C-tenninus (Yasuda et al., 
1996). In addition to direct coupling to the receptor, the Py subunits also contribute to 
the efficiency and specificity o f receptor coupling by localising the heterotrimer at the 
membrane in an orientation that can easily interact with the receptor and by maintaining 
the C-terminus of the a-subunit in a disordered conformation.
Upon coupling with an activated receptor, the G-protein undergoes a 
conformational change that allows exchange of the GDP molecule in the nucleotide 
binding pocket for GTP. This nucleotide exchange event is thought to involve 
movement of the a-helical “lid” domain and the C-teiminal tail. This exposes the 
nucleotide binding pocket and allows GDP to dissociate and Mg^VGTP to enter. 
Analysis of the crystal structures of active (GTPyS bound) and inactive (GDP bound) 
forms of Gta have shown that the y phosphate of the GTP/Mg^^ complex tiiggers a 
substantial re-arrangement of three discrete regions in the G-domain. These three 
regions, designated switch I, II and III, are the only points of re-arrangement in the 
virtually identical ciystal structures (Lambright et al., 1994). Interactions of the y
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phosphate of GTP with Gta induces the switch II region to turn and connect with switch 
III. Switch III in turn draws switch II towards the y phosphate group. The 
confoimational changes at switch II and III are stabilised by ionic interactions between 
basic residues in the two switch regions. During this conformational change, switch I is 
pulled upwards into the nucleotide binding pocket.
Movement of the switch regions has two effects on a-subunit activity. First, the 
re-arrangement of the switch regions disrupts bonding between the a-subunit switch 
region II and the central tunnel o f the P-propeller in the p-subunit, causing the a-subunit 
to dissociate from its py partner. The GTP-bound a-subunit and free Py subunits are 
then able to engage with and activate secondary effectors. Secondly, the re-arrangement 
of switch regions exposes previously hidden determinants involved in effector coupling. 
Chimeric studies by Berlot and Bourne (1992) have identified three sites on the a - 
subunit that are involved in effector coupling. The first of these, the C-terminus of a - 
helix 2, corresponds to a portion of the G-domain encompassing the switch II region. 
The second segment is a loop connecting a-helix 3 to P-strand 5. The third region 
corresponds to the a4p6 loop. An independent observation has shown that a peptide 
corresponding to this loop can activate the effector cGMP-PDE in vitro (Rarick et at., 
1992).
The period of G-protein/effector coupling is regulated by the intrinsic GTPase 
activity o f the a-subunit. Upon GTP hydrolysis, the three switch regions revert back to 
their conformations in the inactive state. The loss of the y phosphate, by the hydrolysis 
of GTP to GDP, destabilises bonds between switch regions II and III, which collapse 
back to their disordered state and so disengage effector coupling. Switch region II twists 
back to a conformation in which it can interact with free py subunits, py subunit re­
association, in combination with the loss of effector determinants, seiwes to attenuate 
frirther G-protein/effector coupling. The heterotrimeric GDP-bound G-protein is then 
once again ready to transduce a signal from an activated cell surface receptor.
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1.4 a-adrenergic receptors
Adrenergic receptors mediate the effects of the catecholamines such as 
adrenaline and noradrenaline by coupling to several of the major signalling pathways 
modulated by G-proteins. The distinction between a  and p adrenoceptor subtypes was 
made as long ago as 1948 by Ahlquist on the basis of their pharmacological 
characteristics. Despite this eai'ly progress, for many years the distinction between 
different members in a receptor subtype remained blurred due to the lack of suitable 
subtype-selective ligands. This situation was not resolved until molecular cloning 
techniques were used to isolate the first GPCR, the P2 adrenoceptor, by Dixon et al. in 
1986. Since then, the isolation of additional family members has allowed the various 
adrenoceptor family members to be classified in the basis of sequence information as 
well as compound selectivity. The current classification system indicated the presence 
of two a-adrenoceptor subtypes, designated a i and a 2. Each of these subtypes and their 
associated family members will now be discussed below, with special emphasis being 
placed on the a 2A adrenoceptor.
1.4.1 ai adrenoceptors
a i adrenoceptors can be distinguished from a 2 adrenoceptors on the basis of the 
potency of the two antagonists yohimbine and prazosin. Prazosin is more potent than 
yohimbine at the a i adrenoceptor, while the reverse is true at the ag adrenoceptors. 
Evidence suggests the presence of four subtypes of a i adrenoceptor, designated a;A , 
aiB , aiC  and aiD. As with other adrenoceptor subtypes, studies into the distribution of 
these receptors has been hampered by the lack of selective ligands. Therefore, 
distribution studies have relied on the detection or receptor mRNA. Based upon 
Northern analysis on rat and bovine tissue, the aiB  and a%D subtypes appear to be 
widely distributed with high levels of expression in peripheral tissues such as lung, 
kidney (aiB), heart and spleen (aiD). Radioligand binding has also shown a similar 
peripheral tissue distribution for the aiA  adrenoceptor. All three adrenoceptors appear 
to show high expression in CNS tissues such as the hippocampus, cerebral cortex and 
brainstem. In contiast to the above three receptors, Northern analysis has failed to 
accurately map aiC  distribution in either rat or bovine tissue. This has led to the 
suggestion that aiC  receptors either display highly specialised tissue distribution, or are 
only expressed during development. Finally, a i adrenoceptors are thought to be coupled
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to the phosphoinositide signalling pathway through the pertussis toxin insensitive 
Gqa/Giia class of G-proteins.
Pharmacological characterisation of the a i adrenoceptor subtypes has been 
hampered by the lack of suitable selective ligands. However, by a process of 
elimination, all four members of the a i family can be resolved through the use of three 
selective antagonists. The a iA  receptor can be distinguished from the other three 
subtypes on the grounds that it cannot be irreversibly inactivated by the antagonist 
chloroethylclonidine. Similarly, the aiB  receptor can be identified by using the 
antagonist WB4104, which is 100 times more potent at the aiA , aiC  and aiD  subtypes. 
Finally, the agonist 5-methylurapadiI, which displays a 100 times greater potency at 
aiC  and ajD  than at a iA  and aiC , can be used to distinguish the a i adrenoceptor 
subtypes aiC  and aiD .
1.4.2.1 aa adrenoceptors
The Œ2A adrenoceptor is one of thiee a 2 adrenoceptor subtypes designated aiA , 
Œ2B and a 2C. The human a 2A adrenoceptor was initially cloned by Kobilka et aL in 
1987, a year after the cloning of the p2 adrenoceptor (Dixon et a l, 1986). Kobilka 
identified this receptor as the principal receptor in human platelets and termed it a 2C 10 
in accordance with its location at chromosome 10 in the human genome. Further 
cloning of the two other family members a 2B (a 2C2) and aaC (a2C4) showed that all 
three genes were encoded by intronless genes located at different chromosomes in the 
human genome (chromosome 2 for a 2B and chromosome 4 for a 2C) (Regan et aL, 
1988; Lomasney et aL, 1990).
Cloning rapidly progressed from the human subtypes to other homologues in a 
wide range of species including- guinea pig, opossum, rat, cow chicken and pig 
(Svensson et aL, 1996; Blaxall et aL, 1994; Chalberg et aL, 1990; Blaxall et al., 1993 
and Guyer et aL, 1990). Subsequent cloning of these receptors highlighted a limitation 
of the original nomenclature as devised by Kobilka. Therefore, the 0 .2  nomenclature was 
revised to the current system based upon the phylogenetic analysis of the receptor 
sequences (Figure 1.4). While this system appears to be adequate for mammalian a 2 
receptor subtypes, the a 2 adrenoceptors of the fish, cuckoo wrasse and goldfish, which 
show little sequence similarity with the mammalian subtypes, are difficult to position in
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Figure 1.4 A phylogenetic representation of the ag adrenoceptor  
su btyp es
Figure 1.4 represents the hypothetical phylogenetic tree of different a i  
adrenoceptor subtypes from a wide variety o f species. The tree was generated from the 
alignment of multiple adrenoceptor primary sequences and was rooted using the amino 
acid sequence of human rhodopsin. The large, divergent third intracellular loop was 
excluded from this study. Sequence divergence is represented through the length of the 
horizontal lines.
Adapted from MacDonald et a/. (1997)
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the a 2 adrenoceptor phylogenetic tiee. This has led to the proposal of an alternate fish 
subtype termed azF (Svensson et aL, 1993). Despite their structural differences, the fish 
subtypes appear to be most closely related to the mammalian a 2C subtypes (Figure 
1.4).
1.4.2.2 The a 2A adrenoceptor
The gene for the human aiA  adrenoceptor encodes a protein 450 residues in 
length with a predicted molecular mass o f 49 kDa. The receptor is subject to a variety of 
post translational modifications including glycosylation at two Asn residues near the N- 
terminus (Asn 10 and 14) and palmitoyiation at a conserved cysteine residue in the C- 
terminal tail (Cys 442). In addition to this, the receptor is thought to form a disulphide 
bond between two cysteine residues in exoloops 1 and 2 (Cys 106 and Cys 188). In 
common with other members of the a 2 adrenoceptor family, the a 2A adrenoceptor has 
an unusually large third intracellular loop (157 residues) and a short C-tenninal tail (20 
residues). Phylogenetic analysis shows the human a 2A adrenoceptor to be closely 
related to other mammalian homologues. Analysis of the sequence of the human ajA  
adrenoceptor with its porcine analogue has shown a 93% amino acid identity (Guyer et 
al, 1990).
The Œ2A adrenoceptor can be pharmacologically distinguished from the other 
two a 2 adrenoceptor subtypes by the selectivity of the weak partial agonist 
oxymetazoline which shows 50-100 times greater affinity at this receptor than at the 
a 2B or QL2C subtypes. The antagonists prazosin and ARC 239 also exhibit a 10-100 fold 
lower selectivity for the Œ2A adrenoceptor relative to the a 2B or a 2C subtypes. The rat 
and mouse homologues of the human a 2A adrenoceptor can be characterised by a 20 
fold lower affinity for the agonist yohimbine. This reduction in affinity for yohimbine 
has been attributed to a serine residue at position 210 instead of a cysteine residue 
which is present at the equivalent position in both the human and porcine receptors 
(Link et aL, 1992). Other determinants affecting ligand binding have been mapped to 
regions of transmembrane domain 7. For example, Suryanarayana et al (1991) have 
shown that a Phe to Asn substitution at residue 341 in the seventh transmembrane 
domain of the a 2A adrenoceptor increases the affinity of the receptor for a variety of (3 
receptor agonists and antagonists by as much as 3000 fold.
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In common with other members of the adrenoceptor family, the aiA  
adrenoceptor has been shown to mediate a variety of responses including- the inhibition 
of adenylyl cyclase, the inhibition of voltage gated Ca^^ channels and the opening of 
channels. In addition to this, the oczA adrenoceptor has also been implicated in the 
activation of phospholipase isoforms C and D, the activation of adenylyl cyclase as well 
as the PTX insensitive inhibition o f adenylyl cyclase (Limbird et aL, 1988; Wong et aL, 
1992). This wide range of effectors has prompted a great deal of research into divergent 
signalling through this receptor in terms of both agonist channelling and G-protein 
coupling.
Divergent signalling through the aiA  adrenoceptor appears to be modulated by 
two primary factors, agonist concentration and agonist structure. For example, Eason et 
aL, (1992) have shown that the agonist UK14304 exhibits a biphasic response at the 
azA adrenoceptor in transfected CHO cells. At low concentrations of UK14304, this 
agonist mediated the inhibition of adenylyl cyclase by the azA adrenoceptor, whilst at 
high concentrations the agonist mediated the activation of adenylyl cyclase activity. In a 
similar experiment in HEK 293 cells, Chabre et aL, (1994) have demonstrated that the 
agonist UK14304 can force sequential coupling of the asA adrenoceptor to the G- 
proteins Gi, Gq and Gs respectively in a concentration dependent manner. The capacity 
of the agonist to promote divergent coupling also appears to be a function of its 
potency. Eason et aL (1994) analysed the capacity of a wide range of agonists to 
stimulate adenylyl cyclase activity through the a%A adrenoceptor. From their findings 
they concluded that agonists vaiy in their capacity to elicit azA/Gga coupling, with full 
agonists such as UK14304 displaying a greater capacity to stimulate divergent coupling 
than weak partial agonists such as ozymetazoline. The structure of the ligand also 
appears to play an important role in detennining the preference of G-protein coupling at 
the aiA  adrenoceptor. In contrast to the biphasic response exhibited by UK14304 
(Eason et aL, 1992) Airriess et aL (1997) have demonstrated that phenolamines such as 
octopamine and synephrine, are only able to couple the a%A adrenoceptor to a 
concentration dependent inhibition of adenylyl cyclase activity.
G-protein coupling at the a 2A adrenoceptor has been demonstrated through the 
use of various techniques including immuno-co-precipitation, photochemical cross 
linking and chimeric studies. The first direct evidence that a G-protein other than Gi
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could couple to the a%A adrenoceptor was presented by Eason et a l  (1992) who co­
precipitated an agonist"a2A~Gsa complex following UK143 04 stimulation of the aiA  
adrenoceptor. The receptor coupling determinants involved in this interaction were later 
resolved through a series of chimeric receptor studies based upon the initial observation 
that a deletion o f residues 218-235 in the Œ2A adrenoceptor N-terminal region of the 
third intracellular loop abolishes Gs coupling (Eason et a l, 1994). Eason et a/.(1994) 
generated a series of a 2A receptor chimeras in which residues 218-235 were substituted 
with the equivalent sequence of either the Gi coupled 5HTia receptor or the 
predominantly Gs coupled p2 adrenoceptor. Upon functional analysis of these chimeras 
Eason discovered that while Gs coupling was lost in both o f the substitutions, Gi 
coupling was generally unaffected,. In order to precisely map which residues were 
involved in Gs coupling, Eason et al{\99A) created two more chimeras, this time 
containing 5HTia receptor sequence in either positions 218-228 or 229-235. When these 
chimeras were analysed for functional coupling, only the chimera containing the limited 
substitution at residues 229-235 showed functional coupling to both Gi and Gs. By a 
process o f elimination, Eason et al{\99A) concluded that while residues 218-228 of the 
Œ2A adrenoceptor are necessary for Gs coupling, they are not essential for Gi coupling.
In a continuation of this work, Eason and Ligget (1996) modified the aaA 
chimeras to include substitutions of the whole of intracellular loop 2 (residues 133-149) 
and the C-terminal region of the intracellular loop 3 (residues 335-371) with the 
equivalent sequence from the Gi coupled 5HT]a receptor and the Gs coupled P2 
adrenoceptor. Eason and Liggett then assayed each of the chimeras with regard to 
hmctional Gi and Gs coupling. From these experiments, they discovered that by 
replacing the 2"^  intracellular loop of the a 2A adrenoceptor with the equivalent 
sequence of the Gi coupled 5HTia receptor they could abolish Gs coupling without 
affecting Gi coupling. Similarly, substitution of the same region with the equivalent 
sequence of the Gs coupled P2 adrenoceptor depressed Gi coupling while leaving Gs 
coupling fully intact. From this Eason and Liggett concluded that the 2"  ^ intracellular 
loop of the (I2A  adrenoceptor contains determinants necessary for functional coupling to 
both Gi and Gs a-subunits. In another experiment, Eason and Liggett (1996) substituted 
either the carboxy or amino terminal segments of the 3^  ^ intracellular loop of the aiA  
adrenoceptor with the equivalent sequence of the 5HTia receptor. Analysis of these 
chimeras showed that while Gi coupling was unaffected, a substitution at either of these
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regions ablated agonist stimulation of adenylyl cyclase activity. In contrast to this, a 
substitution of P2 adrenoceptor sequence at either of these positions had no appreciable 
effect on Gi coupling. However, substitution of P2 adrenoceptor sequence at both of 
these regions significantly impaired the capacity of the chimera to inhibit adenylyl 
cyclase activity. From these observations, Eason and Liggett(1996) concluded that both 
the N and C-terminal regions of the 3'^ intiacellular loop of the a 2A adrenoceptor are 
capable of independently supporting Gi coupling.
To summarise, Liggett and co-workers have identified thiee determinants 
involved in functional coupling o f the 012A adrenoceptor to the G-proteins Gi and Gs. 
Determinants necessary for Gs functional coupling appear to be distributed between the 
2"  ^ intracellular loop and the C-terminal (residues 355-371) and N-terminal (residues 
218-228) regions of inhacellular loop 3. In contrast to this, functional coupling of the 
tt2A receptor to Gi appears to be far more flexible. Functional coupling to Gi requires 
determinants in the 2"^  intracellular loop in combination with determinants in either the 
N- or C-terminal regions of intracellular loop 3.
The observations of Eason and Liggett (1996) have in part been coiToborated by 
photochemical cross linking experiments by Taylor et a l (1996). Taylor et a l{\996) 
have demonstrated that a 14 residue peptide corresponding to the C-terminal region of 
the 3'"'* intracellular’ loop of the a 2A adrenoceptor can be photochemically cross linked to 
a region corresponding to the N-terminal 17 residues of the Gi family member Go«. In 
combination with this, Taylor et a l (1994; 1996) have also shown photochemical cross 
linking of the same region of the a 2A adrenoceptor with the last 60 C-terminal residues 
ofG(3.
1.4.2.3 The agB and a 2C adrenoceptor subtypes
The a 2B and a 2C adr enoceptors share many of the features of the Œ2A subtype. 
The genes for all three subtypes encode proteins of similar length ((X2A 450 residues, 
Œ2B 450 residues, a 2C 461 residues) and molecular mass (49kDa). Analysis of the 
amino acid sequence has shown that all three receptors contain an unusually large 3'^ '^  
intracellular loop (a 2A 157 residues, azB 179 residues, a 2C 151 residues) and a short 
C-terminal tail (a 2A 20 residues, 0128 21 residues, aiC  21 residues). The three receptors 
have also been shown to regulate a common set of effectors tlirough the G i/o family of
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G“proteins. Responses known to be mediated by a^B and a 2C subtypes include -  
inhibition of adenylyl cyclase activity, inhibition of voltage gated Ca^  ^ channels and the 
opening of channels. The three subtypes do however differ in post translational 
processing. The a 2A appears to be the only subtype which is covalently modified by 
both palmitoyiation and glycosylation, the other receptors being either exclusively 
palmitoylated («26) or glycosylated (a 2C). The a 2B and C subtypes also appear to 
differ in tissue disti'ibution, with the a 2B being localised to peripheral tissues such as 
the liver and kidney and the a 2C being exclusively expressed in central nervous tissues 
such as the hippocampus and cerebral cortex. In contrast to this , the Œ2A subtype has 
been detected in both peripheral tissues as well as the central nervous system.
The Œ2B and a 2C adrenoceptor subtypes can be pharmacologically distinguished 
from the a 2A adrenoceptor through the use of the two antagonists prazosin and ARC 
239 which exhibit exhibit a 10-100 fold greater affinity for these receptor subtypes than 
for the Œ2A adrenoceptor. The extensive pharmacological overlap between the Œ2B and 
a 2C subtypes means that at present, these receptors cannot be separated by 
pharmacological means. Alternately they can be identified by either sequence analysis 
or through their differential post translational processing.
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1.5 Aims of Research
The C-terminus of the G-protein a-subunit has been shown to be an important 
determinant in defining the efficiency and specificity of G-protein/receptor coupling. 
Through alanine scan mutagenesis, Osawa and Weiss (1995) have identified several 
residues in the C-terminus of Gta, the mutation of which negatively affect coupling of 
the G-protein with its cognate receptor. One of the residues identified by Osawa and 
Weiss (1995) is a cysteine residue, located four amino acids from the exti'eme C- 
terminus of Gta- This cysteine residue is known to be conserved across the Gi family of 
G-proteins, with the exception of Gza which contains an isoleucine residue at this 
position. Substitution of this residue for tyrosine (C347Y) was seen to result in a loss of 
G-protein/receptor coupling. Similarly, ADP-ribosylation of this residue by the bacterial 
toxin, pertussis toxin, has been shown to have an equally detrimental effect on receptor 
coupling. It could be postulated that since this residue is conserved across the range of 
Gi family members it plays a vital role in G-protein function. However, mutations of the 
equivalent residue (C351) in other Gi family members have shown this not to be the 
case. Substitution of this cysteine residue to glycine in Giai (Senogles, 1994) or serine 
in Gia3 (Hunt et al., 1994) has been shown to result in a less marked decrease in G- 
protein/ receptor coupling, the extent of which has yet to be determined.
In parallel with the above observations, Osawa and Weiss (1995) demonstrated 
that the activity o f the C347Y Gta mutant could be restored by substituting the residues 
adjacent to the point mutation with those of Gqa (D346E, C347Y, G348N, F350V). 
From this study, it would appear that the C-terminus of the a-subunit is more tolerant to 
extensive substitutions than to selective point mutations. Evidence supporting this 
comes from Conklin et al. (1993) who have shown that while a substitution of the last 3 
C-terminal amino acids of Gqa for those of Gi«2 switches the specificity of receptor 
coupling towards Gi linked receptors, it does not affect the capacity of the G-protein to 
be activated or to interact with its cognate effector. The equivalent effect has also been 
demonstrated in more extensive C-terminal substitutions in Gisa and Gsa (Voyno- 
Yasentskya et al., 1994a; Komatsuzaki et a l, 1997), but not as of yet in any of the Gi 
family members.
Based upon the above findings, the aim of this research project was to 
quantitatively determine how mutations and substitutions in the extreme C-terminus of
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Giai affect the efficiency and specificity of G-protein/receptor coupling. In the first 
results chapter, by generating a series of C351 Giai mutants similar to those of Senogles 
(1994), I aim to quantify the effects of substituting cysteine residue 351 in Giai on the 
efficiency of coupling to the a 2A adrenoceptor. In the second results chapter, using a 
series of Gi chimeras similar to those generated by Komatsuzaki et aL (1997), I aim to 
investigate the role the a-subunit C-terminus plays in defining the specificity of G- 
protein/receptor coupling. Finally, in the third results chapter, I aim to quantify how the 
C351 Giai mutants affect the intrinsic activity of agonists at the a 2A adrenoceptor. This 
property will be investigated using fusion proteins between the a 2A adrenoceptor and 
the C351 Giai mutants based on the design of Bertin et aL (1994).
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Chapter 2 
Materials and Methods
2.1 Materials
2.1.1 General R eagents
Alexis Corporation Ltd., Bingham, Nottingham, U. K.
DTT
Amersham International pic., Buckinghamshire, U. K.
Enhanced chemiluminescence reagent, ECL detection film 
BDH
Ammonium persulphate, glucose, glycine, Na^HPOd
Boeliringer Mannheim U. K. Ltd., Lewes, East Sussex, U. K.
App(NH)p, aprotinin, creatine phosophokinase, GDP, GTPyS and restiiction 
enzymes
Calbiochem-Novabiochem Ltd., Beeston, Nottingham, U. K.
Geneticin (G-418)
FMC BioProducts, Rockland, USA 
Agarose
Genosys, Cambridge, U. K.
Oligonucleotides
Gibco BRL Life Technologies Inc., Paisley, U. K.
LipofectamineT^i, TRIS, 1 kb DNA ladder, oligonucleotides, optimem 1
Invitrogen, San Diego, CA, U. S. A.
pcDNA3
Merck Ltd., Poole, Dorset, U. K,
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Agar, NaOH
Oxoid Ltd., Hampshire, U. K.
Tryptone, yeast extract 
Packard Instruments, BV, Netherlands 
Ultima Gold XR liquid scintilation cocktail 
Premier Beverages, Stafford, U. K.
Marvel
Promega Ltd., Southampton, U. K.
Restriction enzymes, Wizard^^"  ^ Miniprep kit. Wizard™ DNA clean-up kit, X- 
Gal, IPTG
Qiagen Ltd., West Sussex, U. K.
Quiagen maxiprep kit
Sigma Chemical Company, Poole, Dorset, U. K.
Alumina, ampicillin, cholera toxin, DOWEX AG50 W-X4 (200-400 mesh), 
forskolin, imidazole, mineral oil, pertussis toxin, TEMED, thimerosal, TRICINE 
Acetic acid, DMSO, EDTA, HEPES, hydrochloric acid, KCl, K H 2PO 4 , 
K 2H P O 4 , MgCl2, NaCl, NazCOs, NaHCO], NaH2P04, sucrose, SDS, 
trichloroacetic acid
Stratagene Ltd., Cambridge, U. K.
Pfu DNA Polymerase, pCR-Script cloning system
Whatman International Ltd., Maidstone, U. K.
Branded GF/C Glassfibre filters
2.1.2 R adiochem icals
Amersham International pic., Buckinghamshire, U. K.
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[^H]RS-79948-197 (specific activity: 79 Ci/mmoi)
Du Pont NEN Ltd., Stevenage, Hertfordshire, U. K.
[y^^P]GTP (specific activity: 30 Ci/mmoi)
[35s]GTPyS (specific activity: 1250 Ci/mmol)
2.1.3 Plasm ids
The porcine a 2A adrenoceptor which was obtained Ifom Dr. L.E. Limbird 
(Vanderbilt University, TN). All other receptors, with the exception of the FLAG™ 
tagged IP prostanoid receptor which was produced in house by Mr. Chee-Wai Fong, 
were obtained fiom Glaxo Wellcome (Stevenage, Herts, UK).
2.2 Cell growth
Cells were cultivated in a continuous monolayer in 75cm^ sterile tissue culture 
flasks (Costal’, Cambridge,USA). The Growth medium used was Dulbecco's Eagle's 
minimal essential medium (DMEM) supplemented with 2mM L-glutamine and 
10%(v/v) new bom calf serum (NBCS). Buffering of media was achieved by growing 
the cells in a 95% air 5% CO2 atmosphere. Cells were cultured in 10ml of the above 
medium in a Nuaire model Nu-2700 incubator (Jencons, Minnesota,USA) at 37°C and 
allowed to reach confluency. Medium was changed every 3 days or when expended, as 
indicated by a change in the phenol red in the medium, which ever was the sooner.
2.3 Maintenance of ce lls
COS 7, HEK 293 and HEK293 Large T cells (Glaxo-Wellcome UK) were 
grown in DMEM containing 10%(v/v) new bom calf serum.
2.4 P assagin g  of confluent cell cultures
upon reaching confluency a flask of cells was subcultured into 4 to 10 flasks 
depending on the particular cell line's growth characteristics. Medium was removed and 
the cell monolayer was first washed and then incubated with 2ml of a sterile 
trypsinisation solution containing 0.1%(w/v) trypsin, lOmM glucose and 0.67iuM 
EDTA, pH7.4. The trypsinisation process was terminated upon cell detachment fioru 
the flask by the addition of 5ml of the appropriate growth medium. The cell suspension
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was transferred from the flask to a sterile 13ml polypropylene tube and centrifuged at 
lOOOrpm for 5 minutes in a Super Minor centrifuge (MSB). The supernatant was 
discarded and the cell pellet was resuspended in 1ml of the appropriate growth medium 
by pipetting. The cell resuspension was further diluted with additional growth medium 
to give a final volume of 1ml per flask, 1ml aliquots of resuspended cells were 
dispensed into an appropriate number of sterile 75cm^ tissue culture flasks each 
containing 9ml of appropriate growth medium. The flasks were then placed into an 
incubator and grown as above.
2.5 Storage and recovery of ce lls
Cell lines not in constant use were cryogenically preserved in liquid nitrogen. 
The cells were fust tiypsinised and centrifuged as detailed in Section 2,4 before being 
resuspended in 1ml per flask o f freezing medium consisting of 90% (v/v) NBCS and 
10% (v/v) DMSO. The resuspended cells were dispensed in 1ml aliquots into sterile 
1.8ml cryogenic storage vials (Nunc, Denmark). A two stage freezing process was used 
to prevent the fomiation of ice crystals in the cells. In the first stage the vials were 
placed in an insulated polystyrene box and stored at -80°C for 18 hours, the second 
stage involved transferring the vials to a liquid nitrogen vat for long term storage.
Cells were recovered from their cryogenic storage by removing the vials from 
the liquid nitrogen vats and thawing the contents at room temperature. The contents of 
the vial were then transferred to a sterile polypropylene tube and diluted with 9ml of 
DMEM growth medium containing 10%(v/v) NBCS before being centrifuged at 1000 
rpm for 5 minutes. After centriftigation the supernatant was discarded and the cell pellet 
was re-suspended into 1ml of DMEM growth medium before being dispensed into a 
sterile 75cm^ tissue culture flask containing 9ml of DMEM growth medium 
supplemented with 10%(v/v) NBCS. Cells were maintained as described in Section 2,2.
2.6 Bacterial toxin treatment of ce lls
2.6.1 P ertu ssis toxin treatment of cells
Cells were treated with pertussis toxin in vivo 18 hours prior to harvesting. 
Medium was removed by aspiration and replaced with fresh medium containing 
pertussis toxin at a final concentration of 50 ng/ml. The toxin was prepared as a lOx 
stock in DMEM and was added to the growth medium prior to use. Following toxin
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treatment, cells were essentially maintained as described in Section 2.2 prior to 
harvesting.
2.6.2 Dual toxin treatment with pertussis and cholera toxin
Cells were treated with a combination of pertussis and cholera toxin essentially 
as described in Section 2.6.1. Pertussis toxin was used at a final concentration of 
50ng/ml while cholera toxin was used at a final concentration of 200ng/ml.
2.7 Harvesting of ce lls
Upon reaching confluency or after toxin treatment cells were harvested as 
follows. Medium was removed by aspiration and cells were washed with 2ml o f ice cold 
phosphate buffered saline (PBS) (137mM NaCl, 4mM Na2HP04, 0.27mM KCl, 
0.15mM KH2PO4 (pH 7.4)). The cell monolayer was scraped into 2ml ice cold PBS 
using a disposable cell scraper (Costar,USA). The scraping procedure was repeated with 
a further 2ml of ice cold PBS and the cell suspensions were pooled into a 13ml 
polypropylene tube chilled on ice. The harvested cells were centrifliged at 20D0rpm for 
5 minutes at 4°C in a TJ-6 bench top cooled centrifuge (Beckman Instruments, 
California, USA). The supernatant was discarded and the pellet was re-suspended in 
1ml ice-cold PBS and transferred to a 1.5ml microcentrifuge tube. The re-suspended 
cells were centrifuged at 21000g for 5 minutes at 4°C in an lEC Micromase RF 
centrifuge (International Equipment Company, MA, USA). The supernatant was 
discarded and the pellet was stored at -80°C until required.
2.8 Transient transfection of mammalian cell lines
c o s  7, HEK 293 or HEK 293 large T cells were used for the transient 
expression of receptor, G-protein or chimeric receptor/G-protein cDNA's. Cells to be 
transfected were seeded at 60% confluency in a 10cm diameter sterile tissue culture 
dishes (Costar) 24 hours prior to transfection. On the day of ti’ansfection cDNA to be 
transfected was diluted to O.lpg/ml in sterile nuclease free H2O. An amount of cDNA 
between 4-lOpg was added to a sterile 13ml polypropylene tube and diluted with 
optimem 1 (Gibco BRL) to a final volume of 600pl. A solution consisting of 20pi 
lipofectamine 580pl optimem 1 was added to the tube and mixed by flicking the tube. 
The cDNA mix was incubated at room temperature for 30 minutes to allow DNA 
liposome complexes to form. During this incubation period medium was aspirated off
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the cells to be transfected and the monolayer was first washed with 5ml optimem 1 
before finally being incubated with another 5ml of fresh optimem 1. At the end of the 
DNA/lipofectamine incubation period 4.8ml of optimem 1 was added to the 
polypropylene tube. The optimem 1 was aspirated off the cells and replaced by the 
DNA/lipofectamine mix. Cells were incubated for 5 hours to allow DNA to enter the 
cells after which 6ml of DMEM supplemented with 20%(v/v) NBCS was added to the 
cells. The medium was replaced with 10%(v/v) NBCS DMEM 24 hours after 
transfection and cells were incubated for a further 72 hours before being harvested as 
described in Section 2.7.
2.9 Preparation o f plasm a membrane fractions
Frozen cell pastes were thawed on ice and re-suspended in 1ml of ice cold TE 
(lOmM Tris (pH7.4), O.IM EDTA) before being transferred to a pre-chilled 13ml 
polypropylene tube. Cells were homogenised for 10 seconds using an Ultra Turrax 
homogeniser (IKA) fitted with a S8n-8g dispersing element. The resulting homogenate 
was transferred to a 1.5ml microcentrifuge tube and re-suspended 10 times with a 1ml 
syringe fitted with a 25 gauge needle.
The homogenate was centrifuged at lOOg for 10 minutes at 4°C in an I EC 
micromase RF centrifuge. The pellet was transferred to a fresh microcentrifuge tube and 
centrifuged at 21000g for 30 minutes at 4°C. The supernatant was discarded and the 
pellet was re-suspended in 500pl of ice cold TE. Samples were then stored in lOOpl 
aliquots at -80^C until required.
2.10 Determination of protein concentration
Protein concentration was determined by the method of Smith et al.(1985) in a 
96 well plate format. BSA was used as a protein standard. The optical density of the 
samples at 492nm were read using a Spectra plate reader (SET-Lab instruments, 
Salzburg, Austria).
2.11 SDS polyacrylamide gel electrophoresis
2.11.1 Lower resolving gel
SDS-FAGE was performed using vertical slab gels of dimensions 11cm x 14cm 
X 1.5mm containing 10%(w/v) polyacrylamide using the discontinuous buffer system of
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Laemmli (1970). Resolving gels were prepared from a stock solution of 30%(w/v) 
acrylamide, 0.8%(w/v) N,N'-methylene bisaciylamide and contained 0.375M Tris-HCl 
(pH8.8) and 0.1% SDS. Polymerisation was initiated by the addition of 0.0375(v/v) 
TEMED and 0.05(w/v) freshly prepared ammonium persulphate. A solution of 
0.1%(w/v) SDS was overlayed on the gels to aid polymerisation. Polymerisation was 
deemed to be complete when a clear interface could be seen between the 
polyacrylamide gel and the 0.1%(w/v) SDS solution. Upper stacking gels were prepared 
as in Section 2.11.2 and electrophoresis was performed as described in Section 2.11.3.
2.11.2 Upper stacking g e ls
The stacking gel was prepared from a stock solution of 30%(w/v) acrylamide, 
0.8%(w/v) N,N'-methylene bisacrylamide and contained 0.125M Tris-HCl (pH6.7) and 
0.1%(w/v) SDS giving a final concentration of 4%(w/v) acrylamide. Polymerisation 
was performed as detailed in Section 2.11,1.
2.11.3 Electrophoresis running conditions
Electrophoresis was carried out in a Tris-glycine buffer containing 25mM Tris- 
HCl (pH8.9), 0.192M glycine and 0.1%(w/v) SDS. Electrophoresis was conducted 
towards the anode at 45mA per gel slab until the bromophenol blue dye front was 1cm 
from the end of the gel.
2.12 W estern Blotting
2.12.1 Transfer of proteins to nitrocellulose m em branes
SDS-PAGE separated proteins were electroblotted from the polyacrylamide 
resolving gel membranes according to the method described by Towbin et a l (1979). 
Transfer was performed towards the anode in a LKB 2005 Transphor electrophoresis 
unit (Wallac, Finland) at 2A for 1 hour. The transfer buffer consisted of 25mM Tris- 
HCl (pH8.9) and 0.192M glycine. The gel/nitrocellulose arrangement was constructed 
according to manufacturers instructions, care was taken not to intioduce any air pockets 
between the polyacrylamide gel and the nitrocellulose membrane. Following 
electroblotting proteins were visualised using ponceau red stain by incubating the 
nitrocellulose filter in a 0.1%(w/v) ponceau S, 3%(w/v) trichloroacetic acid solution for 
5 ruinutes. The nitrocellulose membrane was first de-stained with two 50ml washes of 
de-ionised water after which the membrane was trimmed to remove any unused areas.
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The re-shaped membrane was then fully destained by washing with used electroblotting 
transfer buffer until no more ponceau stain could be seen. Any remaining transfer buffer 
was washed away with two subsequent washes of 50ml of dHiO.
2.12.2 Incubation of n itrocellulose m em branes with antiserum
Unless otherwise stated all antibody incubations were carried out with gentle 
agitation at room temperature. Non-specific binding sites on the membrane were 
blocked by incubation in 5%(w/v) Marvell in TEST (0.02M Tis-HCl (pH7.5), 0.15M 
NaCl, 0.1%(v/v) Tween-20) at 4°C for 18 hours with gentle agitation. The nitrocellulose 
membrane was then incubated sequentially for one hour with a 1:1000 dilution of 
primary antibody (as indicated in Table 2.1) followed by a 1:1000 dilution of donkey 
anti-rabbit IgG horse radish peroxidase conjugated secondary antibody. All antibodies 
were diluted in TEST containing 5%(w/v) Marvell. Niti'ocellulose membranes were first 
rinsed twice with at least 50ml TEST and then washed sequentially for Ix 15 minutes 
and 2x 5 minutes at room temperature with 50ml TEST between non-specific blocking 
and antibody incubations.
2.13 Imaging of im munoblots
specific binding of antiserum to the nitrocellulose bound proteins was 
determined using the ECL Western Blotting analysis system (Amersham Life Science 
Ltd.) according to the manufacturers instructions. Equal volumes of detection solution 1 
and 2 were mixed just prior to detection to give a final volume of 0.125ml/cm^ 
membrane. All excess TEST wash was drained from the membrane by holding it 
vertically from one comer with a pair of forceps and then touching the opposite corner 
on a piece of absorbent tissue before being placed protein side up in a clean 20cm 
diameter petri dish. The niti'ocellulose membrane was then incubated with the detection 
reagents for exactly one minute with gentle agitation. After incubation excess detection 
reagent was drained off as above and the nitrocellulose membrane was sandwiched 
between two transparent pieces of polythene and the nitro-cellulose membrane by 
gently smoothing across the top of the polythene with a piece of tissue, this also helped 
to remove excess detection reagent. Under darkroom safe light conditions a sheet of 
Hyperfilm ECL autoradiography film was placed on top of the nitro-cellulose 
membrane and exposed for 1 minute before being processed in an X-Omat machine
56
Table 2.1 Specificity of antisera
The antisera used in this study are listed in Table 2.1 in combination with the 
corresponding peptide sequence to which the antisera were raised, the location of the 
peptide sequence in the a-subunit, the a-subunits which the antisera identify and the 
references regarding their production. All antisera, with the exception of SMI which 
was a gift from Smithkline Beecham, were produced in house.
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Table 2.1
Antiserum Peptide Amino acid 
sequence
Identification Reference
SGI KENLKDCGLF Gtai 341-350 G {anG ta2
GialjGi(x2
McKenzie& 
Milligan (1990)
l i e LDRIAQPNYI Giai 160-169 Gial Green et a l 
(1990)
SMl ARYLDQINLL Gi6a 363-373 
last 10 aa
G l5 a /G l6 a None Available
CS3 RMHLRQYELL Gsa 385-394 Gsa Milligan &Unson
(1989)
CQ5 QLNLKEYNLV Gqa 351-360 Gqa, G] la Mitchell et a l 
(1991)
(Kodak). The exposure time was varied by referring to the level of background 
exposure on the processed film in order to get a better signal to noise ratio.
2.14 Densitom etric analysis of G-protein expression
Autoradiography images of ECL processed immunoblots were densitometrically 
scanned on a Bio-Rad GS-360 imaging densitometer and analysed on an Apple 
Macintosh Quadra 800 microcomputer pre-loaded with Bio-Rad GS-360 software.
2.15 Radioligand binding a ssa y s
2.15.1 Determination of a 2A adrenergic receptor exp ression
ajA  adrenoceptor expression was determined as according to Wise and Milligan 
(1997). The assay was routinely performed with approximately 1.4nM [3H] RS-79948- 
197 at 30®C for 30 minutes in lOmM Tris-ITCl (pH7.4), 50mM sucrose, 20mM MgCfr 
(binding buffer A) in the absence and presence of lOOpM idazoxan to define maximal 
and non-specific binding respectively. Binding experiments were terminated by rapid 
filtration through Branded FP-200 GF/C filters using a Branded cell harvester. All FP- 
200 filters were pre soaked for at least 10 minutes in binding buffer A prior to use. The 
initial rapid filtration was followed by three washes of the filter with 3x 5ml volumes of 
ice cold binding buffer A. Filters were left to dry at room temperature for 2 hours before 
being soaked overnight in 5ml of Ultima Gold XR liquid scintillation cocktail prior to 
being counted on a scintillation counter (Beckman Instruments Inc., CA, USA).
2.15.2 A gonist stim ulated binding of [^^S] GTPyS
Agonist stimulated [^^S]GTPyS binding assays were performed according to 
Wieland and Jakobs (1994). Membrane suspensions (5-1 Opg) were incubated with 50- 
100 nCi of GTPyS in a reaction mix consisting of 20mM FÎEPES (pFI7.4) 5mM 
MgCb, lOOmM NaCl and 5pM GDP in a total reaction volume of lOOpl. To prevent 
decomposition of the nucleotides the GDP was added to the reaction mix just prior to 
performing the binding and was stored as a lOOmM stock in Tricine (pH 7.4) at -20°C. 
The same was true for the labelled and unlabelled [^^S] GTPyS which was stored in 
ti’icine (pH 7.6), lOmM DTT at -80^C. Unless otherwise stated the reaction was 
incubated at 30°C for 30 minutes in the presence and absence of agonist. Non-specific 
binding was assayed by replacing agonist with lOpM unlabelled GTPyS.
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Reactions were terminated by vacuum filtration through Brandell FP-200 GF/C 
filters pre-soaked in filter wash buffer (20mM HEPES (pH 7.4), 5mM MgCfr). 
Unbound ligand was removed from the filters by three subsequent 5ml washes with ice 
cold filter wash buffer. The filters were then prepared as in Section 2.15.1 before being 
counted. Assays were performed in triplicate.
2.16 High affinity GTPase a ssa y
The high affinity GTPase assay was performed essentially as described by Koski 
and Klee (1981). Aliquots of reaction mix (lOOpl) (2mM App(NH)p, 2mM ATP, 2mM 
ouabian, 20mM creatine phosphate, O.lU/ml creatine phosphokinase, 200 mM NaCl, 10 
mM MgCl2, 4mM DTT, 0.2mM EDTA, 80mM Tris-HCl (pH 7.5), 0.5pM [y-^^P]GTP) 
were added to tubes on ice containing 5-10 pg of membrane protein and either agonist, 
water or GTP (ImM). The reaction was initiated by removing the tubes from the ice 
slurry, vortexing them and then transferring them to a 37°C water bath. The assay tubes 
were incubated at 37°C for 20 min, after which the reaction was terminated by the 
addition of 900 pi of ice cold charcoal mix (5% activated charcoal in lOmM H3PO4). 
After centrifugation at 15000g for 5 min, radioactivity was measured in a 500 ml 
sample by Cherenkov counting on a 1219 Rackbeta liquid scintillation counter (Wallac, 
Finland). The rate of high affinity GTP hydrolysis (pmol/mg/min) was calculated by 
subtracting the reading from the GTP control tube and by taking into account the 
specific activity of the labelled [y-^^P]GTP, the concentration of unlabelled GTP, the 
membrane concentration and the incubation time.
2.17 Trypsinisation protection a ssa y
The trypsinisation protection assay was performed essentially as described by 
Denker et al. (1995). Samples (lOOpl) were incubated in parallel in the presence or 
absence of lOOpM GTPyS for 15 minutes at 37°C in buffer A (20mM Tris-HCl (pH8.0), 
25mM MgCb, 2mM DTT and O.lmM EDTA). At the end of the incubation period, the 
samples were once again incubated in parallel in the presence or absence of TPCK 
inactivated tiypsin for a further 15 minutes at 37, after which the trypsinisation process 
was terminated by the addition of soya bean trypsin inhibitor to a final concentration of 
0.5mg/ml. Following the termination of the reaction, the samples were precipitated by 
the addition of ice cold buffer B (6% TCA, 0.5% deoxycholate), incubated on ice for 15 
minutes and then centrifuged for a further 10 minutes at 15000g. Following the removal
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of the supernatant was then removed, the samples were re-suspended in equivalent 
volumes of 2M Tris-HCl and Laemmli sample buffer, before being boiled at 100°C for 
5 minutes. The samples were finally resolved by SDS-PAGE gel electrophoresis 
(Section 2.11) and transferred to nitrocellulose (Section 2.12.1) before being probed 
with appropriate antisemm as detailed in Table 2.1.
2.18 Growth of Escherichia coli strains
Escherichia coli {E.Coli) strains were grown at 37°C either as liquid cultures or 
on agar plates. E.coli strains grown on agar plates were incubated in a temperature 
controlled room while liquid cultures were propagated in a Stuart Scientific Si50 orbital 
incubator with continuous shaking. The growth medium used was Luria-Bertani 
medium (LB-medium) consisting o f l%(w/v) bacto hyp tone, 0.5%(w/v) bacto yeast 
extract and l%(w/v) NaCl. The LB medium was supplemented with 1.5%(w/v) agar for 
use in 90cm^ petri dishes.
E.coli clones which had been transformed with plasmids containing the 
ampicillin antibiotic resistance gene were selected on LB agar plates containing 
50pg/ml ampicillin. Liquid cultures of transformed clones were also grown in medium 
supplemented with antibiotic. E.coli clones h'ansformed with plasmids containing both 
the ampicillin resistance gene and the (3-galactosidase reporter gene were grown on LB- 
agar plates supplemented with 50pg/ml ampicillin, 20jal of 200mM IPTG and 20pl of 
10%(w/v) X-Gal. Liquid cultures of such clones were grown as above.
All media and solutions, unless otherwise stated, were sterilised by autoclaving 
for 15 minutes at 12LC. Ampicillin (50mg/ml) and IPTG (200mM) were prepared as 
stock solutions and sterilised by filiation through 0.22pm syringe filters.
2.19 Cryogenic storage of transformed E.coli
E.coli bacterial strains were cryogenically preserved as follows. The E.coli 
liquid culture was diluted with 80%(v/v) sterile glycerol to give a final composition of 
15%(v/v) glycerol 85% bacterial culture. Aliquots of 1ml were snap frozen on dry ice 
and stored at ~80°C.
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2.20 Preparation of chem ically com petent E.coli
Untransformed E.coli cells were streaked onto LB-agar plates in the absence of 
antibiotic and incubated overnight at 37°C. From this plate a single colony was picked 
and used to inoculate a 5ml LB medium culture, the culture was incubated overnight at 
37°C with continuous shaking. The 5ml culture was used to inoculate 500ml of LB 
medium which was cultured until it reached a growth density of Ix 10  ^ cells/ml 
(equivalent to OD 600 of approximately 0.25 absorbence units). The culture was then 
cooled on ice for 30 minutes and the bacterial cells were harvested by centrifugation at 
10,000 rpm for 10 minutes at 4®C in a Beckman J-2-21 centrifuge equipped with a Ja-14 
rotor. The supernatant was discarded and the E.coli pellet was re-suspended into 40ml 
sterile ice cold buffer 1 (lOOmM RbCb, lOmM CaCb, 50mM MnCL, 15%(v/v/) 
glycerol and 30mM KAc (pH 5.8)). The E.coli suspension was left to chill on ice for 5 
minutes before being re-centiifuged as before. The supernatant was again discarded and 
the E.coli pellet was re-suspended in 2ml sterile ice cold buffer 2 (lOmM RbCL, 75mM 
CaCb, 15%(v/v) glycerol, lOmM MOPS (pH 6.5)). The resuspended bacteria were 
chilled on ice for a further 15 minutes before being snap fi'ozen and stored at -80°C in 
250pl aliquots.
2.21 Transformation of chem ically com petent ce lls
Care was taken to thaw the competent cells on ice before use so as to minimise 
cell death. An aliquot of lOOpl of competent cells was incubated with either 50ng of 
supercoiled plasmid DNA or lOpl of ligation reaction. The DNA/competent cell mix 
was left to incubate on ice for 15 minutes before being heat shocked at 42°C for 90 
seconds. After the heat shock step the cells were returned to ice for 2 minutes before 
being incubated with 800pl LB at 2>TC for 1 hour with continuous shaking.
Aliquots of 100-200pi of cells were plated onto LB agar plates supplemented 
with 50pg/ml ampicillin and other selection reagents as dictated by the plasmid being 
ti'ansformed. Plates were incubated overnight at 37°C and transformed clones were 
selected and grown in 5ml cultures containing 50pg/ml ampicillin.
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2.22 Preparation of plasmid DNA
2.22.1 Small sca le  DNA preparation
Small scale DNA preparation was performed using the Wizard Plus SV 
miniprep DNA purification system (Promega) as according to manufacturer's 
instmctions. A total of 3ml of overnight bacterial culture was pelleted by centriftigation 
at 21000g in an lEC micromase RF centrifuge. The supernatant was discarded and the 
pellet was re-suspended in 250pl cell resuspension solution (lOmM EDTA, lOOpg/ml 
RNase A, 50mM Tris-HCl (pH7.5)) by vortexing. The cells were then lysed by the 
addition of 250pl of cell lysis solution (0.2M NaOH and 1% SDS), the contents of the 
tube were mixed by inverting. Lysis was deemed to be complete when the lysate 
became translucent. Further lysis was terminated by addition of 350pl of neutralisation 
solution (4.09M guanidine hydi'ochloride, 0.75% potassium acetate (pH4.2), 2.12M 
glacial acetic acid, the contents were once again mixed by inverting the tube 4 times. 
The bacterial lysate was cleared by centrifugation as described earlier. The clear 
supernatant was centrifuged at 14000g for 1 minute and the flow through from the 
column was discarded. The SV miniprep spin column was washed twice with first 
750pl and then 250pi of column wash solution (60mM potassium acetate, lOmM Tris- 
HCl (pH 7.5) and 60% ethanol), each time the spin column was centrifuged and the 
flow through was discarded. The spin column was then allowed to air dry for 5 minutes 
to allow any residual ethanol to evaporate. The plasmid DNA was eluted from the spin 
column and then centrifuging as above.
2.22.2 Large sca le  preparation of plasmid DNA
Large scale DNA preparation for mammalian cell transformation was performed 
using the Quiagen plasmid maxi kit (Quiagen) as according to manufacturers 
instructions. A total of 250ml of overnight bacterial culture was pelleted by 
centrifugation at lOOOOrpm in a Beckman J2-21 centrifuge equipped with a JA-14 rotor. 
The supernatant was discarded and the pellet was re-suspended in 10ml of buffer PI 
(lOmM EDTA, 50mM Tris-HCl (pH8 ) by pipetting and vortexing. The bacterial 
resuspension was lysed by the addition of 10ml of buffer P2 (200mM NaOH, 1% SDS) 
mixing was by gentle inverting. Cell lysis was terminated after 5 minutes by the 
addition of 10ml of buffer P3 (3M potassium acetate pH 5.5). Chromosomal DNA was 
allowed to precipitate by incubating the lysate on ice for 20 minutes. The lysate was
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cleared by centrifuging at 2000rpm for 1 hour in a Beckman TJ-6 centrifuge. Any 
remaining particulate matter which had not been sedimented was removed by filtering 
the supernatant thiough mira cloth. The supernatant was applied to a Quiagen-tip pre­
wetted with 10ml of buffer QBT (750mM NaCl, 0.15% Trition X-IOO, 15% 
isopropanol, 50mM MOPS (pH7.0)). The Quiagen tip was then washed with 2x 30ml of 
buffer QC (IM  NaCl, 50mM MOPS (pH7.0), 15% isopropanol). The plasmid DNA was 
subsequently eluted into a 50ml polycarbonate tube by the addition of 15ml of buffer 
QF (1.25M NaCl, 50mM Tris-HCl (pH 8.5), 15% isopropanol). The plasmid DNA was 
precipitated by centrifugation at 16000rpm as above. The supernatant was discarded and 
the pellet washed with 5ml ice cold 70% ethanol before being dried in a 50°C oven. The 
pellet was re-suspended in 500pl of nuclease-free water.
2.23 Restriction d igestion  of DNA
DNA was digested with one or more of the restriction endonucleases listed in 
Table 2.2 at a final concentration of 0.1 pg/ml in a total reaction volume of not less than 
lOpl. The DNA and restriction endonucleases were incubated at 30^C for 2 hours in a 
Ix concentration of the appropriate buffer as referenced from Tables 2.2 and 2.3.
2.24 Ethanol precipitation of DNA
DNA was precipitated from solution with 0.25 vol. of 3M sodium acetate (pH 
7.0) and 2.5 vol. of absolute ethanol at -20°C for 30 min. The precipitated DNA was 
pelleted by centrifugation at 21000g for 10 minutes. Sodium acetate was removed by 
washing the pellet twice with ice cold 70% (v/v) ethanol. The DNA pellet was then air 
dried at 60°C in an oven before being re-suspended in sterile de-ionised H2O.
2.25 Quantitative and qualitative analysis of DNA
The concentration and quality of a DNA sample produced by large or small 
scale plasmid purification was determined by measuring the absorbance at both 260 and 
280nm (A260, A280). The DNA sample was diluted to 1 in 200 in sterile Milli Q H2O 
to a final volume of 1ml. The A260 reading for the sample was determined on a 
Shimadzu UV-2101 spectrophotometer. The concentration was calculated assuming that 
1 absorbence unit was equivalent to 50pg/ml of double stranded DNA. The purity of the 
DNA was assessed by measuring the A280 in parallel and calculating the ratio of 
A260:A280. A ratio of 1.8 was considered sufficiently pure for use. The concentration
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Table 2.2 Restriction endonuclease buffer requirements
The restriction endonucleases used in this study are listed in combination with 
the buffer required from maximal endonuclease efficiency. The composition of the 
buffers listed in this table are detailed in Table 2.3.
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Table 2.2
Enzyme Buffer
Nru I B
Eco RI H
Bam HI ! EcoRI B
Smal / Bgl II A
Ncol l Not I H
Xho I H
Pvu I / Eco RI / Hind III B
Eco RI / Hind III B
Pvu I H
Not I  / Hind III H
Not 11 Xho I H
Table 2.3 C om position of restriction en d on u clease buffers
Table 2.3 details the composition of buffers used in restriction digestion of 
DNA with the restriction endonucleases listed in Table 2.2. All values listed represent 
the final concentration in mM,
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Table 2.3
Buffer
Reagent A B L M H 4
Tris acetate 33 - " - 20
Tris-HCl - 10 10 10 50 -
Magnesium acetate 10 - - 10
MgClz ” 5 10 10 10 -
Potassium Acetate 66 - « - - 50
NaCl - 100 - 50 100
Dithioerythriotol (DTE) - 1 1 1 -
Dithiothreotol (DTT) 0.5 - - - - 1
2-mercaptoethanol - 1 - - " “
pH at 37°C 7.9 8.0 7.5 7.5 7.5
pH at 2 5 T - " - - - 7.9
of the DNA sample was coiifumed by imaging on an agarose gel against standards of 
known concentration,
2.26 Separation of plasmid DNA by electrophoresis
Restriction enzyme digested DNA was routinely analysed and purified by 
agarose gel electrophoresis. Samples were prepared by the addition of 6 x loading 
buffer (30% (v/v) glycerol, 0.25% (w/v) bromophenol blue) to give a final 
concentration of 1 x loading buffer. DNA fragments between the size of 0.5kb and 7kb 
were separated by electrophoresis through a 1% (w/v) agarose gel containing 1 x TAE 
buffer (40mM Tris-acetate, ImM EDTA (pH 8.0)). Smaller DNA fragments of sizes of 
less than O.Skb were separated on 1.5-2% (w/v) agarose gels.
Electrophoresis was conducted towards the anode at 70-100mA at room 
temperature in a horizontal electrophoresis tank containing 1 x TAE buffer. Upon 
completion of electrophoresis separation DNA fragments were visualised by incubating 
the agarose gel in a 2.5mg/ml ethidium bromide solution for 10 minutes and then 
illuminating with UV light. Fragment sizes were assessed by comparison with DNA 
molecular weight markers of known length,
2.27 Purification of DNA from A garose g e ls
Upon electrophoresis and visualisation of DNA samples (as in Section 2.26) 
DNA fragments of interest were recovered using a modified protocol of the Wizard 
DNA clean-up system (Promega). The fragment to be purified was excised from the 
agarose gel and melted in 300pl of 6M Nal at 65°C. The DNA solution was then cooled 
on ice for 2 minutes before being incubated with 1ml of Wizard DNA clean-up 
purification resin. The resin was incubated with the DNA solution for 2 minutes, mixing 
was achieved by constant gentle inversion. At the end of the incubation period the DNA 
resin mix was applied to a Wizard minicolumn and drawn through under vacuum. The 
wizard minicolumn was then washed with 2ml of 80% (v/v) isopropanol which was also 
drawn thr ough under vacuum. The minicolumn was dried of any remaining solvent by 
centriftigation at 21000g for 2 minutes followed by vacuum drying for a ftirther 5 
minutes.
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The DNA was eluted from the minicolumn by the application of 25pi of 
nuclease free water pre-heated to 80^C followed by centrifugation at 21000g for 1 
minute. The eluted DNA was quantitated as described in Section 2.25.
2.28 P hosphatase treatment of DNA
Restriction enzyme digested vector was treated with calf intestinal 
alkaline phosphatase (Cip) to prevent re-circularisation during ligation by removing the 
5' phosphate. The vector was heat-treated to 70“C for 15 minutes on a hot block 
(Techne) to denature the ends of the DNA. The DNA was cooled on ice for 2 minutes to 
prevent re-ligation of the ends of the denatured vector. Phosphatase treatment was 
performed at 37*^ C for 5 minutes using 1 unit of Cip in a Ix concentration of the 
supplied buffer (0.5M Tris (pH 9.3), lOmM MgCfi, ImM ZnCh and lOmM 
spermidine). The de-phosphoiylation was repeated one more time before being 
terminated by heating the sample to 72°C for 10 minutes. The dephosphoiylated vector 
was purified by agarose gel electi’ophoresis (Section 2.26) and gel extraction (Section 
2.27).
2.29 Ligation o f DNA fragm ents
Ligation of vector and insert DNA was routinely carried out overnight at 
4°C in a reaction volume of lOpl containing a Ix concentration of ligation buffer 
(300mM Tris-HCl (pH7.8), lOOmM MgC12, lOOmM DTT and lOmM ATP), 3 Weiss 
units of T4 DNA ligase plus vector and insert DNA fragments. Reactions were 
performed using vector to insert ratios of 1:10 for fragments with blunt ends or 1:3 for 
fragments with overhanging ends. The vector concentration was kept constant at lOOng 
/ reaction and the insert concentiations were varied for all reactions conducted in this 
study. Ligated DNA was then transformed as described in Section 2.21.
2.30 PCR amplification
DNA amplification by polymerase chain reaction was routinely 
performed in a reaction volume of 50pl containing 50ng of DNA template, dNTPs 
(0.2mM each dATP, dCTP, dGTP, dTTP (Pharmacia)), lOOpmol each of sense and 
antisense oligonucleotide primers (as indicated in Table 2.4 and 1 unit of Pfu DNA 
polymerase (Stratagene) in a Ix concentration of Pfu reaction buffer (200mM Tris-HCl 
(pH8.8), 20mM MgS04, lOOmM KCl, lOOmM (NH4)2S04, l%(v/v) Trition X-100 and
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Img/ml nuclease free BSA). The temperature cycling conditions were as in Table 2.5. 
All reactions were performed using a Perkin-Elmer 9600 thermal cycler.
2.31 DNA seq u en cin g
Sequence data was generated at the dedicated sequencing facility at Glaxo- 
Wellcome Research and Development (Stevenage, UK) using an ABI 377 Prism 
sequencing machine. The sample to be sequenced was presented as 500ng template and 
3.2pmol o f oligonucleotide primer as indicated in Table 2.6 in a total volume of 12pl of 
nuclease-ffee water.
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Table 2.4 Oligonucleotide primers for mutagenesis
Oligonucleotide primers used for mutagenesis of Giai cDNA are listed in 
combination with the specificity of the mutation generated and the nucleotide sequence 
of the primer.
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Table 2.4
Primer Mutation generated Primer sequence (5’ to 3’)
Common 5’ 
primer
none AGCT GAA TTC GCC ACC ATG GGC TGC ACA CTG 
AGC GC
3’ primer 1 to île,Met, Thr, Asn, 
Lys, Ser, Arg
ACGT GAA TTC TTA GAA GAG ACC (G/C)NT GTC 
TTT TAG G
3’ primer 2 Cys^ '^ to Pro, Arg, Leu ACGT GAA TTC TTA GAA GAG ACC (C/G)(A/G/C)G 
GTC TTT TAG G
3’ primer 3 Cys^ *^ to Val, Ala, Asp, Glu ACGT GAA TTC TTA GAA GAG ACC (C/G)(T/G/A)C 
GTC TTT TAG G
3’ primer 4 Cys^ ‘^ to Phe, Tyr, Trp, Leu ACGT GAA TTC TTA GAA GAG ACC (C/G)(C/T/A)A 
GTC TTT TAG G
3’ primer 5 Cys^ ^^  to His ACGT GAA TTC TTA GAA GAG ACC GTG GTC TTT 
TAG G
3’ primer 6 Cys^ *^ to Gin ACGT GAA TTC TTA GAA GAG ACC CTG GTC TTT 
TAG G
3’ primer 7 Cys^ *^ to Lys ACGT GAA TTC TTA GAA GAG ACC CTT GTC TTT 
TAG G
3’ primer 8 Cys^ ‘^ to Thr ACGT GAA TTC TTA GAA GAG ACC TGT GTC TTT 
TAG G
3’ primer 9 Cys^ ‘^ to Ala ACGT GAA TTC TTA GAA GAG ACC CGC GTC TTT 
TAG G
3’ primer 10 Last 6 amino acids of G^a to
Gsa
CCA CGT GAA TTC TTA TTA GAG TTC ATA TTG 
CCT TAG GTT ATT CTT TAT
3’ primer 11 Last 6 amino acids of Gna to 
Gqa
CCA CGT GAA TTC TTA GAC GAG ATT ATA TTC 
TTT TAG GTT ATT CTT TAT
3’ primer 12 Last 6 amino acids of G^a to 
G16a
CCA CGT GAA TTC TTA GAG GAG ATT AAT TTC 
ATC TAG GTT ATT CTT TAT
Table 2.5 Conditions for PCR mutagenesis
Table 2.5 details the temperature cycles used for PCR mutagenesis of Giai 
cDNA in combination with the number of amplifications at each cycle.
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Table 2.6
Denaturing 
(temp./time)
Annealing 
(temp./time)
Extension
(temp./time)
Number of 
cycles
95oC/2min 55oC/45sec 72oC/3min 1
95oC/45sec 55oC/45sec 72oC/3min 30
95oC/45sec 55oC/45sec 72oC/5min 1
Table 2.6 Oligonucleotide primers for sequencing
Oligonucleotide primers used for sequencing in this study are listed in 
combination with the nucleotide sequence of the primer.
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Table 2.6
Prim er Prim er sequence (5' to 3')
SP6 CAT ACG ATT TAG GTG ACA CTA TAG
T7 TAA TAC GAC TCA CTA TAG GGA GA
T3 ATT AAC CCT CAC TAA AGG GA
Chapter 3
The coupling efficiency of C351x Gi«i 
mutants at the a zA  adrenoceptor
3.1 Introduction
G-proteins are membrane associated heterotrimeric GTP binding proteins which 
mediate the transduction of a signal from a cell surface receptor to an effector molecule. 
They are composed of three subunits designated a , (3 and y. The a-subunit contains a 
nucleotide binding pocket into which either GDP or GTP can bind. G-proteins can exist 
in either an active or inactive conformation, in the inactive conformation the a-subunit 
contains GDP in the nucleotide binding pocket and is in tight association with the (3y 
subunits. Activation occurs through receptor catalysed guanine nucleotide exchange in 
the a-subunit. The GDP molecule dissociates from the a-subunit and is replaced by 
GTP; this results in a confoimational change in the (3 subunit binding site and so (3y 
dissociation. The GTP bound G a-subunit and the (3y subimits are then free to interact 
with and activate downstream effectors. G-protein deactivation occurs when the a- 
subunit hydrolyses GTP to GDP, resulting in a conformational change back to the 
inactive state and the re-association of (3y. The rate of hydrolysis varies between the four 
main classes of a-subunit. Osawa and Weiss (1995) demonstrated that PTX sensitive a- 
subunits such as Gta , Goa and Gia posses a higher intrinsic GTP hydrolysis activity than 
PTX resistant forms such as Gqa and Gsa. This high catalytic activity is the basis behind 
assays measuring either the hydrolysis of GTP to GDP (GTPase assay) or receptor 
catalysed exchange of GDP for the non-hydrolysable GTP analogue GTPyS 
([^^S]GTPyS binding assay).
The specificity and efficiency of receptor /G-protein coupling is determined by 
the C-terminal tail of the G% subunit. Alanine scan mutations in the last 7 amino acids in 
the C-terminal tail of Gta have shown that specific mutations can lead to a loss of 
receptor coupling or guanine nucleotide exchange and in some extreme cases both 
functions (Osawa and Weiss, 1995). From this study the leucine residues L344 and 
L349, which are conserved among all Ga subunits, were found to be intolerant to 
mutation in Gta- Substituting alanine at either of these positions resulted in a loss of 
receptor coupling and nucleotide exchange function (Osawa and Weiss, 1995; Garcia et 
a i, 1995). It could be postulated that because these residues are conserved throughout 
all Ga subunits that they play a vital role in G-protein function. However, mutations of 
the equivalent residues in Gsa (L388A) and Gia (L349A) have shown this not to be the 
case, these mutants display little or no decrease in guanine nucleotide exchange or
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receptor coupling. A similar case exists for the Gta C347 residue, which is conserved in 
the ai, ao  and a t subunits. The C347 residue is one of many potential sites for post- 
translational modification by bacterial toxins. Pertussis toxin catalysed ADP- 
ribosylation at this cysteine residue results in a loss of receptor coupling, the molecular 
mechanism behind this is though to be due to steric hindrance by the ADP-ribose group. 
To study the importance o f the C347 residue in Gta,, the residue was mutated to both 
alanine and the equivalent residue of Gqa, tyrosine (C347Y). The two mutants displayed 
profoundly different activities, the C347Y mutation abolished all activity while the 
C347A mutation only resulted in a slight decrease in coupling efficiency (Osawa and 
Weiss, 1995). The mutation o f the equivalent residue in Giai to glycine (C35ÎG) 
(Senogles, 1994) or serine in G,a3 (C351S) (Hunt et a l, 1994) has been shown to confer 
resistance to pertussis toxin treatment whilst retaining receptor coupling and nucleotide 
binding activity. From these findings it seems as if the mutation of the Giai C351 may 
provide a general strategy for the generation of PTX resistant mutants. The effects of 
the Gta C347Y mutation can be reversed by mutating the adjacent amino acids to those 
of Gqa (D346E, C347Y, G348N, F350V) (Osawa and Weiss, 1995). In a similar 
observation Conklin et a/. (1993) has shown that replacement of the last 3 C-tenninal 
amino acids in Gqa to those o f Gia can change the a-subunit’s receptor specificity to that 
o f a Gi subunit. Not all residues in the C-terminal tail of Gta are equally susceptible to 
mutation. The F350 residue in the Gta was shown to be very tolerant to substitution, 
only the removal or insertion of a single amino acid at this position could abolish 
nucleotide binding activity (Osawa and Weiss, 1995). In comparison Denker et 
#7(1992) had previously demonstrated that the deletion of 5,10 and even 14 amino acids 
from the C-terminus of Goa resulted in no loss of GTPyS binding, although the 14 
amino acid deletion did result in a loss of GDP affinity. This would suggest that the 
length of the C-terminal tail may play a more important role in Gta than in other a - 
subunits. These findings would indicate that the specificity of receptor/G-protein 
interaction is determined by the combined structural and physiochemical properties of 
the residues in the C-terminal tail as opposed to specific interactions with one or two 
key residues. It can also be inferred that a-subunits respond differently to mutations in 
the C-terminal tail, therefore it would be unwise to predict the effects of mutating 
equivalent residues in different a-subunits.
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The most convenient way of analysing G-protein mutants, such as those 
described above, is by transient transfection. Transient transfection allows the rapid 
analysis of overexpressed signal transduction components, as well as their mutant 
variants, in the natural enviromnent of the cell membrane. Unfortunately the presence of 
endogenous receptor and G-proteins frequently interferes with the output of several 
biochemical assays used to characterise G-protein function. Since a major source of 
interference comes from endogenously expressed PTX sensitive G-proteins, it can 
easily be removed by PTX treatment. Receptor/G-protein interactions can then be 
assayed through transiently expressed PTX resistant G-protein mutants.
It has already been demonstrated that mutating the cysteine residue 351 in Giai, 
Gia2 or Gia3 to glycine or in Gjas to serine (Senogles, 1994; Hunt et at., 1994) generates 
a pertussis toxin insensitive G-protein mutant capable of coupling to Gia associated G- 
protein receptors. However the Giai C^^^G mutant has been shown to couple an order of 
magnitude less effectively to the a 2A adrenoceptor than the wild type thereby 
producing a lower maximal output (Wise et a l, 1997d). In order to use such a strategy 
in ligand screening it would be advantageous to produce mutants whose coupling 
efficiency was equal to or greater than that of the wild type. In order to find such 
mutants it was decided to systematically substitute the cysteine residue at position 351 
in Giai to all other amino acids.
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3.2 R esults
3.2.1 Generation of C^®^Xaa Giai mutants by PCR m utagenesis
The cysteine residue 351 in rat Giai was mutated to all other amino acids by 
PCR amplification (Section 2.30) of Nrul linearised (Section 2.23) wild type rat Giai 
cDNA in the pBluescript KS(-) (Stratagene) vector. The PCR reaction used lOOpmol 
each of a common 5’ forward primer and one of four degenerate 3’ reverse primers 
(Table 2.4). The reaction conditions were as in Table 2.5.
The amplicons were resolved on a l%(w/v) agarose gel and stained with 
ethidium bromide as in Section 2.26. DNA corresponding to the 1065bp band (Fig. 3.1) 
was excised from the gel and purified (Section 2.27) before being ligated into the pCR- 
Script SK(+) (Stratagene) vector as described in Section 2.29. The ligated DNA 
products were tiansfbrmed into the bacterial strain XL 1-blue (Stratagene) and grown on 
agar plates supplemented with ampicillin, X-gai and IPTG (Section 2.18).
Blue/white colour selection was used to select white clones containing 
recombinant vector, blue clones were deemed to contain empty vector. Twenty-five 
clones were selected and cultured from each of the transformations (Section 2.18) 
giving one hundred samples in total. The plasmid DNA was extracted from the cultures 
by a small scale DNA preparation (Section 2.22.1) and visualised on a l%(w/v) agarose 
gel (Fig. 3.2). Two discrete rates of supercoiled plasmid migration were obseiwed, only 
clones whose DNA migrated the least were analysed for the presence and orientation of 
the insert. Seventy-six clones out of the 100 arbitrarily chosen were found to be positive 
for insert.
A restriction digest with the enzymes Notl and Ncol (Section 2.23) was used to 
screen the orientation of the insert in the pCR-Script vector. The digestion products 
were resolved on a l%(w/v) agarose gel (Fig, 3,3). The presence of two distinct bands 
indicated that the start codon of the G,ai cDNA was next to the T3 promoter priming 
site, such clones were sequenced with the opposing T7 primer. The presence of three 
bands indicated that the start codon was next to the T7 priming site and therefore the T3 
primer was to be used for sequencing. Using this orientation data, the 3’ end of the Giai 
mutant cDNA was sequenced (Section 2.31) by either the T3 or T7 primer (Promega).
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The sequencing profiles were translated to determine the amino acid encoded at 
position 351 in the G-protein mutant Using this approach 13 out of the 18 required 
amino acid substitutions were generated. Dedicated 3’ reverse primers (Table 2.4) were 
used to generate the remaining amino acids -  glutamine, histidine, leucine, threonine 
and alanine. One clone was arbitrarily chosen from each mutation to be subcloned into 
the mammalian expression vector pCDNAS.
The Giai mutants were subcloned into the mammalian expression vector 
pCDNA3 (Invitrogen) according to the following strategy. If the Giai mutant cDNA was 
subcloned into the pCR-Script vector with the start codon next to the T3 promoter 
priming site the cDNA was excised using the restriction enzymes Notl and Xhol and 
subcloned into the pCDNAS vector digested with the same two enzymes. Clones with 
the Giai cDNA in the opposite orientation were similarly subcloned into pCDNA3 using 
the restriction enzymes Notl and EcoRI.
3.2.2 Transient exp ression  of Giai point mutants with the 
porcine a ik  adrenoceptor
The HEK293T cell line was transiently co-transfected (Section 2.8) with the 
porcine aiA  adrenoceptor cDNA in pCDNAS in combination with C^^^Xaa Giai 
mutants in pCDNA3. The transfected cells, with the exception of the wild type Giai co­
transfection, were treated with 50ng/ml of pertussis toxin 12 hours prior to harvesting 
(Section 2.7) in order to inactivate the endogenously expressed (PTX sensitive) G- 
proteins by ADP-ribosylation. At 72 hours post transfection cells were harvested and 
membranes were prepared as in section (Section 2.9).
3.2.3 Immunodetection of the expression  of Giai point mutants 
co-transfected into HEK293T ce lls  with the porcine a^A 
adrenoceptor
The expression levels of the C^^^Xaa Giai mutants co-transfected with the 
porcine azA adrenoceptor were compared in the same membrane preparation as that 
used to generate receptor and GTPyS binding data. A sample of membrane preparation 
was resolved on a 10% SDS-PAGE gel as described in Section 2.11. The resolved 
proteins were subsequently western blotted onto a nitrocellulose membrane (Section 
2.12) which was then probed for Giai immunoreactivity using the antiserum IlC  as 
detailed in Table 2.1. It can be seen from Fig. 3.4 that all C^^’Xaa Giai cDNAs
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transfected were over expressed at levels higher than endogenously expressed Gjcd, in 
cells transfected with receptor alone (lane C-). It was also noted that there was some 
variation in Giai mutant expression between transfections.
3.2.4 The relative exp ression  levels of the porcine azA 
adrenoceptor in HEK293T ce lls  co-transfected with the C^^^Xaa 
Giai mutants are not significantly different
The expression level of the porcine a]A  adrenoceptor was assayed in HEK293T 
cells co-transfected with both empty vector and C^^^Xaa Giai cDNA. The receptor 
binding assay was carried out as described in Section 2.15.1. Analysis of the receptor 
binding data (Fig. 3.5) shows that the porcine a 2A adrenoceptor was expressed at levels 
at or above 9pmol/mg in all o f the co-transfections assayed. From other studies (Wise et 
a l, 1997d) it can be assumed that variation in receptor expression between transfections 
was not large enough to affect [^^S]GTPyS binding in this membrane preparation.
3.2.5 The exp ression  level of C^^^Xaa Gi«i mutants in creases  
upon transfection with increasing am ounts of cDNA
The C^^*A Giai mutant was arbitrarily chosen to examine if a relationship 
existed between the amount of cDNA transfected into the HEK293T cells and the level 
of G-protein immunodetected with the antiserum IlC. HEK 293T cells were co­
transfected with 1.5pg of porcine a2A  adrenoceptor and from 0.15 to 1.5pg of C^^'A 
Giai cDNA. The total amount of cDNA transfected (3 |ig) was standardised in each 
experiment by using empty pCDNA3 vector. The expression level of C^^'A Giai was 
detected by resolving 25 pg of membrane preparation on a 10% SDS-PAGE gel 
followed by western blotting and immunodetection with the IlC  antiserum (Table 2.1). 
From the immunoblot (Fig. 3.6) it can be seen that the expression level of the C^^^A 
Giai mutant was proportional to the amount of cDNA transfected.
3.2.6 A linear function ex ists  between C^ ^^ A Giai expression  and 
[3®S]GTPyS binding at non-limiting receptor expression  levels  
and maximal agon ist concentration
A correlation between C^^^A Giai expression and [^^S]GTPyS binding at non­
limiting receptor and agonist concentrations was determined in HEK293T cells co­
transfected with porcine a 2A adrenoceptor cDNA (1.5 ug) and increasing quantities of
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Giai cDNA (0.15, 0.3, 0.75 and 1.5pg). The cells were treated with PTX to 
remove the endogenous G-protein signalling component 12 hours prior to harvesting 
and membrane preparation. The level of C^^'A Giai expression was quantitated by 
densitometric analysis of a representative immunoblot probed with the Giai specific 
antiserum IlC  (Fig. 3,6). In parallel a [^^S]GTPyS binding assay was performed on the 
same membrane preparation. By stimulating the cognate receptor with UK 14304, an 
azA adrenoceptor agonist, it can be seen in Fig. 3.7 that a linear function describes 
[^^SJGTPyS binding versus the level of G-protein expression.
3.2.7 The relative efficiency of C^^^Xaa Giai mutants to bind 
[3®S]GTPyS in resp on se  to UK14304 stim ulation of the azA 
adrenoceptor
The capacity of each of the C^^^Xaa Giai mutants to bind the non-hydrolysable 
GTP analogue, [^^S]GTPyS, in response to UK14304 stimulation o f the azA 
adrenoceptor was measured as detailed in Section 2.15.2. The dose response data for 
each of the G-protein mutants was plotted using the mathematical package Robosage 
(Fig. 3.8). In parallel, the expression level of each of the mutants was quantitated by 
densitometric analysis of a representative immunoblot probed with the Giai specific 
antiserum IlC  (Section 2.14). The maximal [^^SjGTPyS binding value of each of the 
C^^^Xaa Giai mutants was then normalised with regard to the level of G-protein 
expression. The data (Fig. 3.9), now corrected for variation in G-protein expression, 
depicts the efficacy of the C^^^Xaa Giai mutants to bind [^^SJGTPyS relative to wild 
type Giai in response to activation by the azA adrenoceptor fully occupied by 
UK14304.
3.2.8 Demonstration of the capacity of poorly activated C^^^Xaa 
mutants to bind GTPyS
The capacity of poorly activated mutants to exchange nucleotides was confirmed 
by limited trypsin digestion of such mutants in both the presence and absence of 
GTPyS. In this assay only G-proteins in the GTPyS bound form are resistant to complete 
tryptic digestion. Limited tryptic digestion of these GTPyS bound G-protein subunits 
results in the production of a 38 KDa fragment which is resistant to further tryptic 
cleavage. This protected fragment can be detected by the G;ai specific antiserum IlC . 
The immunoblot in Fig. 3.10 clearly indicates that the poorly activated mutant
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Cys^^^Arg is equally capable of binding GTPyS as some of the more potent mutants 
such as Cys^^’Phe Giau Cys^^^IIe Giai and Cys^^’Gly Giai. It should also be noted that 
the apparent size of the GTPyS bound, protected fragment was the same for each of the 
mutants.
3.2.9 A correlation ex ists  betw een the hydrophobicity of the 
am ino acid at residue in Giai and the capacity of the mutant 
to bind [33S]GTPyS upon UK14304 stimulation
The relationship between the n-octanol/water partition co-efficient of the amino 
acid at position in Giai and the ability of the mutant to bind [^^SJGTPyS was 
determined by plotting the respective values from Table 3.2 to produce Fig. 3.11. It can 
be seen from Fig, 3.11 that a strong correlation does indeed exist between the n- 
octanol/water partition co-efficient of the amino acid at residue and the capacity of 
the mutant to bind [^^SjGTPyS upon stimulation with UK14304. The general rule 
appears to be the more hydrophobic the residue at position the greater the capacity of 
the mutant to bind [^^SjGTPyS. The conelation between the n-octanol/water partition 
co-efficient and [^^S]GTPyS loading capacity gave an even better conelation when the 
amino acid mutants alanine, threonine and glycine were eliminated from the analysis.
3.2.10 The correlation between the hydrophobicity of the amino  
acid at position in the Giai subunit and the pECso derived 
from UK14304 stim ulation.
The relationship between pECso derived from UK14304 stimulated [^^SjGTPyS 
binding and the hydrophobicity of the amino acid at residue was examined by 
plotting the octanol/water partition co-efficient as a function of the pEC50 values in 
Table 3.2 to produce Fig. 3.12. Analysis of Fig. 3.12 shows that a close correlation 
exists between the hydrophobicity of the residue at position and the pECso derived 
from UK14304 stimulation. The general rule appears to be the more hydrophobic the 
residue, the lower the pECso value.
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3.2.11 The C^^^Xaa G;ai m utants do not have different affinities 
for GDP.
The guanine nucleotide affinity o f the two Gjai mutants and was
compared to that of the wild type by assaying maximal agonist stimulated [^^S]GTPyS 
binding in the presence of increasing concentrations of the competitor GDP.
HEK 293 Large T cells were co-transfected with the porcine azA adrenoceptor 
and a combination of wild type Cys^^^Giai or one of the two mutants Cys^^'lle Gjai and 
Cys^^^His Giau Cells transfected with receptor alone were used as control cells. Cells 
co-transfected with one of the pertussis toxin resistant mutants were PTX treated 12 
horns prior to harvesting (Section 2.6.1) and membrane preparation. A membrane 
sample from each of the co-transfections was used to assay UK14304 stimulated 
binding of [^^S]GTPyS in the presence of increasing amounts of the competitor GDP. 
The capacity of each of the mutants to bind [^^S]GTPyS was plotted against the 
concentration of competitor, GDP, in the assay (Fig. 3.13). It can be seen fi'om Fig. 3.13 
that the [^^SJGTPyS binding capacity of each of the Gjai mutants decreased 
proportionally with increasing GDP concentration.
3.2.12 The capacity o f the C^^^Xaa Giai mutants to be activated  
remains linear for up to 40 m inutes
Hek 293 Large T cells were co-transfected with the porcine azA adrenoceptor 
and either wild type Cys^^^Gjai or one of the two mutants Cys^^’His Giai or Cys^^'lle 
Giai. Cells transfected with receptor alone were used as a negative control (C-). 
Transfections involving the peitussis toxin resistant mutants Cys^^*His Gjai and 
Cys^^^Ile Giai were PTX treated (Section 2.6.1) 12 hours prior to harvesting (Section 
2.7) and membrane preparation (Section 2.9), other transfections were not treated. A 
maximal concentration of the azA adrenoceptoragonist, UK14304 (10 pM), was used to 
stimulate [^^S]GTPyS binding in membranes from each of the co-transfections. The 
binding assay was stopped at 0, 5, 10, 20, 30 and 40 minutes after the addition of 
[^^SjGTPyS by filtration through GF/C filters (Section 2.15.2). The agonist stimulated 
[^^S]GTPyS binding of each of the mutants was plotted against the duration of the assay 
(Fig. 3.14).
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3.3 D iscussion
The resistance of mutant Ga subunits to post-translational modification by 
bacterial toxins is an effect which has frequently been exploited to investigate the 
selectivity of receptor/G-protein interactions (Senolges, 1994; Hunt et a l, 1994). 
Pertussis toxin catalysed ADP ribosylation at the cysteine 351 residue of rat Giai has 
been shown to substantially disrupt the interaction between an ADP-ribosylated G- 
protein and its cognate receptor. It is thought that steric hindrance by the ADP-ribose 
moiety is the molecular mechanism behind this loss of protein-protein interaction. From 
the data generated by this study it can be postulated that charge may also be a major 
contributory factor in this effect. Previous pertussis toxin resistant Gia mutants 
substituted the cysteine residue 351 with “conservative” amino acids such as glycine 
(Senogles, 1994) or serine (Hunt et a l, 1994). Although such residues have been shown 
to confer resistance to post translational modification by PTX, they have also been 
shown to negatively affect coupling efficiency when compared to the wild type Giai 
subunit (Wise et a l, 1997d).
In spite of this, little has been done to quantitate the physiochemical properties 
of the amino acid at position 351 and its affect on receptor G-protein coupling. It should 
also be noted that no one has ever comprehensively analysed the affects of substituting 
the cysteine residue 351 to all other amino acids. Since current G-protein assays utilise 
either agonist stimulated binding of the radiolabelled non-hydrolysable GTP analogue 
[^^S]GTPyS or the hydrolysis of y[^^P]GTP by G-protein a-subunits, it is clearly of 
relevance to know what the effects of a particular mutation may have upon the 
sensitivity of an assay or the apparent affinity of various ligands.
Osawa and Weiss (1995) extensively mutated the C-terminal tail of Gta with 
unexpected results. They found that the Gta subunit was severely affected by mutations 
which had little or no effect in Gia (Senogles, 1994; Hunt et a l, 1994) or Goa (Denker 
et. a l, 1992). From these findings it was concluded that it would be restrictive to select 
“a priori” the mutations to be substituted to C351. For this reason it was decided that a 
more comprehensive approach to study the functionality of the cysteine residue at 
position 351 would be to systematically mutate the residue to all other amino acids. The 
ability of each of the mutants to be activated by the porcine azA adrenoceptor was then 
assayed by the [^^S]GTPyS binding assay (Fig. 3.8). From the data in Figures 3.8 and
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3,9 it can be seen that the G-protein mutants displayed a gradient of responses. It should 
also be noted that the naturally occurring wild type G-protein was not the most 
effectively activated by the porcine azA adrenoceptor. It could be argued that such 
discrepancies are due to variations in receptor G-protein expression resulting from poor 
transfection efficiencies. In order to evaluate the influences of these factors, the 
expression level of the azA adrenoceptor was quantitated along with that of the G- 
proteins. In each of the co-transfections the receptor level (Fig. 3.5) was determined to 
be at 9pmol/mg or higher. Previous studies (Wise et a l, 1997d) have demonstrated that 
small variations in receptor expression above 9pmol/mg would not be sufficient to 
explain the range of [^^SJGTPyS binding capacities seen in Figures. 3.8 and 3,9. The 
relative expression of each of the C^^^Xaa Gi«i mutants was determined by an 
immunoblot using Gjai specific antisera (Fig. 3.4 ). Most o f the G-protein mutants were 
overexpressed at levels comparable to that of the overexpressed wild type. However, 
there was some variation in expression and such discrepancies could partially account 
for the differences in efficacy. To address this issue a linear relationship was determined 
between C^^’A Gjai expression (Fig. 3,6) and maximal [^^S]GTPyS binding. It can be 
seen from (Fig. 3.7) that a linear function does exist between G-protein expression and 
[35g]GTPyS binding at a fixed receptor expression level and maximal agonist 
stimulation. This relationship justified the normalisation of the [^^S]GTPyS binding data 
in Fig. 3.8 by densitometric analysis of Fig, 3.4 to produce a rank order of mutant 
effectiveness corrected for variation in expression of the Gjai subunit (Fig. 3.9).
Osawa and Weiss(1995) and Garcia et #7(1995) had previously demonstrated 
that mutations in the C-terminus of Gta could affect both the nucleotide binding capacity 
of the a-subunit as well as receptor coupling. Binding data generated by the [^^S]GTPyS 
assay used a single concentiation of both GDP and GTPyS, it could be argued that any 
reduction in receptor/G-protein coupling could be due to either a loss or diminished 
ability of the a-subunit to exchange nucleotides. Using limited trypsin digestion it was 
demonstrated that poorly activated mutants have retained the capacity to exchange 
nucleotides. The € 3 5 IR Gjai mutant was previously shown to be incapable of binding 
[35s]GTPyS upon agonist stimulation of the porcine a2A adrenoceptor. From (Fig. 
3.10) it can be seen that the same poorly activated mutant is capable of exchanging 
nucleotides as indicated by the presence of the immunodetectable product of incomplete 
tryptic digestion. It was demonstrated that other mutants were equally capable of
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exchanging nucleotides, as indicated by the capacity of the GTPyS bound a-subunit to 
be resistant to complete tryptic cleavage (Fig. 3.10).
The experiments above demonstrated the ability of the Giai mutants to exchange 
nucleotides, but they still have not demonstrated that the mutants do not possess 
different affinities for nucleotides. This issue was addressed by assaying maximal 
agonist stimulated [^^S]GTPyS binding in increasing concentrations of the competitor 
GDP. The wild type a-subunit was assayed along with two arbitrarily chosen mutants 
containing a charged residue (C^^^H Giai) and a strongly hydrophobic Giai)
residue at position 351. It can be seen from Fig. 3.13 that the relative [^^S]GTPyS 
binding capacity between the mutants remained unchanged throughout the range of 
GDP concentrations. From this data it can be concluded that the C^^^Xaa Giai mutants 
do not display different nucleotide affinities when compared to wild type Giai.
It is possible that a mutation at residue 351 could result in a conformational 
change in the nucleotide binding pocket leading to either an increase or decrease in the 
rate o f nucleotide exchange. To determine whether the guanine nucleotide exchange rate 
had indeed been altered the binding capacities of the above two mutants was assayed at 
various time intervals (Fig. 3.14). From this data it can be seen that the nucleotide 
exchange rate between mutants remains unchanged for up to 40 minutes.
After correcting for any discrepancies in Giai subunit expression it may be 
assumed that any remaining variation in the capacity of agonist occupied GPCR to 
activate the G-protein is due to the differential properties of the residue at position 351. 
A relationship was sought between the physiochemical and functional properties of 
residue 351. After analysing parameters such as hydrophobicity, hydrophilicity, size 
descriptors and volume to surface areas, it was noted that the partition co-efficient 
octanol/water (Pliska et a l, 1981) gave the best correlation both with pECso and 
[^^S]GTPyS binding. The correlation between the octanoEwater partition co-efficient of 
the residue at position 351 and mutant efficacy, represented as a dimensionless 
descriptor relative to wild type GTPyS binding capacity, was plotted from the values in 
Table 3.2 to produce Fig. 3.11. The elimination of methionine and proline from the 
equation results in a very strong correlation (r=0.92, Fig. 3.11) between f^SjGTPyS 
binding and the hydrophobicity of residue 351. The correlation co-efficient becomes 
close to 1 (r=0.99, Fig, 3.11) if the values for alanine, threonine and glycine (filled
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circles) are also omitted from the equation. Possible explanations why the residues 
methionine and proline fail to conform to the general trend are as follows. In the case of 
methionine it is possible that the residue was present as methionine sulphoxide, this 
would greatly alter its hydrophobic character and so the octanol/water partition co­
efficient value. As for the effects observed for proline, in mutation studies, Osawa & 
Weiss(1995) have shown that substitution of the glycine residue at position 348 to 
proline in the C-terminal tail of Gt« results in a decrease in receptor binding and to a 
lesser effect on nucleotide binding. This effect is thought to be due to a loss of 
flexibility in the C-terminal tail resulting from the “kink” inttoduced into the peptide 
backbone by proline. Since the equivalent glycine residue lies at position 352 in Giai it 
could be assumed that the loss in frmction is due to a similar loss of flexibility. The 
pECso values of the mutants were also analysed with regard to the physiochemical 
properties of the amino acid at residue 351. Once again the pECso values (Table 3.2) 
correlated well with the octanol/water partition co-efficient giving a correlation co­
efficient of r=0.90 (Fig. 3.12).
The findings of this mutational study would seem to corroborate data generated 
by previous investigations (Senogles, 1994; Hunt et a l, 1994; Osawa and Weiss, 1995). 
While extensive data has shown that the residue Cys^^  ^ in Giai and the equivalent 
residues in other PTX sensitive G a subunits are not the only determinants for receptor 
interaction, the data generated indicates that the previous C^ ^^  Giai mutants were far 
from ideal. The mutants generated herein displayed a spectrum of responses, some 
surprisingly showing greater maximal stimulation than wild type. These responses seem 
to correlate well with the hydrophobic character of the residue at position 351. More 
hydi'ophobic residues such as isoleucine seemed to confer greater coupling efficiency 
than more hydrophillic ones such as aspartate. It would also seem as if a charge at 
position 351 is a greater negative factor than size. This is consistent with evidence that 
protein-protein contact surfaces tend to be of a hydrophobic nature. It should also be 
noted though that an increase in hydiophobic character could affect solubility and so 
dissociation from the receptor. The observed negative implication of a charge at this 
position may play an important role in the mode of action of ADP-ribosylation on G- 
protein receptor association.
The data generated from these experiments has a practical use in the 
development of screens for novel ligands as well as in the characterisation of GPCRs. In
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screening systems it is advantageous to maximise the sensitivity of an assay, this allows 
the use of less protein and thereby reduces cost. In the characterisation of GPCRs it is 
necessary to loiow how a par ticular PTX mutant will alter EC50 values. This information 
needs to be taken into account when assaying the potency of a ligand using an assay 
developed with PTX mutants. Future work could involve characterising the specificity 
of py subunit interaction with each of the G-protein mutants. It would also be interesting 
to see if the mutation has altered the capacity of the mutant to interact with secondary 
effectors. Finally it would be useful to examine if the relative effectiveness of the 
mutants is receptor specific.
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Figure 3.1 PCR amplification of C^^^Xaa Giai mutants of rat Giai
Rat C^^^Xaa Gi«i mutants were generated by PCR amplification of rat Giai 
cDNA with one of four degenerate primers. The PCR reaction products from 
amplification with Prim erl(lanel), Primer2(lane2), Primer3(Iane3) and 
Primer4(lane4) were resolved on a l%agarose gel (lOOpElane) and stained with 
ethidium bromide. The 1065bp DNA fragment (lanes 1-4) corresponds to the expected 
size of the amplified Giai mutant.
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Figure 3.2 A nalysis of c lo n es transformed with the C^^^Xaa Giai 
in the pCR-Scrlpt vector
DNA was isolated from clones thought to be transformed with mutant Giai 
cDNA in the pCR-Script vector. A small sample of supercoiled DNA (2 pi) was 
resolved on a 1 % agarose gel stained with ethidium bromide. Clones were selected on 
the basis of DNA migration, the vector containing the insert (lanes 2, 3, 4, 5, 8, 9, 10, 
11, 12, 13, 15, 17, 18, 19, 20, 21 and 22) migrated less than empty vector alone (lanes 1, 
6, 7, 14, 16, 23, 24 and 25). A 1Kb ladder provided size markers (lane 26).
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Figure 3.3 Analysis of Xaa Giod cDNA orientation in the pCR- 
Script vector by restriction d igestion
Plasmid DNA was isolated from clones transformed with mutant Giai cDNA in 
the pCR-Script vector. Samples were restriction digested with the enzymes Notl and 
iVco/(Section 2.23) and resolved on a 1% agarose gel. When the start codon of the Gi«i 
mutant was next to the T3 promoter priming site in the host vector, the plasmid was 
cleaved to yield fragments o f 11, 260 and 3755 base pairs (lanes 1, 4, 5, 8, 11, 13 and 
14). Cleavage of the vector with the insert in the opposite orientation, with the start 
codon distal to the T3 priming site, yielded fragments o f 11, 805 and 3210 base pairs 
(lanes 2, 3, 6, 7, 9, 10, 12, 15, 16, 17). Lane 18 was loaded with 1Kb molecular weight 
markers.
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Figure 3.4 The exp ression  of C^®^ Xaa mutants transiently c o ­
transfected into HEK293T ce lls  with the porcine a2A  
adrenoceptor
Membranes were prepared from HEK293T cells co-transfected with the a2A 
adrenoceptor and a combination of Giai mutants. Samples (25pg) were resolved on a 
10% SDS-PAGE gel and subsequently probed for Giai immunoreactivity with the 
antiserum IIC  (Table 2.1). The residue at position 351 is identified by the conventional 
three letter code. Membranes prepared from HEK293T cells transfected with receptor 
alone (lanes C-) were used to compare endogenous Giai expression.
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Figure 3.5 The expression  of the porcine azA adrenoceptor c o ­
transfected into HEK293T ce ils  in com bination with the C^^^Xaa 
Giai mutants
Membranes were prepared from HEK393T cells transfected with either the azA 
adrenergic receptor alone (A-) or in combination with one of the C^^^Xaa Giai mutants. 
With the exception of the Giai co-transfection, cells were treated with 50ng/ml 
PTX prior to harvesting. The level of porcine a?A adrenoceptor was assayed in each of 
the membrane samples as detailed in Section 2.15.1. The B.max value for each 
transfection is listed in Table 3.1, the identity of the mutant is denoted by the 
conventional three letter code. The a 2A adrenoceptor transfected alone is represented as 
(A-). The results shown are the means ± S.D. of triplicate measurements for a single 
experiment. The data represents a typical experiment.
90
Figure 3.5
OEac0
1îI(01
16
14
12
10
8
6
4
2
0
(A-) Cys AJa Gly Thr Ser Phe Tyr Trp Val Arg Asn Gin Asp Glu Lys Met Pro Leu lie His
Transfection
Table 3.1 B.max values o f agA adrenoceptor co-transfection
Transfection tt2A expression 
B.max
Transfection « 2A  expression 
B.max
(A-) 11.21 Asn 12.91
Cys 12.67 Gin 11.1
A la 11.28 Asp 13.99
Gly 13.48 Glu 11.47
Thr 11.74 Lys 11.99
S er 13.1 Met 13.3
Phe 12.53 Pro 11.02
Tyr 12.33 Leu 11.78
Trp 10.93 lie 9.28
Val 12.59 His 12.13
Arg 10.19
Figure 3.6 Transient transfection of increasing am ounts of 
Giai cDNA into HEK293T ce iis  results in higher levels of 
C^ ®^ A Giai expression .
Membranes were prepared from HEK293T ceils co-transfected with a constant 
amount o f porcine a 2A adrenoceptor cDNA (1.5pg) in combination with increasing 
quantities of C^^^A Giai cDNA (0.15, 0.3, 0.75 and 1.5pg). A sample of membrane 
preparation was resolved on a 10% SDS-PAGE gel, which was subsequently probed for 
Giai immunoreactivity with the antiserum IlC  (Table 2.1). The quantity of C^^*A Giai 
cDNA used in each transfection is listed below the respective lane.
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Figure 3.7 A linear relationship ex ists  between C^ ®^ A G,ai 
exp ression  and f  ®S]GTPyS binding at a fixed receptor level and 
maximal agon ist concentration
Membranes were isolated from HEK293T cells co-transfected with a constant 
amount of aiA  adrenoceptor cDNA (1.5 pg) and increasing quantities of C^^^A Giai 
cDNA (0.15, 0.3, 0.75 and 1.5 pg). Cells were treated with PTX 12 hours prior to 
harvesting. UK 14304 stimulated (10 pM) [^^SJGTPyS binding was assayed in each of 
the membrane preparations. The expression levels of C^^'A Gi«i were quantitated in the 
same membrane sample by densitometric analysis of a representative immunoblot 
probed with the Giai specific antiserum IlC  (Fig. 3.6). The results from the [^^SJGTPyS 
assay was plotted as a function of the Giai immunoreactivity detected in each of the 
membrane samples. The relationship between G-protein expression and [^^SjGTPyS 
binding can be described by a linear equation whose experimental points correlate with 
a correlation co-efficient of r=0.988. The data shown represents the means of triplicate 
measurements from the same experiment.
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Figure 3.8 The relative coupling efficiency of the Giai mutants 
with the porcine azA adrenoceptor upon UK14304 stimulation
The coupling efficiency of the various mutants was assayed by UK14304 
stimulated [^^S]GTPyS binding in membranes prepared from HEK293T cells co­
transfected with the porcine azA adrenoceptor and a combination of C^^*Xaa Giai 
mutants. All transfections, with the exception of those including the wild type G- 
protein, were pre-treated with 50ng/ml PTX 12 hours prior to harvesting and membrane 
preparation. Each data point in Fig. 3.8 represents the average of duplicate 
measurements of a single experiment. The identity of the mutant is denoted by the 
standard three letter code. The data represents a typical experiment.
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Figure 3.9 A com parison of the efficacy of C^^^Xaa G,ai mutants 
to bind f  ®S]GTPyS at maximal agonist concentrations
The capacity of maximal concentrations of UK14304 (10 pM) to stimulate 
[^^SjGTPyS binding was assayed in membranes prepared from HEK293T cells co­
transfected with a combination of porcine a2A adrenoceptor and G-protein mutants. 
The level of Giai mutant expression was quantitated in the same membrane preparation 
by densitometric analysis of an immunoblot probed for Giai immunoreactivity by the 
antiserum IlC . The efficacy of the mutants was normalised with regard to variation in 
Gfai subunit expression. Results are presented as percentage of wild type Giai 
stimulation. The identity of the residue at position 351 is represented using a single 
letter amino acid symbol.
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Figure 3.10 An immunoblot dem onstrating the capacity of 
poorly activated C^^^Xaa Gîai mutants to exchange nucleotide
Membranes were prepared from HEK293T cells transfected with either empty 
pCDNA3 vector (lanes 1-3) or one of the following C^^^Xaa Gjai subunits- ^^^Cys (lanes 
4-6), Cys^^Gly (lanes 7-9), Cys^'Arg (lanes 10-12), Cys” ‘Phe (lanes 13-15) and 
Cys^^'lle (lanesl6-18). The capacity of the G-protein to exchange nucleotides was 
assayed by limited tryptic digestion (Section 2.17) of a membrane sample (100 pg) in 
the absence (lanes 3, 6, 9, 12, 15 and 18) or presence of GTPyS (lanes 2, 5, 8, 11, 14 and 
17). Untreated membrane samples were then resolved on a 10% SDS-PAGE gel and 
probed for Giai immunoreactivity with the antiserum IIC (Table 2.1). Fig. 3.10 is a 
representative immunoblot.
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Figure 3.11 The correlation between the hydrophobicity of the 
amino acid at residue 351 and G-protein mutant coupling  
efficiency at maximal agon ist concentration
Membranes were isolated from HEK293T cells co-transfected with the porcine 
tt2A adrenoceptor in combination with C^^^Xaa Giai mutants. A sample of membrane 
preparation was used to assay [^^S]GTPyS binding in each of the transfections upon 
stimulation with maximal agonist concentrations (10 pM UK14304). The coupling 
efficiency of the mutants was normalised with regard to variation in G-protein 
expression and presented as the percentage of binding relative to the wild type Giai 
subunit (Table 3.2). This binding index was plotted as a function of the 
log(octano 1/water) partition co-efficient of the amino acid at residue 351 (Table 3.2). 
When the methionine and proline mutants were excluded from the analysis, the 
relationship between the hydrophobicity of amino acid 351 and its effect on efficiency 
could be described by the linear equation GTPyS= 1.237(±0.617) + 0.522(±0.054) 
Iogp(octanol/water). The figures in parenthesis in the above equation denote the 95% 
confidence intervals. The experimental points correlate with a correlation co-efficient of 
r=0.924, where the number of forms of Giai (n)=18 and standard deviation (s)=0.213. 
Elimination of alanine, threonine and glycine (filled circles) gave a better correlation 
between the two factors (r=0.989).
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Figure 3.12 The correlation between the hydrophobicity of the 
amino acid at residue 351 and the pECso value derived by 
UK14304 stimulation
Membranes were isolated from HEK293T ceils co-transfected with the porcine 
aiA  adrenoceptor in combination with C^^’Xaa G,ai mutants. A sample of membrane 
was used to assay [^^S]GTPyS binding in each of the transfection conditions at a range 
of agonist concentrations (10‘^  to 10'^ ® M UK143 04). pEC# values were calculated 
from the binding data using the mathematical package Robosage (Table 3.2) and 
plotted as a function of hydrophobicity o f the amino acid at position 351 (values taken 
from Table 3.2). The relationship between the hydrophobicity of residue 351 and its 
influence on pECso was described by the linear equation pEC5o-8.246(±0.133) + 
0.351(±0.055) logP(octanoEwater), where the number of forms of Giai (n)=14 and 
standard deviation (s)=0.129. The figures in parenthesis in the above equation 
correspond to the 95% confidence intervals. The experimental points correlated with a 
correlation co-efficient of r=0.90. Omitting the glycine mutant from the analysis, as 
indicated by the filled circle, resulted in a tighter correlation with the correlation co­
efficient increasing to r=0.916.
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Figure 3.13 No difference w as observed in the nucleotide  
binding affinity between C^^^Xaa Gjai mutants
Membranes were prepared from HEK293T cells which were co-transfected with 
the porcine a^A adrenoceptor in combination with either Cys^^^His Giai, Cys^^^Ile Giai, 
wild type Giai or empty pCDNA3 vector (C-). Cells co-transfected with the Cys^^^His 
and Cys^^'lle Giai mutants were PTX treated with 50ng/ml PTX 12 hours prior to 
harvesting. A sample of membrane was used to assay [^^SjGTPyS binding at maximal 
agonist concentration (10 pM UK143 04) in a modified assay mix containing increasing 
quantities of the competitor nucleotide GDP (0, 1, 2, 4, 10, 16, 32 and 64 pM). The 
[^^S]GTPyS binding values were plotted against concentration of competitor (GDP). 
The [^^SjGTPyS binding data was not normalised with regard to G-protein expression. 
The values shown are the means ± S.D. of triplicate measurements in a representative 
experiment of three performed.
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Figure 3.14 The nucleotide exchan ge rate of the various C^ ®^ Xaa 
Giai mutants remains proportional for up to 40 m inutes.
Membranes were prepared from HEK293T cells co-transfected with the porcine 
azA adrenoceptor in combination with either Cys^^^His Gjai, Cys^^'lle Giai, wild type 
Giai or empty pCDNA3 vector (C-). Cells co-transfected with Cys^^^Ile and Cys^^^His 
Giai were PTX treated 12 hours prior to harvesting. A sample of membrane was used to 
assay [^^SJGTPyS binding at maximal UK14304 concentration (10 pM) over a period of 
40 minutes. Reactions were stopped by filtration ( as described in Section 2.15.2) at 0, 
5, 10, 20, 30 and 40 minutes after the addition of [^^SJGTPyS. The [^^S]GTPyS binding 
values were plotted in fimction o f time, the data presented is not normalised with regard 
to variation in G-protein expression. The values shown are the means ± S.D. of 
triplicate measurements in a representative experiment o f three performed.
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Table 3.2 A table summarising the order of EC5 0 , partition co­
efficient (octanoi/water) and f  ®S]GTPyS binding capacity of 
each of the C^ ®^ Xaa Gw mutants with regard to the porcine a 2A 
adrenoceptor and the agonist UK14304.
The [^^SJGTPyS binding capacity index for each of the mutants was calculated 
relative to the binding capacity of the wild type Cys^^^Giai G-protein subunit using the 
following equation-
[^^S]GTPyS capacity = (Cpm mutant - Cpm wild type)
Cpm wild type
The variation in the level of mutant Giai expression was taken into account as 
described in Fig. 3.5. The EC50 values were derived from the dose response data in Fig. 
3,8 using the mathematical computer package Robosage. The (octanol/water) partition 
co-efficient of each of the amino acid residues at position were taken from the 
findings by Pliska et a l { \9^ \ ) .
1 0 0
Table 3.2
Amino Acid
GTPyS
Index EC5o(M)
logP
(octanol/water)
I 0.51 1.6 X 10'  ^j: 8.2x10"'^ -1.72
L 0.44 2.9 xlO"“ ± 2.5x10-'' -1.61
F 0.38 1.6x10 '“ ±1.9x10-'' -1.63
W 0.32 3 .1 x 1 0 '“ ±1 .6x10 '^ -1.75
A 0.18 4.8 X 10'“ ±2.9 X 10-'' -2.89
Y 0.06 3 .2x10 '“ ±2.3x10-'' -2.42
V 0.01 4.2 X 10'“ ± 1.6 X 10-'' -2.08
C 0.00 3.7 X 10'“ ±3.2 X 10-'' -2.49
S -0.44 7.3 X 10'“ ±7.5 X 10-'' -3.30
Q -0.45 8.2 X 10'“ ±5.7 X 10-'' -3.15
N -0.50 9.1 X 10'“ ± 9.1 X 10-'' -3.41
H -0.68 8.4x 10'“± 1.1 X 10'“ -3.56
T -0.78 5.4 X 10'“ ±2.9 X 10'“ -2.91
E -0.84 7.8 X 10'“ ±3.5 X 10'“ -4.19
G -0.87 1.4 X 10'“ ±9.9 X 10''' -3.25
D -0.87 -4.25
P -0.94 -2.50
M -0.99 -1.84
R -1.00 -4.20
K -1.00 -4.44
Chapter 4
The role of the G-protein C-terminus in 
defining the specificity of receptor coupling
4.1 Introduction
Heterotrimeric GTP binding proteins (G-proteins) mediate the transduction of a 
signal from cell surface receptors, characterised by seven transmembrane repeats, to 
secondary messenger producing enzymes or ion channels. G-proteins are composed of 
three subunits designated a , (3, y. The a-subunit is folded to form a guanine nucleotide 
binding pocket which can accommodate either GDP or GTP. G-proteins can exist in 
either active or inactive conformations, in the inactive conformation the a-subunit 
contains GDP in the nucleotide binding pocket and is in tight association with the py 
subunits. Activation occurs thiough receptor-mediated guanine nucleotide exchange in 
the a-subunit, which results in a lower affinity for GDP in the nucleotide binding 
pocket. Consequently, the GDP molecule in the a-subunit nucleotide binding pocket is 
replaced by GTP, which is in the cell at a ten times higher molar concentration than 
GDP. This guanine nucleotide exchange event causes a conformational change in the p 
subunit binding site resulting in Py subunit dissociation. The GTP bound a-subunit and 
the Py subunits are then fiee to interact with downstieam effector molecules. G-protein 
de-activation is regulated by the hydrolysis of GTP to GDP by the catalytic activity of 
the a-subunit. This results in a conformational change in the a-subunit, which allows Py 
subunit reassociation and so reversion to the inactive heterotidmeric state.
G-protein a-subunits couple rather selectively to membrane bound receptors and 
activate specific effector molecules. Receptor selectivity is thought to be determined by 
the structure of the a-subunit C-terminus, while determinants for effector recognition 
are more scattered. These recognition sites, in part, have been mapped by the use of 
chimeric G-proteins and further characterised by co-crystallography with effector 
molecules. Chimeric G-proteins are hybrids of the primary stmctures of two or more a- 
subunits. The signal output of a chimera is determined by the enzymatic and 
transducing properties of the relative a-subunit components. It has been demonstrated 
that short substitutions in the a-subunit C-terminal tail often preserve effector 
specificity, while switching receptor selectivity (Voyno-Yasentskaya et a i ,  1994a; 
Komatsuzaki et a l ,  1997; Conklin et a l ,  1993), The substitution of as little as three 
amino acids in the C-terminal tail of Gqa for those of Gi^z is sufficient to switch the 
selectivity of the chimera to G i-coup led receptors (Conklin et a l ,  1993). Such a 
substitution resulted in a switch of receptor coupling specificity but did not prevent the
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chimera (Gq /^Giaz) from interacting with it’s natural effector, phospholipase C. In 
similar studies, involving 5 amino acid substitutions in the C-terminal tail, Voyno- 
Yasentskaya et a l  (1994a) have demonstrated that a Goa/Gza chimera can activate Na^- 
H'*’ exchange upon agonist stimulation of the dopamine D2 receptor. In addition 
Komatsuzaki et al (1997) have shown that upon agonist stimulation of the SSTR3 
somatostatin receptor, the chimeras Gsa/Gia(i/2), Gsa/Gna and Gsa/Gi6a can activate the 
Gs effector adenylyl cyclase.
The efficacy of receptor/chimera interactions appears to be related to the length 
of the C-terminal substitution. Conklin et a l  (1993) demonstrated that increasing the 
length of amino acid substitutions in the C-terminal tail of Gqa for the corresponding 
sequence of Gi«2, first conferred an increase in receptor coupling efficacy, but then 
resulted in a gradual loss of receptor/Gi coupling. From this data it could be inferred 
that additional substitutions in the C-terminal tail of the a-subunit generated 
conformational changes which result in uncoupling of the receptor from the chimera. 
Conformational changes may also affect other functions associated with the a-subunit. 
Woon et al (1989) demonstrated that substituting the C-terminal 38 amino acids of Gsa 
with those from G,a2, resulted in the constitutive activity of the Gsa moiety, as assayed 
by the production of the secondary messenger cAMP. From this it may be inferred that 
conformational changes in the a-subunit can result in either an increase in affinity for 
GTP or a reduction or loss of GTPase activity. In a similar observation Osawa et al. 
(1990) demonstrated that a chimera, created by Masters et al (1988), featuring both the 
receptor and effector putative recognition sites in the C-terminal portion, is not only 
constitutively active, but also interacts with effectors cognate to the C-terminal portion 
of the chimera. This chimera was composed of the 60% N-terminal region of Gia2 and 
the 40% C-terminal region of Gs». Masters et a l  (1988) have shown that while the 
above chimera is constitutively active, agonist stimulation of a co-transfected p2 
adrenergic receptor can further stimulate adenylyl cyclase in a dose-dependent manner. 
From these results it can be inferred that while limited substitutions in the C-terminus 
may result in conformational changes detrimental to chimera activity, more extensive 
chimerism may re-stabilise a functional conformation and therefore biological activity.
The hypothesis that the conformational stiucture of the a-subunit is altered by 
substitutions in the N or C-termini is supported by the findings of Osawa et al (1990),
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who used CTX catalysed ADP-ribosylation to assess the conformation of QsJO\a2 
chimeras. Cholera toxin was previously shown to catalyse ADP-ribosylation of the Arg 
201 residue in Gsa, but not in a Gsa chimera composed of the last 38 amino acids of 
Gia2. The insensitivity o f this Gsa/Gia2 chimera is thought to be related to a 
conformational change in the a-subunit, which prevents CTX access to the catalytic 
core in order to ADP-ribosylate Arg 201. Osawa et al. (1990) also demonstrated that by 
substituting 54 amino acids in the N-terminus of the chimera to those of G;a2 or 
reducing the number of substitutions in the C-terminus to 8 amino acids, restored 
sensitivity to CTX catalysed ADP-ribosylation. However, a restricted substitution of 
only 54 amino acids in the N-terminus of Gsa failed to confer sensitivity to CTX. From 
this data it would appear that substitutions in both the N and C-termini of a chimera are 
prone to confer confonnational changes in the a-subunit with repercussions on the 
catalytic domain, the nature o f which can be quite laborious to understand. The limited 
trypsin digestion assay is a useful method of determining the active conformation of a- 
subunits, as only a-subunits in the GTP bound form are resistant to full tryptic 
digestion. The presence of the non-hydrolysable GTP analogue, GTPyS, in the 
nucleotide binding pocket stabilises the a-subunit in an active conformation in which 
many of the tryptic cleavage sites are inaccessible to the actions of trypsin. These 
conformations are different for both Gia2 and Goa, resulting in different tryptic cleavage 
patterns. The idea that substitutions in the N-terminus of the chimera can influence the 
conformation of the rest of the protein is supported by limited tpyptic digestion data on 
Gia2/Goa chimeras. Denker et al. (1995) demonstrated that the tryptic protection patterns 
produced by GTPyS protected chimeras composed of the 60% N-terminal region of 
either Gia2 or Goa and the 40% C-terminal region of the opposing a-subunit were the 
same as those of the N-terminal donor G-protein. From these findings it can be assumed 
that the sequence of the N-terminus is a major determinant on the active, GTP bound, 
conformation of Gia2/Goa and Goa/Gia2 chimeras.
Komatsuzaki et al. (1997) systematically substituted the carboxyl-terminal 5 
amino acids of Gsa for those of all other a-subunits and demonstrated how G-protein 
chimeras can be used to assay receptor specificity. However, a problem arises with this 
approach in respect of the use of secondary messenger production to measure 
receptor/chimera interactions. The experiment was flawed as the molecular origin of the 
secondary messenger measured could be due to direct activation of the effector by the
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chimera or by f3y subunits dissociated as a result of receptor activation of either the 
chimera or endogenous G-proteins cognate to the receptor being assayed. A more direct 
method of determining receptor/chimera interactions would have been to assay the rate 
of receptor catalysed guanine nucleotide exchange. However, in the experiment 
conducted by Komatsuzaki et a l  (1997) this was not feasible due to tire low guanine 
nucleotide exchange rate present in Gsa-
Receptor-catalysed guanine nucleotide exchange is the basis of a number of 
assays, measuring either receptor-catalysed exchange of GDP for the non-hydrolysable 
GTP analogue [^^S]GTPyS ([^^SjGTPyS binding assay) or the hydrolysis of y-phosphate 
labelled GTP to GDP (GTPase assay). In order to produce a chimera, whose activity 
could be measured by the above assays, the chimera would require a high guanine 
nucleotide exchange rate in combination with good coupling efficacy. Since the guanine 
nucleotide exchange rate varies between the four main classes of a-subunit (Osawa and 
Weiss, 1995), only the subclass of PTX sensitive a-subunits such as at, ao  and ai 
display a nucleotide exchange rate high enough for use in the above assays.
Osawa and Weiss (1995) have previously demonstrated that Giai not only 
possess a high guanine nucleotide exchange rate, but is also tolerant to mutations in the 
extreme C-terminus. The above findings suggest that Giai would make an excellent 
candidate as the N-terminal donor for the G-protein chimera. It was therefore decided to 
substitute the last 6 amino acids of Giai to those of Gsa, Gqa and Gi6a- This decision was 
made based on the findings of Conklin et a l  (1993) who demonstrated that optimal 
coupling of the Gqa/Gia2 chimera was obtained by substituting between 5 and 9 amino 
acids in the C-terminus, these chimeras also displayed activation of the effector 
molecule cognate to the N-terminal donor a-subunit. Larger C-terminal substitutions 
were not deemed suitable, as they have been shown to confer constitutive activity 
(Woon et al, 1989) and to switch effector selectivity (Osawa et al, 1990). The coupling 
efficacy of the chimeras was then assayed with a panel of GPCRs.
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4.2 Results
4.2.1 Generation of Giai chim eras by PGR m utagenesis
The last 6 amino acids of rat Giai were mutated to those of Gqa, Gsa and G16a by 
PGR amplification with mutagenic primers. The pertussis toxin insensitive mutant 
Cys^^^Asp Giai in the pCDNA3 vector (fnvitrogen) was used as the template. The PCR 
reaction used respectively 50 pmol of a common 5’ forward primer, annealing on the 
Giai DNA sequence, and one of three dedicated 3’ reverse primers, encoding the hybrid 
GiiaGxa sequence (Table 2.4). The reaction conditions were as in Table 2.5.
The amplicons were resolved on a l%(w/v) agarose gel and stained with 
ethidium bromide as in Section 2.26. The expected 1065 bp band (Fig. 4,1) was excised 
from the gel, purified and ligated into EcoRY linearised, alkaline phosphatase treated 
pCDNA3. The ligation reaction was used to transform the DH5a bacterial strain, which 
was subsequently grown on agar plates under ampicillin selection (Section 2.18).
Five clones were arbitrarily chosen from each of the transformations and 
cultured as in section (Section 2.18). Plasmid DNA was extiacted from the cultures by 
small scale DNA preparation (Section 2.21) and digested with, the restriction enzyme, 
Æ'coRl (Section 2.23). The restriction digests were resolved on a 1% agarose gel and 
stained with ethidium bromide (Fig. 4.2). The presence of a DNA fragment with an 
apparent molecular weight of 1065 bp, corresponding to the expected size of the 
GiiaGxa chimera, indicated recombinant clones, while a single fragment of 5.4 Kb 
indicated re-ligated vector.
A restriction digestion with the enzyme Ncol was used to screen the orientation 
of the insert in the pCDNA3 vector in DNA extracted from recombinant clones. The 
digested products were resolved and visualised on a 1% agarose gel stained with 
ethidium bromide (Fig. 4.3). The presence of a 1831 bp DNA fragment indicated that 
the start codon of the GnaGxa chimera was next to the T7 promoter priming site in the 
pCDNA3 vector. This is the orientation required for transient expression of the 
subcloned cDNA in mammalian cells. The presence of two bands of 1145bp and 
1026bp indicated that the start codon was distal to the T7 promoter site and therefore 
not in suitable orientation for transient expression. Only DNA samples containing the 
GiiaGxa chimera in the correct orientation were chosen for sequencing.
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The 3’ end of the GnaGxa chimeras were sequenced using a primer annealing on 
the SP6 promoter priming site (Section 2.31) in the pCDNA3 vector. The sequencing 
profiles were translated to confirm the identities of the last 6 amino acids in the C- 
terminal tail of each of the chimeras.
4.2.2 Transient exp ression  of GüaGxa chim eras with G-protein 
coupled receptors
The HEK 293T cell line was ti'ansiently co-transfected (Section 2.8) with 1.5 pg 
GPCR cDNA in the pCDNA3 vector in combination with either 1.5 pg GuaGxa chimera 
in pCDNA3, rat Giai in pCDNA3 or with empty pCDNA3 vector. The cells transfected 
with GiiaGxa chimera were treated with 50 ng/ml of pertussis toxin 12 hours prior to 
hai'vesting (Section 2.7) in order to inactivate, by ADP-ribosylation, endogenously 
expressed PTX-sensitive G-proteins. At 72 hours after transfection the cells were 
harvested and membranes were prepared as in Section 2.9.
4.2.3 Immunodetection of GnaGxa chimera expression  in 
HEK293T cells
The expression of the GiiaGxa chimeras were detected by immunoblotting with 
antisera raised against an internal epitope of Giai (11C) and with the C-terminus of Giai 
and Gia2 (SGI). HEK 293T cells were co-tmnsfected with 1.5 pg of GiiaGxa chimera 
cDNA in pCDNA3 in combination with 1.5 pg of empty pCDNA3 vector to standardise 
the total amoimt of DNA to 3 pg. Following membrane preparation samples (25 pg) 
were denatured in Laemmli buffer and resolved in duplicate on 8% SDS-PAGE gels 
(Section 2.11). The resolved proteins were subsequently western blotted onto 
nitrocellulose membranes (Section 2.12), which were probed for Giai and Giai/2 
immunoreactivity with the antisera IIC and SGI respectively (Table 2.1). It can be seen 
from Figure 4.4(b) that chimera expression was not detectable by antiserum SGI, 
raised against the C-terminus of Giai and Gia2- Membrane samples probed with this 
antiserum displayed the same immunogenicity as the mock-transfected cells (lane C-). 
A membrane sample of rat brain cortex (25 pg), rich in Giai, was used as a positive 
control. In contrast, chimera expression was detected on the duplicate blot by the 
antiserum raised against the internal epitope of Giai (11C). It can also be seen from 
Figure 4.4(a) that chimeras were over-expressed at levels higher than endogenously 
expressed Giai in the mock transfected cells (lane C-).
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4.2.4 Immunological characterisation of GnaGxa chim eras 
exp ressed  in HEK293T ce lls
The GiiaGxa chimeras were characterised by immunodetection with antisera 
raised against an internal epitope in the chimera in combination with immunodetection 
of the C-terminal donor sequence. HEK 293T cells were transiently transfected with 
either GuaGxa chimera cDNA or with empty pCDNA3 vector. Membranes were 
prepared and samples (25 pg) were resolved in triplicate on 10% SDS-PAGE gels as in 
Section 2.11. The resolved protems were western blotted onto nitrocellulose and probed 
with antiserum directed against the internal epitope of Gjai (11C) in combination with 
antisera raised against the C-terminal residues of Gsa (CS3), Gq« (CQ5) and Giea (SBl) 
as detailed in Table 2.1. It can be seen from Figures 4.5(a); 4.5(b) and 4.5(c) that each 
of the chimeras displayed immunoreactivity with antiserum raised against an internal 
epitope of Giai(IlC) as well as with antisera directed against the donor C-terminal 
residues. In each instance the immunoreactive bands co-migrated and were in excess of 
endogenously expressed a-subunits.
4.2.5 Characterisation of chim eric GiiaGxa receptor specificity  
by agon ist stim ulated [^®S]GTPyS binding
The receptor specificity of the GiiaGxa chimeras was assayed by the efficacy of 
the chimera to bind the non-hydrolysable GTP analogue, [^^SJGTPyS, in response to 
agonist stimulation of a panel of GPCRs. The receptors chosen for this study are as 
follows -  muscarinic M l, P2Y2, P2Y4, P2Y6, P2 adrenergic, V2 vasopressin, adenosine 
A2a, serotonin 5HT5a, serotonin 5HT5b, TRH, a2A adrenergic, oxytocin, glutamate 
mGluRla and glutamate mGiuR5a. HEK 293T cells were co-transfected with one of the 
above receptors in combination with GuaGxa chimera, Giai or empty pCDNA3 vector. 
Cells co-transfected with the GuaGxa chimeras were treated with PTX to remove the 
endogenous G-protein signalling component 12 hours prior to harvesting. Agonist 
stimulated [^^S]GTPyS binding was assayed in membrane preparations from each of the 
co-transfections as detailed in Section 2.15.2, the concentration response data was 
subsequently plotted using the mathematical package robosage. It can be seen that 
agonist stimulation of the P2Y4 (Fig 4.6) and TRH (Fig. 4.7) receptors catalysed 
guanine nucleotide exchange in the GuaGqa chimera. Similarly, agonist stimulation of 
the p2 adrenergic (Fig. 4.8) and V2 vasopressin (Fig. 4.9) receptors stimulated
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[^^SjGTPyS binding in the GnaGsa chimera. Despite the diversity of receptors assayed, 
none were seen to catalyse [^^S]GTPyS binding in the GüaGiea chimera.
4.2.6 Evidence for the exp ression  of receptors incapable of 
activating GnaGxa chim eras
Some of the receptors assayed failed to induce agonist stimulated [^^S]GTPyS 
binding in any of the chimeras. In these cases receptor expression was demonstrated in 
membrane preparations by agonist stimulated [^^SjGTPyS binding. In Figure 4.10 it can 
be seen that agonist stimulation of the mGluRSa receptor in the Giai wild type co­
transfection resulted in [^^SJGTPyS binding, while agonist stimulation of the chimera 
co-transfections or receptor alone failed to elicit such a response. Similar observations 
were seen for the mGluRla, a 2A adrenoceptor, SHTsa, adenosine A2A, P2Y2 and P2Y6 
receptors (data not shown)
4.2.7 The expression  of G^aGxa chim eras co-transfected into 
HEK293T ce lls  in com bination with a bank of G-protein coupled  
receptors
The same membrane preparation as that used to generate [^^S]GTPyS binding 
data was used to assay the relative expression levels of the co-transfected G-proteins. A 
sample of membrane preparation was denatured in Laemmli buffer and resolved on a 
10% SDS-PAGE gel (Section 2.11). The resolved proteins were subsequently western 
blotted onto nitrocellulose membrane (Section 2,12) which was probed for 
immunoreactivity against an internal epitope of Gjai using the antiserum IIC as 
described in Table 2.1 It can be seen from Figures 4,11 and 4.12 that all G-protein 
cDNAs co-transfected with the P2 adrenergic, V2 vasopressin and the mGluRSa 
glutamate receptors were overexpressed at levels higher than endogenously expressed 
Giai in cells transfected with receptor alone. It was also noted that although there was 
some variation in expression between chimeras co-transfected in combination with the 
different receptors, there was no variation in expression within a receptor co­
transfection. The same obsei-vation was seen for the rest of the receptor/chimera co­
transfections.
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4.2.8 Demonstration of the capacity of the non-activated  
GiiaGi6cc chimera to bind GTPyS
The capacity of the non-activated GuaGi^a chimera to exchange nucleotides was 
confunied by limited trypsin digestion in both the presence and absence of GTPyS. In 
this assay the exchange o f GDP for GTP in the chimeric a-subunit stabilises a 
conformation which is resistant to eomplete tryptic digestion. Limited tiyptic digestion 
o f GTPyS bound G-protein a-subunits results in the production of a 38kDa fragment, 
which is resistant to further tryptic cleavage. The protected fragment can be detected by 
the Giai specific antiserum IlC . The immunoblot in Figure 4.13 clearly indicates that 
the non-activated chimera GnaGiea is equally capable of binding GTPyS as the other 
chimeras. It should also be noted that the tryptic protection pattern for each of the 
chimeras was the same as that o f wild type Giai.
4.2.9 The efficacy of the GnaGsa chimera to bind [^®S]GTPyS in 
resp on se to maximal agon ist stimulation of the human IP 
prostanoid receptor
The capacity of the GüaGsa chimera to bind the non-hydrolysable GTP 
analogue, [^^S]GTPyS, in response to maximal iloprost stimulation of the Flag™-tagged 
human IP prostanoid receptor was assayed as described in Section 2.15.2. Clone 13 
cells, HEK 293 cells stably expressing the Flag-tagged human IP prostanoid receptor at 
2.5 pmol/mg, were transfected to express the GnaGsa chimera or mock transfected with 
empty pCDNA3 vector. Membranes were prepared from each of the transfections along 
with parental HEK293 cells and samples were used to assay iloprost stimulated (10 pM) 
[^^SJGTPyS binding. It can be seen from Figure 4.14 that agonist stimulated 
[^^SJGTPyS binding was much greater in membrane preparations from the GnaGsa 
transfection than HEK293 cells or clone 13 cells alone. It should also be noted that a 
degree of agonist stimulated [^^S]GTPyS binding was detected in membrane 
preparations from clone 13 cells, but not in parental HEK293 membranes
4.2.10 The GjiaGsa chimera is resistant to post translational 
modification by the bacterial toxins PTX and CTX
Agonist stimulated [^^SJGTPyS binding was used to assay GiiaGsa chimera 
sensitivity to post translational modification by both PTX and CTX. Clone 13 cells were 
transfected with Giai, Gsa, GiiaGsa or empty pCDNA3 vector. In pai’allei the cells were
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treated with vehicle or a combination of 200 ng/ml CTX and 25 pg/ml PTX to remove 
the Gsa and Gja signalling component 16 hours prior to hai'vesting. Membrane 
preparations from each o f the transfections were used to assay both basal and iloprost (1 
pM) stimulated [^^S]GTPyS binding. It can be seen from Figure 4.15 that [^^S]GTPyS 
binding in membrane preparations from the GuaGsa transfection were least affected by 
bacterial toxin treatment. It should also be noted that the loss of [^^SjGTPyS binding in 
GiiaGsa transfected cells was equivalent to that seen in mock transfected cells.
4.2.11 The relative efficacy of the GnaGsa chimera to catalyse  
the hydrolysis of [^^P]GTP in resp on se to iloprost stimulation of 
the IP prostanoid receptor
Clone 13 cells, stably transfected with the Flag™~tagged human IP prostanoid 
receptor, were used to assay the efficacy of agonist stimulated [^^PJGTP hydrolysis by 
the GiiaGsa chimera in relation to both endogenous and overexpressed Giai and Gsa- 
Clone 13 cells were either mock transfected or transiently transfected to express wild 
type Giai, Gsa or GüaGsa chimera. Membranes were prepared from each of the 
transfections, along with parental HEK293 cells as a negative control, were used to 
assay maximal agonist stimulated ( cone ) [^^PJGTP hydrolysis. It can be seen in Figure 
4.16 that the rate of [^^P]GTP hydrolysis in membranes prepared from the GüaGsa 
transfections was significantly greater than that seen in any of the other transfections. It 
was also noted that the overexpression of either Giai or Gsa gave little or no increase in 
the rate of [^^P]GTP hydrolysis over mock-transfected cells. Membranes from parental 
HEK293 cells failed to respond to agonist stimulation, indicating that all effects were 
mediated through the stably expressed human IP-prostanoid receptor.
4.2.12 The relative efficacy of agon ist stimulated [^^P]GTP 
hydrolysis by the GnaGsa chimera is not related to the 
exp ression  level
The expression levels of Giai and GnaGsa chimera were compared in the same 
membrane preparations as used to generate the high affinity [^^P]GTP hydrolysis data. 
Membrane samples (lOpg) from clone 13 cells transfected with Giai, Gsa, or GnaGsa 
were denatured in Laemmli buffer and resolved on a 10% SDS-PAGE gel (Section 
2.11). The resolved proteins were subsequently western blotted onto nitrocellulose 
membrane (Section 2.12) which was then probed for immunoreactivity to an internal
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epitope of Giai with the antiserum IlC  as described in Table 2.1. It can be seen from 
Figure 4.17 that both Giai and Gii«Gsa were expressed at roughly equivalent levels. It 
was also noted that both G-proteins were detected at levels substantially higher than 
those of endogenously expressed Giai.
I l l
4.3 D iscussion
Conservative G-protein chimeras, containing only a few amino acid 
substitutions in the C-terminus, can be used as adapter molecules allowing agonist 
stimulated activation of an effector molecule not normally cognate to the receptor 
(Voyno-Yasentskaya et a l,  1994a; Conklin et a l,  1993; Komatsuzaki et a l,  1997). This 
property has been exploited to investigate the selectivity of receptor/G-protein 
interactions (Komatsuzaki et a l ,  1997). However, a problem with this approach lies in 
the use of effector molecule activation to assay receptor/chimera interactions as well as 
receptor/G-protein selectivity. It is often laborious to prove that increases in secondary 
messenger are solely the result of chimera/effector interactions, as frequently the 
activity of the effector can integrate the signal output from Py subunits dissociated from 
either the chimera or from endogenous G-proteins cognate to the receptor. A less 
ambiguous method of determining receptor/chimera interactions would be to assay 
receptor catalysed guanine nucleotide exchange, either by agonist stimulated binding of 
[^^S]GTPyS or by agonist stimulated hydrolysis of [^^P]GTP. At present these assays are 
best suited to characterising receptors coupled G-proteins that are the target of PTX. 
PTX-sensitive G-proteins, such as Gi, Go and Gt, display a substantially higher guanine 
nucleotide exchange rate than other classes of a-subunit. Therefore, non PTX-sensitive 
a-subunits are not suited to the above assays as they give a poor signal to noise ratio. To 
summarise, it would be exti'emely advantageous to develop a universal ligand screening 
strategy, in which receptor stimulation by any newly synthesised molecule, with 
agonistic interest, could be characterised by the output of a single non-ambiguous 
biochemical assay.
Although 5 amino acids substitutions in the extreme carboxyl terminus of an a - 
subunit are sufficient to switch receptor selectivity, as various studies have shown 
(Voyno-Yasentskaya et a l ,  1994a; Komatsuzaki et a l,  1997; Conklin et a l ,  1993), this 
switch has no discernible effect on effector selectivity. Conklin et a l  (1993) have 
shown that chimera efficacy can be increased by substituting up to 9 amino acids in the 
C-terminus of Gq«, but substitutions beyond this point are incompatible in terms of 
receptor coupling. Based on these findings, in order to produce a generic ligand 
screening strategy whose output could be measured by guanine nucleotide exchange 
based biochemical assays, it was decided to substitute the 6 extreme C-terminal amino 
acids of Gtai with those of Gqa, Gsa and Gi6a- Each of the chim,eras was then
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immunologically characterised with antisera raised against an internal epitope of Giai 
(Fig. 4.4(a)) or the extreme C-termini of Giai/Giaz (Fig. 4.4(b)), Gsa (Fig. 4.5(b)), Gqa 
(Fig, 4.5(a)) and Gi6a (Fig. 4.5(c)). It can be seen from Figure 4.4(a) that all of the 
chimeras displayed immunoreactivity to the antiserum IlC  directed against the internal 
epitope of Giai, but failed to display immunoreactivity to antiserum SGI, directed to the 
extreme C-terminus of Giai and Giaa- As expected, the immunoreactive bands co- 
migi'ated with wild type Giai, which determined the final molecular mass of the 
chimeras. It could be argued that the loss of SGI immunoreactivity was due to the 
production of a truncated Giai G-protein, as opposed to the generation of a chimera. 
While the co-migration of the chimera with the wild type would suggest that both 
polypeptides are of the same molecular mass, a more comprehensive method of 
demonstrating frill length translation would be to immunologically characterise the 
sequence of the extreme C-terminus, Using this strategy, each of the chimeras was 
probed for immunoreactivity against both the extreme C-terminus of the chimera and 
the internal epitope of Giai. It can be seen from Figures 4.5(a), 4.5(b) and 4.5(c) that 
each of the chimeras displayed immunoreactivity to antisera directed against the internal 
epitope of Giai and the extiome C-terminus of either Gsa, Gqa or Gi6a- It should also be 
noted that the immunreactive bands, in each instance, co-migrated with wild type Giai. 
From this data it can be concluded that each of the chimera cDNA constructs expressed 
a full-length chimera composed of the first 349 residues of Giai and the last 6 residues 
of G s a ,  G q a  Or G i^ a*
The chimeras were then assayed for receptor catalysed GTPyS binding, in 
order to assess functional coupling. It can be seen from Figures 4.6 and 4.7 that agonist 
stimulation of the P2Y4, TRH and oxytocin receptors resulted in enhanced [^^SjGTPyS 
binding of the G,iaGqa chimera. Similarly, agonist stimulation of the V2 vasopressin 
(Fig. 4.9) and the P2 adrenergic (Fig. 4.8) receptor catalysed guanine nucleotide 
exchange in the GnaGsa chimera. However, none of the receptors assayed in this study 
stimulated GDP/[^^S]GTPyS exchange in the GnaGiea chimera. All of the above 
receptors displayed a high level of selectivity in coupling, in so far as the receptor was 
not seen to stimulate guanine nucleotide exchange in any of the other G-proteins 
assayed.
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Previous studies have shown that the level of G-protein expression can influence 
GTPyS binding (Wise et a l,  1997a), it could therefore be argued that the apparent 
selectivity in receptor/chimera coupling was due to a variation in chimera expression 
resulting from different tiansfection efficiencies between groups. To determine if this 
was the case the relative expression levels of the chimeras were determined by 
immunodetection with antisemm IIC, directed against the internal epitope of Giai, in 
the same membrane preparation as that used to generate the [^^S]GTPyS binding data. It 
can be seen from Figure 4.11 that in the p2 adrenergic and V2 vasopressin receptor co­
transfections the expression levels of the chimeras were equivalent to those of 
transfected Giai and significantly higher than endogenous Giai, which is not detectable. 
It should also be noted that although there was variation in chimera expression between 
the transfected receptors, there was no variation in expression within a particular 
receptor co-transfection. Similar obseiwations were made for all other receptor co- 
ti'anfections in this study. From these findings it can be concluded that the apparent 
specificity of chimera activation was not due to a variation in chimera expression.
Many of the receptors assayed in this study failed to activate any of the 
chimeras. It was previously demonstrated that all of the chimeras were expressed at 
equivalent levels, it could therefore be assumed that the lack of chimera activation was 
not due to a variation in chimera expression. Based on the study by Wise et al., (1997a), 
who demonstrated that variations in receptor expression can influence [^^SjGTPyS 
binding, it would have been prudent to assay receptor expression to determine if this 
was negatively affecting [^^S]GTPyS output. Unfortunately, the lack of suitable 
radiolabelled ligands restricted this readily available simple control; although in a few 
cases receptor expression was indfrectly demonsti'ated by agonist enhanced binding of 
[^^S]GTPyS in the wild type Giai co-transfection. It can be seen, for instance, in Figure 
4.10 that agonist stimulation of the mGluRSa receptor promoted [^^S]GTPyS binding in 
wild type Giai, but not in any of the other chimeras. The same membrane preparation 
was used to assess the relative expression levels of Giai and each of the chimeras. From 
Figure 4.12, it can be seen that all of the G-proteins were expressed at equivalent 
levels. It can therefore be assumed that the selectivity of receptor coupling was not due 
to a variation of chimera expression. Throughout the study the chimera expression 
levels were remarkably consistent within a receptor co-transfection. From this finding, it 
could be assumed that the levels of receptor expression would be equally consistent
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between a set of co-ti'ansfections. Therefore, agonist enhanced binding of [^^SjGTPyS in 
the Giai co-transfection would lead us to believe that the receptor was expressed at 
equivalent levels throughout the co-tiansfections. It may therefore be concluded, in such 
cases, that the lack of chimera activation is solely due to the receptor incompatibility for 
the chimera.
Osawa and Weiss (1995) and Garcia et al. (1995) have demonstrated that 
mutations in the C-terminus of Gt« can affect the capacity of nucleotide binding, as well 
as receptor coupling. From these observations, it could be argued that the absence of 
agonist stimulated [^^SJGTPyS binding in the GuaGiga chimera could be associated 
with either a loss or diminished ability of the chimeric a-subunit to exchange 
nucleotides. To determine whether this was the case, the GuaGiea chimera was assayed 
by limited trypsin digestion in the presence and absence of the non-hydrolysable GTP 
analogue, GTPyS. From Figure 4.13 it can be seen that the GuaGiea chimera is capable 
of exchanging nucleotides as indicated by the immunodetectable products of incomplete 
tryptic digestion. The GuaGsa and GuaGqa chimeras, known to undergo activation by 
the GPCRs assayed in this study, were also shown to be able to exchange nucleotides. 
(Fig. 4.13). From this data it can be concluded that the apparent inability of the GuaG,6a 
chimera to be activated by any of the receptors assayed, is not due to a loss of guanine 
nucleotide exchange. In Figure 4,13 it was also noted that all of the GnaGxa chimeras 
produeed the same tryptic protection pattern as wild type Gjai. Denker et al. (1995) have 
shown that the N-terminal regions of Gi/Go and Go/Gi chimeras can influence the 
conformation of the peptide, which in turn influences the tryptic protection pattern. The 
findings of this study corroborate those of Denker et al. (1995) and it may be assumed 
that since all three chimeras produced the same tryptic protection pattern that they all 
share a common conformational structure.
Osawa et al. (1990) have previously demonstrated that the loss of bacterial toxin 
ADP-ribosylation sites in the G-protein chimera can confer insensitivity to bacterial 
toxin treatment. While both Giai and Gsa are susceptible to ADP ribosylation by the 
respective bacterial toxins PTX and CTX, the ADP-ribosylation sites lie in different 
regions on the a-subunit primary sequence. PTX ribosylates the cysteine 351 residue, 
which in the GDP complexed a-subunit faces the core of the protein, while CTX acts 
upon the arginine 201 residue located in the guanine nucleotide binding pocket. Post-
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translational modification of either of these G-proteins results in a loss of receptor 
catalysed guanine nucleotide exchange. Fortunately, GiiaGsa chimera is composed of 
the first 349 residues of Giai and the last 6 residues of Gsa and therefore contains neither 
of the above ADP-ribosylation sites. The loss of these ADP-ribosylation sites should 
result in insensitivity to both PTX and CTX. To determine whether this was the case, 
the GiiaGsa chimera was characterised in detail along with the human IP prostanoid 
receptor. The ability of the GnaGsa chimera to be activated by the human IP prostanoid 
receptor was demonstrated by both agonist enhanced binding of [^^S]GTPyS and high 
affinity GTPase activity. It can be seen from Figure 4.14 that co-expression of the 
GiiaGsa chimera and the IP prostanoid receptor greatly enhanced agonist stimulated 
[35s]GTPyS binding compared to expression of receptor alone. No increase in 
[35s]GTPyS binding was observed in membranes prepared from parental HEK293 cells. 
From these findings, it can be concluded that agonist stimulation of the GuaGsa chimera 
was mediated by the IP prostanoid receptor. The rate of GTP hydrolysis should be 
higher in the GuaGsa chimera than in the Gs« subunit as the rate is controlled by the Gi 
moiety. To investigate this hypothesis G,ai, Gs« and the GüaGsa chimera were co­
expressed with the IP prostanoid receptor and assayed for agonist enhanced GTPase 
activity. It can be seen from Figure 4.16 that agonist stimulated GTPase activity was 
approximately 3 times higher in membranes containing the GüaGsa chimera than in 
membranes overexpressing either Giai or Gsa- No increase in high affinity GTPase 
activity was seen in membranes prepared from parental HEK 293 cells. From this data it 
can be concluded that the 6 amino acid substitution in the C-terminus of the GüaGsa 
chimera is sufficient to switch the receptor specificity of Giai while retaining the G- 
protein’s high guanine nucleotide exchange rate.
To investigate whether the GnaGsa chimera was a substrate for either PTX or 
CTX, agonist stimulated [^^S]GTPyS binding was assayed in membranes prepared from 
cells treated in vivo with either a combination of PTX and CTX or vehicle. It can be 
seen from the data in Figure 4.15 that treatment with bacterial toxins abolished agonist 
stimulated [^^S]GTPyS binding in membranes prepared from cells transfected to express 
Gsa, Giai or receptor alone, but did not abolish agonist enhanced binding in the GuaGsa 
chimera. The small loss of [^^S]GTPyS binding in the GuaGsa chimera upon toxin 
treatment was equal to the reduction seen in membranes prepared from cells transfected
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with receptor alone. From this data it may be concluded that the GiiaGsa chimera is 
insensitive to both PTX and CTX and that the observed drop in [^^S]GTPyS binding was 
due to the ADP-ribosylation of endogenously expressed Gsa- Since all of the above data 
was generated in membranes prepared from a cell line stably expressing the human IP 
prostanoid receptor, the level of receptor expression is identical between transfections. 
It can therefore be concluded, that the [^^SJGTPyS binding data was not affected by 
variations in receptor expression. However, the G-proteins were ti'ansiently tiansfected 
and so may have been expressed at different levels m each of the transfections. In order 
to evaluate what influence the level of a-subunit expression may have had on agonist 
stimulated [^^SJGTPyS binding, the same membrane preparation was used to determine 
the relative expression levels of each of the transiently transfected a-subunits by 
immunoblotting with antisera raised against Giai and Gsa. From Figure 4.17 it can be 
seen that while Giai expression is equivalent to that of the GnaGsa chimera, the 
expression of Giai was four times greater than that of Gsa- When the a-subunit 
expression levels are related to the [^^SjGTPyS data in Figure 4.15 it can be seen that 
while Giai expression may have been four times greater than that of Gsa, over 
expression of either a-subunit had no effect upon agonist stimulated [^^S]GTPyS 
binding. In contrast, transient tiansfection of the GuaGsa chimera greatly elevated 
agonist stimulated [^^SJGTPyS binding even though it was expressed at equivalent 
levels to Giai. From this data, it can be concluded that the observed insensitivity of 
GiiaGsa to both PTX and CTX was not due to a variation in receptor or G-protein 
expression.
The data generated herein has shown that while a 6 amino acid substitution in 
the extreme C-terminus of Giai for Gsa or Gqa is sufficient to alter receptor selectivity, it 
has no measurable effect on the conformation of the a-subunit or its capacity to 
exchange nucleotide. It can also be concluded that the C-terminus does not appear to be 
the only determinant for receptor interaction, in fact, many of the receptors assayed in 
this study failed to activate any of the chimeras. In this respect, receptor recognition 
could have been influenced by the Giai like conformation of the a-subunit or by the 
absence of recognition sequences located more N-terminally in the C-terminal donor a- 
subunit.
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The G-protein chimeras created in this study have several advantages over 
previous chimeras that used secondary messenger production to assay receptor/chimera 
coupling and agonist potency. A problem arises with this approach in respect that the 
output of secondary messenger assays is prone to being affected by free (3y subunits 
dissociated thiough receptor catalysed activation of the chimera or endogenous G- 
proteins cognate to the receptor being assayed. A more direct way of determining 
receptor/chimera interaction is thi'ough guanine nucleotide exchange-based assay. 
However, due to the low guanine nucleotide exchange rate in previously generated 
chimeras, this has not been a feasible approach. In contiast, the high catalytic activity 
conferred by the Gi moiety in the GnaGxa chimeras allows receptor/chimera coupling to 
be measured by guanine nucleotide-based assays. Therefore, the chimeras generated in 
this study provide a more accurate means of assaying potentially new agonists and 
antagonists than was previously available. In addition, the loss of the PTX and the CTX 
ADP-ribosylation sites in the GnaGsa chimera has conferred insensitivity to these 
bacterial toxins, while retaining the high guanine nucleotide exchange rate associated 
with PTX sensitive G-proteins. This propeity has proved to be particularly useful in 
selectively evaluating the signal output from the GnaGsa chimera when PTX and CTX 
are used to uncouple endogenously expressed Gsa subunits and remove noise generated 
by PTX sensitive G-proteins. In conclusion, the chimeras generated herein, provide a 
useful tool to screen ligands for certain receptors not normally linked to PTX-sensitive 
G-proteins.
Bacterial toxin treatment reduced agonist stimulated [^^SJGTPyS binding in the 
GiiaGsa chimera when compared to non-treated control. This observation would suggest 
that receptor/chimera interactions are not saturated and therefore coupling efficacy may 
be improved. Future work could involve identifying further receptor chimera 
recognition sites by systematically substituting regions of the a-subunits in order to 
increase receptor coupling efficacy.
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Figure 4.1 PCR amplification of GnaGxa chimeras of rat Gia1
GiiaGxa chimeras were generated by PCR amplification of the PTX insensitive 
Giai mutant with one of three hybrid primers. The PCR reaction products from 
amplification with primer 12 (lane 2), primer 13 (lane 3) and primer 14 (lane 4) were 
resolved on a l%(w/v) agarose gel (50 pl/lane) and stained with ethidium bromide. The 
1065bp DNA fragment (lanes 2-4) corresponds to the expected size of the amplified 
GiiaGxa chimera. A 1Kb ladder provided size markers (lane 1).
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Figure 4.2 Analysis of clones transformed with GnaGxa chimera 
cDNAs in the pCDNA3 vector
DNA was isolated from clones thought to be transformed with GiiaGxa chimera 
cDNA in the pCDNA3 vector. Samples (2 pi) were digested with the restriction enzyme 
EcoRl (Section 2.23) and resolved on a 1% (w/v) agarose gel. The 1065bp band (lanes 
2, 3 and 5) corresponds to the expected size of the cleaved insert and indicated 
recombinant clones. The single 5.4 Kb DNA fragment (lanes 4 and 6) corresponds to 
the expected size of the pCDNA3 vector and indicated clones containing empty vector.
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Figure 4.3 Analysis of GüaGxa chimera cDNA orientation in the 
pCDNA3 vector by restriction digestion
Plasmid DNA was isolated from clones transformed with GiiaGxa chimera 
cDNA in the pCDNA3 vector. Samples (2 pi) were restriction digested with the enzyme 
Ncol (Section 2.23) and resolved on a l%(w/v) agarose gel. When the start codon o f the 
Giai mutant was next to the T7 promoter priming site in the pCDNA3 vector, the 
plasmid was cleaved to yield fragments of 340, 260, 735, 1831 and 3299bp (lanes 5, 6, 
7 and 8). Cleavage of the vector with the insert in the opposite orientation, with the start 
codon distal to the T7 priming site, yielded fragments o f 260, 735, 1026, 1145 and 
3299bp (lanes 2, 3 and 4). A 1Kb ladder provided size markers (lane 1).
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Figure 4.4 Immunological characterisation of the GnaGxa 
chimeras
Membranes were prepared from HEK293T cells transiently transfected to 
express GjiaGsa (lane 1), GnaGqa (lane 2) or GnaGiea (lane 3). Samples of membrane 
preparation (25 pg) were resolved in duplicate on 10% SDS-PAGE gels, and 
immunoblotted with antiserum IlC  (internal epitope o f Giai)(Fig. 4.4(a)) or antiserum 
SGI (C-tenninus of Giai and Gia2)(Fig. 4.4(b)). Membranes prepared from mock 
transfected HEK293T cells (lane 4) were used to compare endogenous Giai expression. 
A membrane sample (25 pg) o f rat brain cortex, rich in Gi«i, was used as a positive 
control (lane 5).
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Figure 4.5 Immunological characterisation of the C-terminal 
sequence of the GnaGxa chimeras
HEK293T cells were either mock transfected (lanes 1) or transiently transfected 
to express GiiaGqa (lanes 2), GiiaGsa (lanes 3) or GuaGiea (lanes 4). Membrane samples 
(25 pg) prepared from these cells were resolved by SDS-PAGE and immunoblotted 
with antiserum IlC  (internal epitope of Giai) (left panels A, B and C) in combination 
with antiserum CQl (C-terminus of Gq«) (right panel A), CSl (C-terminus of Gsa) (right 
panel B) and SBl (C-terminus of Gi6a) (right panel C).
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Figure 4,6 The relative coupling efficiency of the GnaGxa 
chim eras with the P2Y4 purinergic receptor upon stimulation  
with UTP
Membranes were prepared from HEK293T cells co-transfected to express the 
P2Y4 purinergic receptor in combination with Gjai wild type (2), GuaGqa (3), GuaGi^a 
(4) or receptor alone (1). All transfections, with the exception of those including the 
wild type G-protein or receptor alone, were pre-treated with 50 ng/ml PTX 12 hours 
prior to harvesting and membrane preparation. UTP stimulated [^^SJGTPyS binding was 
assayed in the membrane preparations as detailed in Section 2.15.2. Each data point 
represents the average of duplicate measurements of a single experiment. The data 
shown represents UTP stimulated [^^SJGTPyS binding above basal and was taken from 
a representative experiment.
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Figure 4.7 The relative coupling efficiency of the GnaGxa 
chim eras with the TRH receptor upon stimulation with TRH
Membranes were prepared from HEK293T cells co-transfected to express the rat 
TRH receptor in combination with Gi«i wild type (2), GiiaGqa (3), GnaGiea (4) or 
receptor alone (1). All transfections, with the exception of those including the wild type 
G-protein or receptor alone, were pre-treated with 50 ng/ml PTX 12 hours prior to 
harvesting and membrane preparation. TRH stimulated [^^SJGTPyS binding was 
assayed in the membrane preparations as detailed in Section 2.15.2. Each data point 
represents the average of duplicate measurements of a single experiment. The data 
shown represents TRH stimulated [^^SJGTPyS binding above basal and was taken from 
a representative experiment.
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Figure 4.8 The relative coupling efficiency of the G;iaGxa 
chimeras with the (32 adrenergic receptor upon stimulation with 
Isoprenallne
Membranes were prepared from HEK293T cells co-transfected to express the ^ 2  
adrenergic receptor in combination with Giai wild type (2), GiiaGiea (3), GnaGsa (4), or 
receptor alone (1). All transfections, with the exception o f those including the wild type 
G-protein or receptor alone, were pre-treated with 50 ng/ml PTX 12 hours prior to 
harvesting and membrane preparation. Isoprenallne stimulated [^^S]GTPyS binding was 
assayed in the membrane preparations as detailed in Section 2.15.2. Each data point 
represents the average of duplicate measurements of a single experiment. The data 
shown represents Isoprenallne stimulated [^^S]GTPyS binding above basal and was 
taken from a representative experiment.
126
Figure 4.8
600
CL
500 -O)
"O
300 ^
<D 200
100Q.
1.00E-09 1.00E-08 1.00E-07 1.00E-06 1.00E-05 1.00E
e (1)
A (2)
X( (3)
+ (4)
[Isoprenaline] (M)
Figure 4.9 The relative coupling efficiency o f the GnaGxa 
chim eras with the V2 vasop ressin  receptor upon stimulation  
with vasop ressin
Membranes were prepared from HEK293T cells co-transfected to express the Y 2  
vasopressin receptor in combination with Giai wild type (2), GnaGiôa (3), GüaGsa (4) or 
receptor alone (1). All transfections, with the exception of those including the wild type 
G-protein or receptor alone, were pre-treated with 50 ng/ml PTX 12 hours prior to 
harvesting and membrane preparation. Vasopressin stimulated [^^SJGTPyS binding was 
assayed in the membrane preparations as detailed in Section 2.15.2. Each data point 
represents the average of duplicate measurements o f a single experiment. The data 
shown represents Vasopressin stimulated [^^S]GTPyS binding above basal and was 
taken from a representative experiment.
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Figure 4.10 The relative coupling efficiency of the GhaGxa 
chim eras with the glutamate mGluRSa receptor upon 
stimulation with glutamate
Membranes were prepared from HEK293T cells co-transfected to express the 
glutamate mGluR5a receptor in combination with Giai wild type (2), GjiaGqa (3), 
GjiaGifia (4) or receptor alone (1). All transfections, with the exception of those 
including the wild type G-protein or receptor alone, were pre-treated with 50 ng/ml 
PTX 12 hours prior to harvesting and membrane preparation. Glutamate stimulated 
[^^SJGTPyS binding was assayed in the membrane preparations as detailed in Section
2.15.2. Each data point represents the average of duplicate measurements of a single 
experiment. The data shown represents glutamate stimulated [^^SJGTPyS binding above 
basal and was taken from a representative experiment.
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Figure 4.11 The expression  of GnaGxa chim eras transiently c o ­
transfected Into HEK293T ce lls  in com bination with the p2 
adrenergic and the Vg vasop ressin  receptors
Membranes were isolated from HEK293T cells co-transfected with the p2 
adrenergic receptor (lanes 2-4) or the V2 vasopressin receptor (lanes 5-7) in combination 
with either Giai wild type (lanes 2 and 5), GiiaGiea (lanes 3 and 6) or GiiaGsa (lanes 4 
and 7). Samples (25 pg) were resolved on a 10% SDS-PAGE gel and immunoblotted 
with antiserum IlC  (Table 2,1). Membranes prepared from mock transfected HEK293T 
cells (lane 1) were used to compare endogenous Giai expression.
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Figure 4.12 The expression  of GnaGxa chim eras transiently c o ­
transfected into HEK293T ce lls  in com bination with the 
glutam ate mGluRSa receptor
Membranes were prepared from HEK293T cells co-transfected with the 
glutamate mGluRSa receptor in combination with either Gjai wild type (lane 2), GiiaGqa 
(lane 3) or GitaGiea (lane 4). Samples (25 pg) were resolved on a 10% SDS-PAGE gel 
and immunoblotted with antiserum IlC , raised against the internal epitope of Giai. 
Membranes prepared from HEK293T cells transfected with receptor alone (lane 1) were 
used to compare endogenous Giai expression.
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Figure 4.13 An immunobiot dem onstrating the capacity of 
GuaGxa chim eras to exchan ge nucleotides
Membranes were prepared from HEK293T cells transfected with either empty 
pCDNA3 vector (lanes 1-3), wild type Giai (lanes 13-15) or one of the following 
chimeras- GüaGsa (lanes 4-6), GuaGqa (lanes 7-9) and GuaGiea (lanes 10-12). The 
capacity of the G-proteins to exchange nucleotides was assayed by limited tryptic 
digestion (Section 2.17) of a membrane samples (100 pg) in the absence (lanes 3 ,6 ,9 ,  
12 and 15) or presence of GTPyS (lanes 2, 5 , 8 , 1 1  and 14). Untreated membrane 
samples were used as a negative control (lanes 1,4, 7, 10 and 13). Membrane samples 
were then resolved on a 10% SDS-PAGE gel and probed for Giai immunoreactivity 
with the antiserum IlC  (Table 2.1). The figure shown is a representative immunobiot.
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Figure 4.14 The exp ression  of GnaGsa en h an ces iloprost 
stim ulated [^®S]GTPyS binding in ce lls  stably exp ressin g  the 
human IP prostanoid receptor
Iloprost stimulated (10 pM) [^^S]GTPyS binding was assayed in membranes 
prepared from parental HEK293T cells (1), clone 13 cells, stably expressing the Flag™. 
tagged human IP prostanoid receptor (2), and clone 13 cells transiently transfected to 
express GüaGsa (3). The results shown represent non-specific (dots), basal (lines) and 
10 pM iloprost stimulated (filled) binding of [^^S]GTPyS in a typical experiment. All 
data points are means ± S.D. of triplicate measurements from a single experiment.
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Figure 4.15 The effects of cholera and pertussis toxin on 
iiopost stim ulated [^®S]GTPyS binding
Iloprost stimulated (1 pM) [^^SJGTPyS binding was assayed in membranes 
isolated from clone 13 cells mock transfected (1) or transiently transfected to express 
Giai (2), Gsa (3) or GiiaGsa (4). The cells were treated with either a combination of PTX 
(25ng/ml) and CTX (200ng/ml) (lines) or vehicle (dotted bars), 16 hours prior to 
harvesting. The results shown represent iloprost stimulation above basal and are the 
means ±  S.D. of triplicate measurements from a single experiment. The data represents 
a typical experiment.
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Figure 4.16 The high affinity GTPase activity of the GiiaG* 
chimera upon iloprost stimulation of the iP prostanoid receptor'sa
The coupling efficacy of the GiiaGsa chimera was assayed by iloprost stimulated 
(1 pM) high affinity GTPase activity in membranes prepared from clone 13 cells mock 
transfected (1) or transiently transfected to express either Gsa (2), Giai (3) or GiiaGsa 
(4). Parental HEK293 cells, transiently transfected to express GiiaGsa (5), were used as 
a negative control. The results shown represent iloprost stimulation above basal and are 
the means ± S.D. of triplicate measurements from a single experiment. The data 
represents a typical experiment.
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Figure 4.17 The relative exp ression  of the GnaGsa chimera 
transiently transfected into clone 13 ce lls
Membranes were prepared from clone 13 cells transiently transfected to express 
Giai (lanes 1 and 5), GüaGsa (lanes 2 and 4) or Gsa (lanes 3 and 6). Samples (25 pg) 
were resolved in duplicate on 10% SDS-PAGE gels which were subsequently 
immunoblotted with antiserum 11C, directed against the internal epitope of Giai (panel 
A) and antiserum CSl (panel B) raised against the C-terminus of Gsa (Table 2.1).
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Chapter 5
The modulatory effects of substituting 
residue C351 in Giai on agonist intrinsic 
activity at an agA-CSSIx Giai fusion
construct
5.1 Introduction
Agonist activation of a G-pmtein coupled receptor (GPCR) triggers the 
transduction of a chemical, photon or mechanical signal to secondary messenger 
producing enzymes or ion channels following the stimulation of heterotrimeric GXP 
binding proteins. All G-protein coupled receptors are characterised by a highly 
conserved primary structure, which includes an extracellular N-terminal segment, seven 
putative transmembrane repeats, which form the transmembrane core, connected by 
three extracellular loops, three cytoplasmic loops, and an intracellular C-terminal 
segment. G-protein coupled receptors exist in either inactive (R), active (R*) or 
desensitised (R*-P) confoiniations. Agonist binding causes a conformational change 
that stabilises the receptor in the active (R=^ ) conformation. This conformational change 
is in turn transmitted to a heterotrimeric GXP binding protein (G-protein).
G-proteins mediate the transduction of extracellular signals from GPCRs to 
secondaiy effectors. G-proteins are composed of three subunits designated a , {3 and y. 
The a-subunit is characterised by a guanine nucleotide binding pocket, common to 
many guanine nucleotide exchanging proteins, into which either GDP or GXP can bind. 
G-proteins exist in either inactive (GDP bound) or active (GXP bound) conformations. 
In the inactive conformation the a-subunit contains GDP in the nucleotide binding 
pocket and is in a high affinity complex with the (3y subunits. These (3y subunits are 
thought to play a pivotal role in stabilising receptor/G-protein interactions. Activation 
occurs through receptor catalysed guanine nucleotide exchange in the a-subunit. The 
conformational change in the agonist bound receptor (R"^ ) is transmitted to the G~ 
protein a-subunit. This confoimational change in the a-subunit results in a lower 
affinity for (3y subunits, increased affinity for and decreased affinity for GDP.
Consequently, the GDP molecule dissociates and is replaced by a Mg^"^GXP complex. 
The GXP bound a-subunit and py subunits are then free to interact with downstream 
effector molecules. G-protein de-activation is regulated by the hydrolysis of GXP to 
GDP, the rate o f which is determined by the intrinsic catalytic activity of the a-subunit 
and by ancillary proteins such as regulators of G-protein signalling (RGS). This results 
in a conformational change in the a-subunit, which allows Py subunit re-association and 
therefore reversion back to the inactive heterotrimeric state.
136
GPCRs and their associated G-proteins are expressed in the cell as separate 
components. These single components have the capacity to interact with or be regulated 
by other molecules, thereby generating signal transduction cascades. These signal 
transduction cascades create the potential to elicit a diverse range of responses from a 
single stimulus. However, this “cross talk” between the various components can be 
problematical in characterising a single aspect, for example agonist efficacy, which is 
extremely dependent on the relative expression of the individual components. To 
restrict and simplify the model, Beilin et al. (1994) constructed a fusion protein 
consisting of the P2 adrenoceptor covalently linked to the Gsa G-protein. This fusion 
was designed to maintain a 1:1 ratio of receptor to G-protein expression and to limit 
receptor interactions with other G-proteins, so forcing a receptor to channel its signal 
through a pre-determined G-protein. Despite this, the characterisation of this and other 
fusion constructs has shown the design by Bertin et al. (1994) to be only partially 
effective in limiting receptor signalling through non-covalently linked G-proteins
The act o f covalently linking a receptor to a G-protein has been shown to 
enhance agonist stimulated receptor/G-protein output when compared to the separately 
expressed components. Seifert et a i  (1998a) have demonstrated that a higher percentage 
o f P2 adrenoceptors in a (32-Gsa fusion protein are stabilised in the high affinity state for 
agonist, when compaied to separately expressed P2 adrenoceptors. The percentage of 
P2-Gsa fusion receptors in the high affinity state was reduced by the addition of the non- 
hydrolysable GTP analogue, GTPyS, which uncouples the G-protein from the receptor. 
Under these conditions, the fusion protein had the same percentage of receptors in the 
high affinity state as the non-linked receptor. These findings would suggest that the 
close proximity of the G-protein to the receptor in the fusion protein favours a “pre­
coupled” state that stabilises the receptor/G-protein fusion in the high affinity state for 
the agonist. It has been postulated that the covalent link between the receptor and the G- 
protein may play a role in stabilising the ternary complex in a similar fashion to the py 
subunits. This hypothesis is supported by the findings of Seifert et al. (1998a) who 
demonstrated that while the presence of Py subunits increased the percentage of 
separately expressed P2 adrenoceptors in the high affinity state, it made little impact in 
the p2-Gsa fusion. This observation can not be attributed to a loss of Py subunit binding 
in the fusion protein. The bacterial toxin, cholera toxin (CTX), can only efficiently 
ADP-ribosylate the Gsa subunit at residue Arg 201 when the G-protein is present in its
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heterotrimeric state. Bertin et al. (1994) have demonstrated that CTX catalysed ADP- 
ribosylation of the Gs« moiety in the p2"Gs« fusion protein is dependent on the presence 
of Py subunits. Similarity, Wise et al. (1997b) have shown that co-expression of py 
subunits with a fusion protein constructed from the azA adrenoceptor and the PTX 
insensitive G-protein mutant, C351G Giai (a2A-C351G Giai) enhanced the signal output 
upon agonist treatment. Despite the fact that the covalent link has been shown to 
stabilise the receptor in the high affinity state, no change in the pharmacological profile 
of a receptor has been noted (Wise et a l ,  1997c; Burt et a l ,  1998). The covalent link 
between the Pz receptor and the Gs« G-protein has also been shown to confer a greater 
capacity to activate the secondaiy effector, adenylyl cyclase, when compared to the 
freely interacting components (Bertin et al., 1994; Seifert et a l ,  1998a; Wenzel-Seifert 
et a l,  1998). This increase in the capacity of the pz-Gsa fusion to activate adenylyl 
cyclase could be due to a stabilisation of the ternary complex by the covalent link. 
Seifert et a l  (1998b) have also demonstiated that the pz adrenoceptor in the Pz-G^a 
fusion construct has properties o f a constitutively active receptor. From this it can be 
infened that the direct physical link may bias stabilisation of the receptor in the active 
(R*) conformation in the absence of agonist.
While Bertin et al. (1994) hoped that the covalent link between the receptor and 
G-protein would unequivocally prevent cross talk between different signal transduction 
pathways, it would appear that the different receptor/G-protein fusions vary in their 
capacity to interact with other components of the signal transduction cascade. It has 
been demonstrated that the Pz-Gsa fusion protein can activate the downstream effector, 
adenylyl cyclase, in an agonist dependent manner (Bertin et al., 1994; Wenzel-Seifert et 
a l,  1998). However, the azA-C351G Giai fusion protein shows no such capacity to 
directly interact with the same downstream effector (Burt et a l ,  1998). Since the C- 
terminal tail of the azA adrenoceptor (20aa) is significantly shorter than that of the pz 
adrenoceptor (84aa), it could be argued that the difference in function between the 
fusions was due to the size of the C-terminal tail in the azA-C351G Giai fusion 
construct. To investigate the relationship between the length of the receptor C-terminal 
tail in the fusion protein and its effect on downstream effector activation, Wenzel- 
Seifert et al  (1988) deleted 26 and 70 amino acids from the extreme C-terminus of the 
pz adrenoceptor in the pz-Gsa fusion protein. Contrary to what would be expected from 
the azA-C351G Giai model, reducing the length of the receptor C-terminal tail in the pz-
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Gsa fusion increased the capacity of agonist to activate the secondary effector adenylyl 
cyclase. These findings are of particular interest as the 70 amino acid deletion reduces 
the C-terminal tail length to less than tliat of the azA adrenoceptor in the azA-C351G 
Giai fusion. The difference in the capacity of the two fusions to interact with adenylyl 
cyclase could be explained by the following hypothesis. The covalent link between the 
receptor and the G-protein stabilises both signal tiansduction components in a 
conformation in which various molecular determinants involved in signal transduction 
component recognition and interaction may become obscured. This hypothesis can also 
be used to explain other features peculiar to the fusion proteins, but not the separately 
expressed components. Bertin et al. (1994) have demonstrated that the Pz-Gsa frision 
protein is less prone to desensitisation than the fieely interacting pz adrenoceptor. This 
effect may be due to the fusion being stabilised, by the covalent link, in a conformation 
which blocks access to molecular detenninants involved in receptor desensitisation. In 
another observation, Sautel and Milligan (1998) have shown that the azA-C351G Giai 
flision protein couples to free G-proteins more selectively than separately expressed 
receptor. The azA adrenoceptor couples predominantly to Gia subunits, but can also 
couple to Gsa G-proteins. The azA-C351G Giai can still couple to free Gia subunits, but 
has lost the capacity to interact with Gsa subunits. From this observation, it can be 
inferred that the G-protein in the fusion may limit access to some, but not all molecular 
determinants involved in G-protein coupling.
Transient transfection provides a convenient method of overexpressing signal 
transduction components in order to assess agonist efficacy. However, in co- 
transfectional studies, quantitation and consistent reproduction of transfection 
efficiencies is often problematic. This is especially true with regard to the transient 
transfection of G-proteins where there is no accurate way of measuring G-protein 
expression levels. The variation in transfection efficiency and so expression can have 
serious implications in the assessment of agonist efficacy. Agonist efficacy 
measurements are veiy susceptible to variations in the ratio of signal transduction 
component expression. Reconstituted systems containing known quantities of purified 
signal transduction components provide a more reproducible system for measuring 
agonist efficacy. However, due to the difficulties involved in purifying sufficient 
quantities of functional receptors and G-proteins this is often not a viable option. Many 
of the above problems can be solved by covalently linking the receptor to the G-protein
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and then measuring agonist efficacy with G-protein based biochemical assays. The use 
of the fusion protein has many advantages over co-tranfection of the individual 
components. Fusion protein expression ensures a l.T stoichiometi’ic ratio of receptor to 
G-protein expression which is impossible with current co-tiansfectional techniques. The 
covalent link between the two components also ensures cellular co-localisation. Finally, 
the fusion protein provides an accurate means of quantitating G-protein expression 
through receptor binding assays. This infoiTnation can be used to accurately assess the 
catalytic activity of a particular G-protein.
Carr et a l ,  (1998) have previously demonstrated that agonist efficacy at the 
a2A-C351G Gjai fusion protein is lower than in a similar constmct containing wild type 
Giai sequence. This fusion construct has also been shown to couple to endogenously 
expressed Gia subunits in stably transfected cells Burt et a l,  (1998). This endogenous 
G-protein coupling affects the 1:1 stoichiometric ratio of receptor;G-protein expression, 
so confounding agonist potency measurements. While endogenous G-protein coupling 
can be abolished in the fusion protein containing the PTX insensitive G-protein, so 
restoring the l.T ratio, this approach is not feasible for the fusion containing the PTX 
sensitive wild type Giai sequence. To determine if agonist efficacy at the azA-C351X 
Giai fusion protein is modulated by the physiochemical properties of residue 351 in the 
G-protein moiety, it was decided to create a range of azA-C351X Giai flision proteins 
each containing a different reside at position 351. The PTX insensitive nature of each of 
the G-proteins should allow the use of PTX to uncouple endogenous PTX sensitive G- 
protein coupling, thus ensuring a 1:1 ratio of receptor to G-proteins. Agonist potency 
would then be assessed in each of the a2A-C351X Giai fusions.
Î40
5.2 Results
5.2.1 Construction of a2A-C351X Giai fusion proteins
Pertussis toxin insensitive mutants o f the a%A adrenoceptor C351 Giai fusion 
protein were constructed by substituting the last 707bp of the cDNA sequence 
corresponding to the C-terminus o f the fusion protein with the equivalent cDNA 
sequence from PTX-insensitive C^^^Xaa Giai mutants
The azA-C351 Giai fusion protein cDNA in the pCDNA3 vector was digested 
with the restriction enzymes EcoKl and SacII to remove the last 707bp of the cDNA 
sequence as described in Section 2.23. The digestion products were resolved on a 1% 
(w/v) agarose gel and stained with ethidium bromide (Figure 5.1.). The expected 7163 
bp fragment corresponding to the pCDNA3-azA-C351 Giai fusion protein was excised 
from the gel and purified as in Section 2.27.
The PTX-insensitive C^^^Xaa Giai mutants were similarly digested with the 
restriction enzymes EcoRl and Sac II to liberate a DNA fragment corresponding to the 
last 707bp of the Gi«i cDNA sequence. The digestion products were resolved on a 1 % 
(w/v) agarose gel and stained with ethidium bromide. The expected 707bp bands were 
excised, purified and ligated into the Eco Rl/Sac II digested pCDNA3 vector containing 
the azA-Giai fusion protein cDNA. The ligation reactions were used to transform the 
DH5a bacterial strain, which was subsequently grown on agar plates under ampicillin 
selection (Section 2.18).
Five clones were arbitrarily chosen from each of the transformations and 
cultured as in Section 2.18. Plasmid DNA was extracted from the cultures by small 
scale DNA preparation (Section 2.22.1) and digested with the restriction enzymes, 
EcoRl and Asp 718 (Section 2.23). The restriction digests were resolved on a 1% (w/v) 
agarose gel and stained with ethidium bromide (Figure 5.2.). The presence of a DNA 
fragment with an apparent molecular size o f 2461 bp, corresponding to the expected 
size o f the azA-C351X Giai fusion protein cDNA, indicated recombinant clones.
The 3’ end of the a2A-C351X Giai fusion protein cDNAs were sequenced using 
a primer annealing on the SP6 promoter priming site in the pCDNA3 vector. The
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sequencing profiles were translated to confirm the identity of the residue at position 351 
in the G-protein.
5.2.2 Transient exp ression  of the a2A-C351X Gi i^ fusion  
proteins
The HEK293T cell line was transiently transfected with either 10 pg of a^A- 
C351X Giai or a2A-C351 Giai cDNA in the pCDNA3 vector. The cells, with the 
exception of those transfected with a2A-C351 Giai, were treated with 50ng/ml of 
pertussis toxin 12 hours prior to harvesting (Section 2.7) in order to inactivate, by ADP- 
ribosylation, endogenously expressed PTX-sensitive G-proteins. At 72 hours after 
transfection, the cells were haiwested and membranes were prepared as in Section 2.9.
5.2.3 The exp ression  level of the a2A-C3511 Gjai fusion protein 
in creases upon transfection with increasing am ounts of cDNA
The a2A-C351I Giai fusion protein was arbitrarily chosen to see if a relationship 
existed between the amount of cDNA transfected into HEK293T cells and the amount 
of fusion protein detected by the azA adrenergic receptor binding assay. This was in 
order to assess a convenient amount of cDNA required to obtain a reasonable 
expression level. HEK293T cells were transiently transfected with 2, 4, 6, 8 and 10 pg 
of a2A-C351I Giai cDNA in the pCDNA3 vector. The total amount of cDNA 
transfected (10 pg) was standardised in each experiment by using empty pCDNA3 
vector. The expression level of the a2A-C351I Giai fusion protein was quantitated by 
the azA adrenergic receptor binding assay. Analysis of the receptor binding data in 
Figure 5.3. shows that the expression level of the azA-C351I Giai fusion protein 
increased upon transfection with up to 6 pg of cDNA, after which very little variation in 
expression was seen.
5.2.4 Quantitation of agA-C351X Giai fusion protein expression  
in HEK293T cells
The relative expression levels of the a2A-C351X Giai fusion proteins were 
quantitated by a receptor binding assay directed against the receptor portion of the 
fusion protein. The azA adrenergic receptor binding assay was carried out as described 
in Section 2.15.1. Analysis of the receptor binding data in Figure 5.4. shows that azA-
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C351X Giai flision expression fluctuated between 10 and 21 pmol/mg. It was also noted 
that no expression was detected in non-ti'ansfected HEK293T control cells.
5.2.5 A linear function ex ists  between a2A-C351l Gi^ exp ression  
and [^®S]GTPyS binding at a maximal agon ist concentration
A correlation between a2A-C351I Giai expression and [^^S]GTPyS binding at a 
non-limiting concentration of UK14304 (100 pM) was determined in HEK 293T cells 
transfected with increasing amounts o f a2A»C351I Giai cDNA (0, 2, 4, 6, 8 and 10 pg). 
The cells were treated with 50ng/ml PTX to remove the endogenous G-protein 
signalling component 12 hours prior to harvesting and membrane preparation. The level 
o f a2A-C351I Giai fusion protein expression was quantitated by an azA adrenergic 
receptor binding assay (Figure 5.3.) as described in Section 2.15.1. In parallel, a 
[^^SJGTPyS binding assay was performed on the same membrane preparation. By 
stimulating the azA-C351I Giai fusion protein with UK14304, an azA adrenoceptor 
agonist, it can be seen in Figure 5.5, that a linear function described [^^S]GTPyS 
binding versus the level of fusion protein expression. The experimental points correlate 
with a correlation co-efficient close to 1 (r=0.98).
5.2.6 The relative efficacy of the Œ2A-C351X Giai fusion proteins 
to bind [^®S]GTPyS in resp on se  to UK14304 stimulation
The capacity of each of the azA-C351X Giai fusion proteins to bind the non­
hydro ly sab le GTP analogue, [^^SJGTPyS, in response to UK143 04 stimulation of the 
azA adrenoceptor moiety in the fusion protein was measured as detailed in Section
2.15.2. In parallel, the expression level of each of the mutants was quantitated by an 
azA adrenoceptor binding assay as described in Section 2.15.1 The maximal 
[^^S]GTPyS binding value of each of the fusion proteins was then normalised with 
regard to the level of fusion protein expression. The data (Figure 5.6.), now corrected 
for variation in G-protein expression, depicts the efficacy of the fusion proteins to bind 
[^^S]GTPyS in response to activation by a non-limiting concentration of the azA 
adrenoceptor agonist, UK14304.
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5.2.7 A gonist efficacy in the a2A-C351X Gjai fusion  proteins is 
m odulated by the identity of residue 351 in the G-protein moiety
The azA-CSSlX Giai fusion proteins containing the residues cysteine, isoleucine 
and glycine at position 351 in the Giai moiety were arbitrarily chosen to assess the 
identity of residue 351 and its effect on agonist efficacy. COS-7 cells were transfected 
to express azA-C351X Giai fusion proteins containing cysteine, glycine and isoleucine 
at position 351 in the G-protein moiety. Cells transfected with a2A-C351I Giai or azA- 
C351G Giai were treated with PTX to remove the endogenous G-protein signalling 
component 12 hours prior to harvesting. The efficacy of agonists on the fusion protein 
were measured by agonist stimulated [y^^PJGTP hydrolysis in membrane preparations 
from each of the transfections. The following agonists were assessed in this study -  
adrenaline, nor-adrenaline, a-methylnoradrenaline, UK14304, dexmeditomidine, BHT- 
933, xylazine, clonidine, guanobenz and oxymetazoline. The results were then plotted 
as a percentage o f the activity stimulated by 100 pM adrenaline (Figure 5,7.). It can be 
seen from Figure 5.7. that the order o f intrinsic activity relative to adrenaline in each of 
the fusion proteins was as follows- Ile>Cys>Gly. This order was conserved throughout 
all of the partial agonists assayed.
5.2.8 The efficacy of clonidine is modulated by the identity of 
residue 351 in the G-protein
The efficacy and potency of clonidine was assayed through its ability to 
competitively stimulate [y^^PJGTP hydrolysis in the azA-C351X Giai fusion proteins in 
the presence of adrenaline. COS-7 cells were tiansiently transfected to express azA- 
C351X Giai fusion proteins containing cysteine, glycine and isoleucine at position 351 
in the G-protein. Cells transfected to express azA-C351I Giai or a2A-C351G Giai were 
treated with PTX to remove the endogenous G-protein signalling component 12 hours 
prior to harvesting. Agonist stimulated [y ^^P]GTP hydrolysis was assayed in membrane 
preparations from each of the transfections tieated with varying concentiations of 
clonidine competing with a maximally effective concentration of adrenaline (100 pM). 
The capacity of the agonists to stimulate [y ^^P]GTP hydrolysis was recorded and 
presented as a percentage of the activity stimulated by 100 pM adrenaline alone. It can 
be seen from Figure 5.8. that at a maximal concentration of clonidine, the efficacy of 
this drug to activate the fusion proteins was the same as estimated from direct
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stimulation by a maximally effective concentration of clonidine (Figure 5.7.), The 
relative order of intrinsic activity for clonidine in the fusion proteins was as follows -  
Ile>Cys>Gly
5.2.9 The capacity of agA adrenoceptor agon ists and 
antagon ists to com pete with f  H]RS-79948-197 binding to the 
a2A-C351 Giai fusion protein
The capacity of azA adrenoceptor antagonists and agonists to compete with 
[^H]RS-79948-197 binding to the azA-CSSlX Giai fusion proteins was measured by a 
competition binding assay (Section 2.15.1). Membranes were prepared from COS-7 
cells transiently transfected to express the azA-CSSl Giai fusion protein. Samples of 
membrane preparation were used to assess the capacity of yohimbine, adrenaline, 
oxymetazoline and clonidine to compete with InM [^H]RS-79948-197 for binding to 
the azA adrenoceptor moiety o f the fusion protein at a range o f ligand concentrations. 
The competition binding data was plotted with the mathematical package Kaleidagraph 
(Fig. 5.9). It can be seen from Figure 5.9. that the antagonist and agonists displayed 
different affinities to compete with [^H]RS-79948-197 binding for the azA-C351 Giai 
fusion protein. The order of affinity of the drugs at the azA-C351 Giai fusion protein is 
as follows- yohimbine> oxymetazoline> clonidine> adrenaline.
5.2.10 The affinity of yohim bine for the Œ2A-C351X Giai fusion  
proteins is not affected by the identity of the residue at position  
351 in the G-protein
The capacity of yohimbine, an azA adrenoceptor antagonist, to compete with the 
radiolabelled antagonist, [^H]RS-79948-197, for binding to azA-C351X G,ai fusion 
proteins was measured by a competition binding assay. COS-7 cells were transiently 
transfected to express azA-C351X Giai fusion proteins containing either a cysteine, 
glycine or isoleucine residue at position 351 in the G-protein moiety. Competition 
binding experiments were performed between InM [^H]RS-79948-197 and varying 
concentrations of yohimbine in membranes prepared from each of the transfections. The 
competition binding data was plotted with the mathematical package Kaleidagraph. It 
can be seen from Figure 5.10 that none of the fusion proteins displayed any difference 
in antagonist binding affinity. Therefore, the ligand binding site in the receptor moiety
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is not affected by the covalent link with the G-protein mutant or by the mutations 
introduced in the G-protein moiety.
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5.3 D iscussion
Fusion proteins, composed of a receptor physically linked to its cognate G- 
protein, provide us with useflil tools for determining pharmacological constants, such as 
agonist efficacy, with high precision (Bertin et a l,  1994; Huit et a l ,  1998; Seifert et a l,  
1988a and Wise et a l,  1997c). Measurements of agonist efficacy are highly susceptible 
to variations in the ratio of G-protein to receptor expression. Fusion proteins provide a 
means of predetermining a stoichiometric ratio of one G-protein for one receptor, and in 
addition ensure co-localisation of the receptor and its cognate G-protein in the same 
subcellular compartment, features which are extremely difficult to keep constant in 
simple transient tiansfection experiments. Unfortunately, the capacity of the receptor 
moiety of the fusion protein to also activate endogenously expressed G-proteins can 
modify the predicted 1:1 ratio (Burt et a l,  1998). To address this problem, as discussed 
in previous chapters, PTX-insensitive G-protein mutants have been employed as the G- 
protein moiety in the fusion construct (Wise et a l,  1997b, 1997c; Burt et a l, 1998). 
Following PTX treatment, endogenous PTX-sensitive G-protein coupling to the azA 
adrenoceptor is abolished by ADP-ribosylation, so restoring 1:1 G-protein to receptor 
stoichiometry. No such action needs to be taken to prevent endogenous Gsa G-protein 
coupling, as it has been demonstiated that the receptor moiety in the aiA-CSSlG Giai 
fusion constmct has lost the capacity to activate this G-protein (Sautel and Milligan, 
1998).
In spite of these advantages, there are some possible shortfalls in the use of 
receptor-G-proteiii fusions. It is possible that the covalent attachment of a G-protein to 
the extreme C-terminus of a receptor may alter or restrict the possible conformations 
adopted by the receptor moiety, so inhibiting its natural function. This is reflected in the 
findings of Burt et a l  (1998) who have shown that a fusion construct between the azA 
adrenoceptor and the PTX resistant Giai mutant (C351G Giai) lacks the capacity to 
activate the secondary effector adenylyl cyclase. There is also evidence to suggest that 
the covalent attachment of the G-protein moiety to the extreme C-terminus of a receptor 
may result in the constitutive activity in the absence of agonist (Seifert et a l  1998b). 
Whilst this is a feature which can be exploited to identify inverse agonists, such a 
property can have negative implications on the assessment on agonist efficacy.
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It has been demonstrated that agonist efficacy at the a2A-C351G G\ai flision 
protein is lower than at a fusion constructed from the wild type Gjai G-protein (Carr et 
al,  1998). The residue C351 in Gjai lies in the C-terminal tail of the G-protein a- 
subunit, a region which has been shown to undergo a dramatic conformational change 
during G-protein activation (Kisselev et al. 1998; Yang et al. 1999). Considering the 
important role the C-terminal tail o f the G-protein a-subunit plays in receptor coupling 
and specificity, it would be of extreme interest to determine what effect the use of PTX- 
insensitive mutants may have on measurements of agonist efficacy using such fusion 
proteins.
Expression of the a2A-C351X Giai fusion constructs was confirmed by a 
receptor ligand binding assay using the a 2A adrenoceptor antagonist [^H]RS-79948- 
197. It can be seen fiom Figure 5.4. that while fusion protein expression was restricted 
to transfected cells, there was variation in expression between transfections. In order to 
accurately pharmacologically characterise a range of agonists at the fusion constmcts, it 
was necessary to deteraiine the window of expression in which agonist-stimulated 
[^^SjGTPyS output could be accurately compared. The a2A-C351I Gjai cDNA was 
arbitrarily chosen to determine the expression levels of fusion protein as a flinction of 
transfection with increasing amounts of plasmid cDNA. It can be seen from Figure 5.3. 
that a2A-C351I Giai expression increased upon transfection with up to 6 pg of cDNA, 
after which expression was seen to plateau. Maximal agonist stimulated [^^SjGTPyS 
binding was determined in membranes expressing known quantities of a2A-C351I Gi«i 
fusion construct. From the data in Figure 5.5. it can be seen that the a2A-C351I Gjai 
fusion construct was insensitive to ADP-ribosylation by PTX. It was also noted that a 
linear function can be extrapolated from maximal agonist stimulated [^ ‘*’S]GTPyS 
binding in function of fusion protein expression. From these findings it was concluded 
that fusion protein expression levels determined in Figure 5.4. were suitable for 
assaying agonist efficacy at the fusion proteins using the [^^SjGTPyS binding assay. 
Maximal (100 pM) UK143 04 stimulated [^^SjGTPyS binding was then assessed for 
each of the fusion constructs. The [^^S]GTPyS binding data was normalised with regard 
to fusion protein expression, to produce a ranlc order of coupling efficiency at each of 
the fusion proteins (Figure 5.6.). From the data in Figure 5.6, it can be seen that, with 
the exception of the wild type Gi«i fusion protein, all of the fusion proteins were 
insensitive to ADP-ribosylation by PTX. It was also noted that the efficacy of the
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agonist UK14304 varied between the fusion constructs. The agonist UK14304 was seen 
to be less efficacious at the a2A-C351G Giai hision protein when compared to the 
equivalent construct composed of wild type Giai sequence. Interestingly, many o f the 
fusion constructs assayed performed better than the wild type fusion protein, with aiA - 
C351I Giai demonstrating the greatest efficiency of G-protein activation with UK14304. 
The rank order of efficiency of fusion protein activation of UK 143 04 correlates very 
closely with the order of coupling efficiency generated by co-transfectional studies 
involving freely interacting G-protein mutants with the Œ2A adrenoceptor (Figure 3.9 
C hapter 3). In fact, all o f the fusion constructs demonstrated the same order of 
coupling efficiency upon maximal stimulation with UK 14304 as the respective C351X 
Giai mutants expressed independently from the receptor, with the exception o f the azA- 
C351A Giai fusion construct, which appeared to display greater efficiency of G-protein 
activation when compared to the separately expressed C351A Giai subunit. However, 
the error associated with this particular measurement shows that this reversal of order is 
not significant. It has already been demonstrated in Chapter 3 that the coupling 
efficiency of C351X Giai mutants to the azA adi'enoceptor is closely related with the 
hydrophobicity of the residue at this position, with the general mle that the more 
hydrophobic the residue at this position, the greater the coupling efficiency of the 
mutant. Conversely, a charge at this position was seen to negatively affect G-protein 
coupling efficiency. Since the only difference between the fusion constructs lies in the 
identity of residue 351 in the Gjai moiety, it can be inferred that efficiency of agonist 
stimulated G-protein/receptor coupling is in part modulated by the physiochemical 
properties of residue 351.
The rank order of coupling efficiency of the fusion constructs was generated 
using a single agonist. It could be argued that the physiochemical properties of residue 
351 in the Giai moiety could affect the phaiinacological profile of the receptor moiety. 
To determine whether this was the case, the intrinsic activity compared to adrenaline of 
a range of full and partial agonists was assayed on three selected fusion proteins. From 
the data in Figure 5.7. it can be seen that partial agonist relative intrinsic activity was 
consistently lower in the Œ2A-C351G Gjai fusion construct than in the fusion protein 
constructed from wild type Giai sequence for all of the partial agonists assayed. 
Similarly, agonist relative intrinsic activity was shown to be consistently greater at the 
a2A-C351I Giai fusion protein than for wild type regai'dless of the agonist assayed.
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From these findings, it can be concluded that the order of coupling efficiency between 
the fusions cannot be related to the agonist, demonstrating that the pharmacological 
profile of the receptor moiety is not altered by the covalent addition of the C351X Giai 
mutants.
It is possible that the receptor moieties in the fusion proteins may display 
different affinities for the same agonist and therefore behave as different receptors. To 
determine the rank order of agonist potency at the fusion proteins, the capacity of 
clonidine to compete with adrenaline for stimulation of high affinity GTPase activity 
was compared in the same three fusions used to assess the relative intrinsic activity of a 
range o f agonists. It can be seen from the data in Figure 5.8. that clonidine was able to 
compete with 100 pM adrenaline at each o f the three fusion constructs with IC50 values 
o f (a2A-C351G G i„ i)  4.8±0.5xlO'^M, (ajA-CSSl Giai) 2.5±1.3x10'’M and (a2A-C351I 
Giai) 4.1±0.4xl0‘^ M. While there was greater divergence of efficiency o f G-protein 
activation between the fusion constructs towards maximally effective concentrations of 
clonidine, the rank order of efficiency of G-protein activation in the fusion proteins 
remained unchanged throughout the agonist concentrations. It could be argued that the 
divergence in efficiency of G-protein activation in the constructs at maximally effective 
concentrations of clonidine could be due to the inability of clonidine to frilly compete 
with adrenaline for binding at the receptor moiety in the flision construct. To determine 
if this was true, the capacity of clonidine and adrenaline to compete with [^H]RS- 
79948-197 binding was determined in the wild type fusion construct. It can be seen 
from Figure 5.9. although both clonidine and adrenaline could completely displace 
binding of [^H]RS-79948-I97 from the receptor moiety of the fusion construct, 
clonidine had a higher affinity. Therefore, at maximally effective concentrations of 
clonidine (Figure 5.8.) the plateau of stimulated GTPase provides a direct measurement 
of the relative intrinsic activity of clonidine versus adrenaline. These values mirrored 
those produced by direct addition of clonidine alone (Figure 5.7.).
It could be argued that the covalent bond linking the azA adrenoceptor to the 
Giai mutant might alter ligand binding affinity at the receptor moiety. To determine 
whether the ligand binding site was affected by the presence of the covalently linked G- 
protein, the capacity of the antagonist yohimbine to compete with the radiolabelled 
antagonist [^H]RS-79948-197 for binding at the receptor moiety was determined for 
each of the three selected fusion proteins. It can be seen from Figure 5.10. that all of the
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fusion proteins displayed a similar affinity for yohimbine (Kp3.1-4.0xl0'^M). This 
observation is in good accord with the findings of Bertin et al, (1994), Seifert et al 
(1988a) and Burt et a l  (1998), who have shown that agonist and inverse agonist affinity 
at the receptor moiety in the fusion protein is that same as that at the fi'eely expressed 
receptor. It can therefore be concluded that differences in the relative agonist efficacy at 
the fusion proteins is not related to a modification in the ligand binding affinity at the 
receptor moiety, but more probably to the capacity of the receptor to activate its 
covalently linked G-protein.
The data generated herein has demonstrated that agonist efficacy at the azA- 
C351X Giai fusion proteins can be modulated by the physiochemical properties o f the 
residue 351 in the Gjai moiety. This modulation of agonist efficacy cannot be attiibuted 
to a modification in the agonist affinity or pharmacological profile of the receptor 
moiety in the fusion construct. Therefore, agonist efficacy at the fusion constructs must 
be related to the coupling efficiency of the G-protein mutant to the receptor, which is in 
turn defined by the hydrophobicity of the residue at position 351 in the Giai moiety. 
These findings are in good accord with the observations of Kisselev et al. (1998) and 
Yang et al. (1999), who have presented evidence that, in the GDP bound inactive form, 
the hydrophobic residues in the C-terminal tail of Giai adopt an ordered conformation 
the hydrophobic nature of which is stabilised by receptor/G-protein interactions. 
Receptor catalysed guanine nucleotide exchange in the a-subunit causes the 
transmission of a conformational change to the C-terminal tail resulting in stabilisation 
of the hydrophobic residues by alternate means and so loss of receptor association. 
Therefore, as the data generated herein has shown, increasing the hydrophobic nature of 
the C-terminal tail should strengthen G-protein/receptor coupling. In conclusion, the 
fusion proteins generated herein provide valuable tools to measure agonist efficacy and 
efficiency of G-protein/receptor coupling. In order to use flision proteins to measure the 
efficacy of agonists at other Gi coupled receptors, it would be of interest to determine if 
PTX-insensitive mutant coupling to other Gi linked receptors is similarly modulated by 
the hydrophobic nature of residue 351. Future work could involve constructing PTX- 
insensitive Giai-protein/Gi linked receptor fusions and then characterising the efficiency 
of G-protein activation in combination with specificity of endogenous G-protein 
coupling and effector activation.
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Figure 5.1 A nalysis of the restriction d igestion  products of the 
a2A-C351 Giai fusion protein cDNA in the pCDNA3 vector
azA-CSSl Giai fusion protein cDNA in the pCDNA3 vector was digested with 
the restriction endonucleases EcoRl and SacII (Section 2.23) and resolved on a 1% 
agarose gel. Cleavage of the vector containing the construct yielded two fragments of 
7163 and 707 bp (lane 2). A 1Kb ladder provided size markers (lane 1).
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Figure 5.2. A nalysis of c lo n es transformed with a2A-C351X Giai 
fusion protein cDNA in the pCDNA3 vector
DNA was isolated from clones thought to be transformed with an azA-CSSlX 
Giai fusion protein cDNA in the pCDNA3 vector. Samples (1 pg) were restriction 
digested with the enzymes EcoRl and Asp7I8 (Section 2.23) and resolved on a 1% 
agarose gel. Cleavage of the vector containing the insert yielded fragments of 5456 and 
2461 bp (lanes 1, 4 and 5).
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Figure 5.3. Transient transfection of increasing am ounts of 
a2A-C351l G,cxi cDNA into HEK293T ce lls  results in higher levels  
of a2A-C351l Giai exp ression
Membranes were prepared from HEK293T cells transfected with increasing 
quantities of a2A-C351I Giai cDNA (2, 4, 6, 8 and 10 p,g). The amount of DNA 
transfected was standardised to lOpg with empty pCDNA3 vector. All cells were treated 
with 50ng/ml PTX 12 hours prior to harvesting and membrane preparation. The level of 
a2A-C351I Giai expression was measured in each o f the membrane samples by the a2A 
adrenoceptor binding assay. The results of the receptor binding assay were plotted as a 
function of the amount of a2A-C351I Giai cDNA transfected. Each data point represents 
the average o f triplicate measurements ± S.D. of a single experiment. The data 
represents a typical experiment.
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Figure 5.4. The expression of a2A-C351X Giai fusion proteins 
transfected into HEK293T cells
Membranes were prepared fi’om HEK293T cells transfected to express a^A- 
C351X Giai fusion proteins. With the exception of untransfected cells or the a2A-C351 
Giai transfection, cells were treated with 50ng/ml PTX prior to harvesting. The level of 
fusion protein expression was assayed in each of the membrane samples by the (X2A 
adrenergic receptor binding assay (Section 2.15.1). The identity of the residue 351 in 
the G-protein portion of the fusion protein is denoted by the conventional three letter 
code. Membranes prepared from untransfected cells (C) were used to assay endogenous 
aaA adrenoceptor expression. The results shown are the means ± S.D. of triplicate 
measurements from two separate experiments (1 and 2)
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Figure 5.5 A linear relationship ex ists  between a2A-C351l Giai 
expression  and [^®S]GTPyS binding at a maximal agon ist  
concentration
Membranes were isolated from HEK293T cells transiently transfected with 
increasing amounts of a2A-C351I Giai cDNA (2, 4, 6, 8 and 10 fig). Cells were treated 
with 50ng/ml PTX 12 hours prior to harvesting. UK14304 stimulated (100 pM) 
[^^S]GTPyS binding was assayed in each of the membrane preparations. The levels of 
a2A-C351I Giai expression were quantitated in the same membrane samples by the a 2A 
adrenergic receptor binding assay. The results from the [^^SJGTPyS assay were plotted 
as a function of a2A-C351I Giai expression in each of the membrane samples. The 
relationship between fusion protein expression and agonist stimulated [^^SJGTPyS 
binding can be described by a linear equation whose experimental points correlate with 
a co-efficient of r=0.98. The data shown represents a typical experiment.
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Figure 5.6. A com parison of the efficiency of a2A-C351X Giai 
fusion proteins to bind [^®S]GTPyS at maximal UK14304 
concentrations
The capacity of maximal concentrations of UK 14304 (100 pM) to stimulate 
[^^S]GTPyS binding was assayed in membrane preparations prepared from HEK293T 
cells transfected to express a2A-C351X Giai fusion proteins. All transfected cells, with 
the exception of those transfected with the wild type fusion cDNA, were treated with 
50ng/ml PTX 12 hours prior to harvesting and membrane preparation. The level of Œ2A- 
C351X Giai fusion protein expression was quantitated in the same membrane 
preparation by the a2A adrenergic receptor binding assay. The [^^SJGTPyS binding 
capacity mdex for each of the mutants was calculated by dividing agonist-stimulated 
|-35s]GTPyS binding by the level of fusion protein expression. The identity of the 
residue at position 351 in the G-protein is denoted by the conventional three letter code. 
The results shown are the means ± S.E.M. of triplicate measurements from four separate 
experiments.
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Figure 5.7. The relative intrinsic activity of agon ists on the a 2A- 
C351X Giai fusion proteins
Membranes were prepared from COS-7 cells transfected to express one of three 
a2A-C351X Giai fusion proteins containing either He (open bars), Gly (filled bars) or 
Cys (hatched bars) at position 351 in the G-protein. The capacity of maximally effective 
concentrations of adrenaline (1), noradrenaline (2), a-methylnoradrenaline (3), 
UK 14304 (4), dexmeditomidine (5), BHT-933 (6), xylazine (7), clonidine (8), 
guanobenz (9) and oxymetazoiine (10) to stimulate [y^^PJGTP hydrolysis was measured 
in membrane preparations from each of the transfections. The results shown are 
represented as a percentage of 100 pM adrenaline stimulation, which was considered as 
a full agonist. The data shown represents the means of three independent experiments; 
errors in all cases were less than 5%.
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Figure 5.8. The relative intrinsic activity of clonidine is 
dependent upon the identity of the G-protein residue 351 in the 
a2A-C351X Giai fusion protein
Membranes were isolated from COS-7 cells transfected to express either a 2A- 
C351Ï Giai (squares), a2A-C351G Giai (circles) or Œ2A-C351 Giai (triangles). Cells 
ti’ansfected with a2A-C351I Giai or a2A-C351G Giai were treated with 50ng/ml PTX 12 
hours prior to harvesting. Adrenaline stimulated (100 pM) high affinity GTPase activity 
was measured in each of the membrane samples in the presence of varying 
concentrations of clonidine. In the experiment shown, clonidine was seen to inhibit the 
effects of adrenaline with IC50 values of (a2A-C351G Giai) 4.8±0.5xl0'^M, (a2A-C351 
Giai) 2.5±1.3x10‘^ M and (a2A-C351I Giai) 4.1±0.4xl0'^M. The results shown are 
represented as a percentage of stimulation generated by 100 pM adrenaline, which was 
treated as a full agonist. The data shown represents the means ± S.D. of triplicate 
measurements of a single experiment. The results represent a typical experiment.
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Figure 5.9 The capacity of a 2A adrenoceptor agon ists and 
antagon ists to com pete with [^H]RS-79948-197 for binding to 
the a2A-C351 Gjai fusion protein
Membranes were prepared from COS-7 cells transfected to express the Œ2A- 
C351 Giai fusion protein. Membrane samples were used to assess the capacity of 
yohimbine (filled circles), oxymetazoiine (filled triangles), clonidine (open triangles) 
and adrenaline (open circles) to compete with (1 nM) [^H]RS-79948-197 binding for the 
azA-CSj 1 Giai fusion protein. The results shown are represented as a percentage of 
[■^H]RS-79948-197 binding in the absence of competing agonist or antagonist. The data 
shown represents the means ± S.D. of triplicate measurements o f a single experiment. 
The results represent a typical experiment.
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Figure 5.10. The ability of yohim bine to com pete with f  H]RS- 
79948-197 binding to the a2A-C351X Gjai fusion proteins is not 
affected by the identity of the residue at position 351 in the G- 
proteln
Membranes were prepared from COS-7 cells transiently transfected to express 
a2A-C351X Giai fusion proteins with either Gly (circles), Cys (triangles) or He 
(squares) at residue 351 in the G-protein. The capacity of yohimbine to compete with (1 
nM) [^H]RS-79948-197 binding for the a2A-C351X Giai fusion proteins was assessed 
in membrane preparations from each of the transfections. In the experiment shown, each 
of the fusions displayed a similar affinity for yohimbine to compete for specific binding 
o f [^H]RS-79948-197 (Ki~3.1-4.0xl0'^M). The results shown are presented as a 
percentage of [^H]RS-79948-197 binding in the absence of yohimbine. The data shown 
represents the means ±  S.D. of triplicate measurements of a single representative 
experiment.
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Final Discussion
Final d iscu ssion
The characterisation of the G-protein coupling specificity of receptors is often 
confounded by the interaction of multiple G-protein subtypes with the same receptor. A 
simple solution to this problem has been to use bacterial toxins to functionally uncouple 
selected G-proteins, so that the true extent of G-protem/receptor coupling can be 
analysed. One frequently used bacterial toxin is pertussis toxin (PTX) from the 
bacterium Bordetella pertussis. This toxin has been shown to act with a high degree of 
specificity at Gi family members which contain a cysteine residue four amino acids 
from the C-terminus. In such G-proteins, pertussis toxin catalyses the ti'ansfer of an 
ADP-ribose group ft om NAD^ to this cysteine residue, resulting in the loss of G-protein 
receptor coupling. This loss of receptor coupling is assumed to be due to steric 
hindrance of the ADP-ribose moiety. The Gza subunit, which contains an isoleucine 
residue at this position, has been shown not to be substrate for this toxin. Based on this 
observation, Senogles (1994) and Hunt et a l (1994) have shown that replacement of 
this cysteine residue in both Giai and G,a3 can also confer resistance to post-translational 
modification by PTX. This would suggest that the substitution of this cysteine residue 
might provide a general strategy for the production of PTX insensitive Gi protein 
mutants.
While the substitution of such residues has been shown to confer resistance to 
pertussis toxin, one major flaw in this strategy has been that these mutants tend to 
couple less efficiently than the pertussis toxin sensitive wild type G-protein (Wise et a i, 
1997d). As such, without prior investigation into the effects that these substitutions may 
have on the efficiency of G-protein/receptor coupling, these mutants are of little or no 
use in characterising agonist efficacy at a receptor. In spite of this limitation, little has 
been done to quantify the physiochemical properties of the substituted residue and its 
affect on receptor/G-protein coupling. It should also be noted that there has never been 
comprehensive study in which the cysteine residue was substituted to all other amino 
acids.
In the first results chapter, I have focussed on these limitations in the current 
understanding of PTX resistant mutants. Senogles (1994) and Hunt et a l (1994) have 
shown that the substitution of the conserved cysteine residue (C351) in Gjai or Gias 
confers resistance to ADP-ribosylation catalysed by pertussis toxin. From these findings 
it has been postulated that the substitution of this cysteine residue may provide a general
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strategy for the production of pertussis toxin resistant G-protein mutants. In order to 
assess if this was a feasible strategy, the conserved cysteine residue (C351) in Giai was 
systematically substituted to all other amino acids to provide a comprehensive set of G- 
protein mutants. The coupling efficiency of each of these mutants was then assessed 
following agonist stimulation o f the Gi linked azA adrenoceptor. As expected, the 
substitution of this cysteine residue did confer resistance to pertussis toxin. Indeed, 
these finding confinn that pertussis toxin is specific in its substrate requirements as, 
with the exception of the wild type Gjai, none of the mutants generated in this study 
were seen to be substrates for ADP-ribosylation.
Substitution of this conseiwed cysteine residue in Gi family members has only 
ever been observed to negatively affect G-protein receptor coupling. Wise et al. (1997d) 
have shown that a glycine substitution at this position in Gjai reduces coupling 
efficiency at the aaA adrenoceptor by an order of magnitude when compared to the wild 
type a-subunit. Similarly, Osawa and Weiss (1995) have demonstrated that the 
substitution of the equivalent residue for alanine in Gt« (C347A) also results in a 
reduced affinity of the G-protein for its cognate receptor. In a more extreme example, 
the substitution of a tyrosine residue at this position in Gta has been shown to 
completely ablate coupling of this G-protein to its cognate receptor (Owasa and Weiss, 
1995). These finding would lead us to believe that the cysteine residue is an essential 
components for optimal G-protein receptor coupling and therefore, the substitution of 
any other amino acid at this position would be detrimental to the capacity of the G- 
protein to couple to its cognate receptor. The findings of this study provide the first 
direct evidence challenging this preconception. While, as expected from the findings of 
Wise et al. (1997d), certain substitutions such as glycine did indeed reduce the capacity 
of the mutants to couple to the a^A adrenoceptor, other substitutions such as isoleucine 
were shown to enhance G-protein/receptor coupling relative to the wild type G-protein. 
To summarise, the mutants assayed in this study displayed a spectrum of responses 
when assessed for coupling efficiency at the a^A adrenoceptor. Since this was the first 
experiment of its kind to comprehensively substitute this residue for all other amino 
acids, the data generated herein was used to analyse possible relationships between the 
physiochemical properties of the residue at position 351 and the coupling efficiency of 
the G-protein. Following analysis o f various amino acid descriptors such as 
hydrophobicity, hydrophilicity, and volume to surface area, a strong relationship was
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finally determined between the octanol/HaO partition co-efficient of the substituted 
residue and the capacity of the mutant to couple to the azA adrenoceptor. This 
relationship indicated that the more hydrophobic the amino acid at this position, the 
greater the coupling efficiency at the azA adrenoceptor. This same descriptor also 
demonstrated the best congelation with the predicted EC50 value of the agonist UK 14304 
to stimulate the mutant. Analysis of the physiochemical properties o f the residues also 
revealed some other interesting relationships, one of which was that the size of the 
residue did not appear to be a negative factor in G-protein receptor coupling. Evidence 
for this came from the capacity o f G-protein mutants containing bulky amino acids such 
as tyrosine to couple to the azA adrenoceptor with greater efficiency that the C351G 
Giai mutant. This is contrary to what might be expected according to the current model 
of attenuation of receptor coupling following ADP-ribosylation at this position. In 
contrast to this, charge was shown to be a negative factor in G-protein/receptor 
coupling. The substitution of charged residues such as arginine or lysine at this position 
was seen to result in a total loss of G-protein/receptor coupling. From these findings, it 
would seem as if the mechanism underlying the loss of G-protein/receptor coupling 
following ADP-ribosylation may be related more to the charge associated with this 
group than, as previously thought, size.
Amino acids which failed to conform well to the proposed hydrophobicity rule 
include pro line and methionine. Possible explanations why these residues failed to 
conform to the general trend are as follows. For the methionine residue, it is possible 
that the amino acid was present as methionine sulphoxide. If this was the case, this 
would drastically alter the hydrophobic character of the residue and so its octanol/HiO 
partition co-efficient value. As for the pro line residue, this amino acid is Icnown to 
introduce a kink into the peptide backbone which, in turn, can result in a loss of 
flexibility. The substitution of this residue at position 351 in Giai may have resulted in a 
loss of flexibility in the extreme C-terminus of the a-subunit and so a loss of G- 
protein/receptor coupling. Evidence supporting this hypothesis comes from the findings 
of Osawa and Weiss (1995) who have shown the substitution of a proline residue in Gta 
at a position equivalent to residue 352 in Giai to result in loss of receptor coupling at 
this G-protein.
The findings of Osawa and Weiss (1995) have also identified another side effect 
o f substituting the conserved cysteine residue in Gi G-proteins, the loss of nucleotide
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binding. It could have been assumed that the differential coupling efficiencies obsei'ved 
at the C351x Giai mutants were due to a modification in the capacity of the G-protein 
mutant to bind or exchange nucleotide. Contrary to what would be expected from the 
study of Osawa and Weiss (1995), none of the mutants assayed in this study 
demonstrated any detectable change in either the capacity or the rate of guanine 
nucleotide exchange relative to the wild type Giai subunit. From these findings it can be 
concluded that the difference in capacity of C351x mutants of Giai to couple to the 012A 
adrenoceptor are not due to a modification in nucleotide binding or exchange.
To summarise, this study shows that the capacity of PTX resistant Gi«i mutants 
to couple to the a%A adrenoceptor can be influenced by the physiochemical properties 
of the residue present at position 351 in the Giai moiety.
In the second results chapter I examined the role the C-terminal tail of the G- 
protein plays in defining the specificity of G-protein/receptor coupling. Various groups 
including Komatsuzaki et a l  (1997), Voyno-Yasenetskaya et a l (1994a) and Conklin et 
a l  (1993) have shown that the substitution of as little as three amino acids in the 
extreme C-temiinus of a G-protein is sufficient to switch the receptor selectivity of the 
G-protein while preserving the specificity of effector coupling. These studies have 
concentrated on the use of pertussis toxin insensitive G-proteins and have measured the 
efficiency of chimera coupling through secondary messenger based assays. A limitation 
of this approach lies in the use of effector activation to assay receptor/chimera 
selectivity. Measurements of effector activation can frequently be modulated, either 
synergistically or in opposition, by free f3y subunits dissociated either from the chimera 
or from endogenous G-protein cognate to the receptor being assayed. It is therefore 
laborious to prove that the chimera under investigation is solely modulating effector 
activation. A more accurate way of measuring receptor/chimera interactions would be to 
assay chimera activation at the level o f the G-protein through guanine nucleotide 
binding or exchange based assays. However, the low guanine nucleotide exchange rate 
associated with PTX insensitive G-proteins does not make this a viable option. It would 
therefore be useful to determine if G-proteins of the Gi family, which possess a higher 
intrinsic guanine nucleotide exchange rate, could be feasibly used as the functional 
partner of the G-protein chimera, and if the substitution of the extreme C-terminus in 
these subunits could switch receptor selectivity in a manner similar to that seen in PTX 
insensitive G-proteins.
165
To detenuine if this was the case, the last 6 amino acids o f Gjai were 
substituted for those of Gsa, Gqa or Gi6a- The length of this substitution was 
determined from the findings of Conklin et a l (1993) who have shown optimal 
coupling of a Gqa/Gia2 chimera at the A 1 adenosine receptor following the 
substitution of between 4 and 9 amino acids, substitutions beyond this point were 
shown to negatively affect the coupling efficiency of this chimera. Each of the 
chimeras generated in this study was then assayed for functional coupling at a bank 
of non-Gi linked receptors. The findings of this study show that the substitution o f 6 
amino acids in the C-terminus o f Giai is not sufficient to confer coupling of the G- 
protein to all non-Gi linked receptors. O f the chimeras assayed in this study, the 
GiiaGqa chimcra was only seen to functionally couple to the P2Y4, TRH and oxytocin 
receptors. Similarly, the GjiaGga chimera was only seen to functionally couple with 
the V2 vasopressin receptor and the P2 adrenoceptor. Interestingly, none of the 
receptors assayed in this study were shown to functionally couple to the GnaGiea 
chimera. This is in direct opposition to what would be expected from the findings of 
Offermans et a l (1995) who have demonstrated Gi6a coupling at quite a diverse 
array of receptors. Further immunological characterisation of the chimeras showed 
that the lack of functional coupling in the GüaGiea chimera could not be attributed to 
either a variation in chimera expression or the expression of an incomplete protein 
product. Nor, as determined by tryptic protection assays, could it be attributed to a 
loss or diminished ability of the chimera to exchange guanine nucleotides.
Wise et a l (1997a) have shown that variations in receptor expression can 
influence the output from guanine nucleotide binding assays. Therefore, it could be 
argued that the lack of functional coupling at many of the receptors assayed in this 
study could be due to variations in their expression levels. In light of this, it would 
have been prudent to assay receptor expression to determine if this was indeed 
adversely affecting the observation of receptor/chimera coupling. Unfortunately, the 
lack of suitable radiolabelled ligands restricted the use of this readily available 
simple control. However, in a few select cases, receptor expression was indirectly 
demonstrated through activation of the wild type Giai subunit in a selective manner. 
As immunological characterisation showed the levels of chimera expression to be 
remarkably consistent between transfections, it was assumed that receptor expression 
would be equally consistent. Therefore, it can be concluded that in such cases, the
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lack of chimera activation was solely due to incompatibility of the receptor for the 
chimera.
Osawa et a l (1990) have previously demonstrated that the loss of bacterial 
toxin ADP-ribosylation sites in G-protein chimeras can confer insensitivity to 
bacterial toxin treatment. To determine if this was the case in the GiiaGsa chimera, 
which is missing ADP-ribosylation sites for both pertussis and cholera toxin, 
functional coupling of this chimera was assayed at the IP prostanoid receptor 
following treatment with either a combination of PTX and CTX or vehicle. As 
expected from the findings of Osawa et a l (1990), the data generated in this study 
shows that the elimination o f bacterial toxin ADP-ribosylation sites in the GuaGsa 
chimera confers resistance to both PTX and CTX. The data herein also indicate that 
the substitution of the C-terminus o f Giai for Gsa is sufficient to switch receptor 
specificity of Giai while retaining the G-proteins high guanine nucleotide exchange 
rate. Further analysis o f this data showed a loss of total functional coupling in the 
assay following treatment with bacterial toxins. This loss of functional coupling was 
attributed to coupling to endogenous bacterial toxin sensitive G-proteins. These 
findings therefore indicate that coupling of the chimera to the receptor is not 
saturating, and that while the substitution of the last 6 amino acids of Giai for those 
o f Gsa is sufficient to switch the coupling specificity of the G-protein, it is not 
sufficient to provide optimal coupling at non-Gi linked receptors.
To summarise, the findings of this study corroborate those of Voyno- 
Yasenetskaya et a l (1994a), Komatsuzaki et a l (1997) and Conklin et a l (1993) in 
demonstrating that the substitution of the exti’eme C-terminus of a G-protein is 
sufficient to switch the specificity of receptor coupling. However, the data generated 
herein also address issues not covered in previous studies and show that while the C- 
terminus of the a-subunit is unarguably an important determinant of receptor 
specificity, it is not the only determinant involved in G-protein/receptor coupling.
Finally, in the third results chapter, I investigated the effects of substituting 
the residue C351 in Giai on the measurement of agonist relative intrinsic activity at 
the a 2A adrenoceptor. Measurements of agonist intrinsic activity are extremely 
susceptible to variations in the ratio of signal tiansduction component expression. 
This can be particularly problematic when assessing agonist intrinsic activity in 
systems constructed fiom transiently ti'ansfected components. While transient
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transfection provides a convenient means of overexpressing signal transduction 
components, quantitation and consistent reproduction of transfection efficiencies is 
often problematic. This is especially true with regard to the transient expression of 
G-proteins, for which there is no convenient way of measuring expression levels. 
Reconstituted systems containing loiown quantities of purified signal transduction 
components provide a more reproducible system for measuring agonist intrinsic 
activity. However, due to the difficulties involved in purifying sufficient quantities of 
functional receptors and G-proteins, this is often not a viable option. In contrast to 
these two systems, a thfrd approach, first proposed by Bertin et a l (1994), of 
covalently fusing the receptor to the G-protein provides the convenience of transient 
transfection with the reproducibility o f a reconstituted system. The fusion approach 
also ensures a 1:1 stoichiometric ratio o f receptor to G-protein expression, cellular 
co-localisation o f the signal transduction components as well as an accurate means of 
quantifying G-protein expression through receptor bmding assays.
Recently, the fusion strategy, as proposed by Bertin et a l (1993), has been 
shown to be flawed. While Sautel and Milligan (1998) have shown that a fusion 
construct of the a%K adrenoceptor and Giai has lost the ability to couple to 
endogenous Gsa subunits, Burt et a l (1998) have demonstrated that this flision 
retains the capacity to interact with endogenous Giai. This endogenous G-protein 
coupling can be expected to upset the predicted 1:1 stoichiometric ratio of 
receptor:G-protein expression, so confounding agonist potency measurements. While 
the 1:1 ratio of G-protein to receptor can be restored by using a PTX resistant G- 
protein in the fusion construct in combination with PTX treatment to abolish 
endogenous G-protein coupling, the use of this PTX insensitive mutant itself has 
been shown to affect measurements of intrinsic activity. Carr et a l (1998) have 
shown the intrinsic activity of adrenaline at a PTX insensitive azA-CSSlG Giai 
fusion construct to be significantly lower than at an equivalent construct containing 
the wild type G-protein. Residue 351 in Giai is located four amino acids from the 
extreme C-terminus of the a-subunit, in a region which is known to undergo a 
conformational change during G-protein activation (Kisselev et a l 1998; Yang et a l 
1999). Considering the predicted role of this region in defining the efficiency and 
specificity of receptor coupling, it would be of interest to determine what effects a 
substitution at this position may have on the measurements or agonist relative 
intrinsic activity.
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To determine if intrinsic activity at aiA-CSSÎx Giai fusion proteins can be 
modulated by the physiochemical properties of residue 351 in the Giai moiety, 
agonist relative intrinsic activity was assayed in a series of oi2A-C351x Giai fusion 
constructs each containing a different residue at position 351. The fusion constructs 
assayed in this study showed a spectrum of responses to the agonist UK14304. In 
accordance with the findings of Can’ et al. (1998), the fusion constmct containing the 
G-protein mutants C351G Giai displayed lower inti’insic activity for UK 14304 
compared to adrenaline than an equivalent construct containing the wild type 
sequence. However, in contrast to this, relative to the wild type Giai fusion, 
UK14304 displayed greater relative intrinsic activity at the fusion construct 
containing an iso leucine residue at position 351 in the Giai moiety. Further analysis 
of these fusion constructs showed that the order o f intrinsic activity o f UK 14304 
closely mii’i’ored the order o f coupling efficiency previously determined using the 
sepai’ately expressed components.
To determine if the pharmacological profile of the receptor moiety of the 
fusion construct was altered by the covalent addition of the G-protein, the study was 
repeated using a diverse array of agonists at 3 selected fusion constructs containing 
either isoleucine, glycine or cysteine at position 351 in the Giai moiety. Analysis of 
these fusion constiucts showed that the order of agonist intrinsic activity relative to 
adrenaline was consei'ved regardless of the agonist being assayed. This observation is 
consistent with the findings of Wise et al. (1997c) and Burt et al. (1998), who have 
not been able to detect a change in the pharmacological profile of the a%A 
adrenoceptor following its ftision with Giai. The measurements of relative intrinsic 
activity could also be affected by a change in the agonist affinity at the receptor 
moiety. To investigate this property, agonist and antagonist affinity was assessed in 
the same three fusion constructs used to determine the pharmacological profile of the 
receptor moiety. None of the fusions assayed in this study were shown to differ in 
affinity for the antagonist yohimbine. Also, the affinity of the antagonist yohimbine 
at the fusion consti*ucts was seen to be comparable to that detei’mined in the 
separately expressed receptor. This observation is in good accord with the findings of 
Bertin et a l (1994), Seifert et a l  (1998a) and Burt et a l (1998), all of whom have 
shown agonist and antagonist affinity at a fusion construct to be comparable to that 
displayed by the freely expressed receptor.
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To summarise, the findings of this study have expanded on those of Carr et 
a l (1998) and have shown that the intrinsic activity of partial agonist at the azA 
adrenoceptor, relative to adrenaline, can be modulated by the physiochemical 
properties of residue 351 in the Giou moiety. This discrepancy of relative intrinsic 
activity at the fusion proteins can not be attributed to a change in the 
pharmacological profile of the receptor moiety or to a modification of its affinity for 
agonist. In conclusion, the data generated throughout the three results chapters serves 
to reinforce the importance of the C-terminus of the G-protein a-subunit in defining 
the efficiency and specificity of G-protein/receptor coupling.
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